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Dose scaling is a critical component of dose individualisation that helps 
ensure that the required amount of drug exposure is achieved in each and 
every patient. This is typically achieved by scaling the pharmacokinetic (PK) 
parameters by relevant covariates, on the assumption that variability in drug 
response is linked to PK. Body size is the most important covariate when 𝐶𝐿 is 
scaled for differently sized populations, e.g. obese or paediatric patients, in 
order to calculate the maintenance dose. Conventionally, total body weight 
(𝑊𝑇) has been used as the size scaler, however, fat-free mass (𝐹𝐹𝑀) is a suitable 
alternative as it accounts for body composition as well.  
Accurate scaling of 𝐶𝐿 by body size needs an accurate value of the scaling 
exponent (i.e. the allometric exponent). Since there is no consensus on the true 
value of the exponent, it is often empirically chosen from the a priori 
recommended values (2/3, 3/4, 1) or estimated. In either situation, the 
accuracy of the empirical value would depend on the study design, which is 
assessed in this thesis by modelling and simulation. The finding indicates that 
sub-optimal study designs risk bias to the allometric exponent, which in turn 
risks bias to 𝐶𝐿 prediction.  
For sub-optimal study designs, it is recommended to use a biologically 
plausible a priori value for the allometric exponent. While a theoretical value 
exists for 𝑊𝑇, it is currently lacking for 𝐹𝐹𝑀. Therefore, the value for 𝐹𝐹𝑀 was 
investigated by modelling the relationship between liver size and 𝐹𝐹𝑀. Further 
attempt was made to empirically estimate the exponent from literature data. A 
literature based meta-analysis revealed a disconnect between the theoretical 
(expected) and the empirical values; this needs further research.   
Given the issue with the choice of the allometric exponent, an alternative 
‘bottom-up’ approach could be used to scale 𝐶𝐿 by in vitro-in vivo extrapolation 
(IVIVE). Unlike the classical ‘top-down’ approach above, the accuracy of 




‘functional’ liver size, instead of study design. In this thesis, lean liver volume 
(𝐿𝐿𝑉) was identified as a more accurate descriptor of ‘functional’ liver size by 
comparing its predictive performance with the conventional descriptor, total 
liver volume (𝐿𝑉).  
Another issue is that 𝐹𝐹𝑀  is not a readily measurable covariate and 
hence, accuracy of 𝐹𝐹𝑀 prediction is of utmost importance in dose scaling. 
Janmahasatian’s 𝐹𝐹𝑀  model, although extensively used, is known to over-
estimate 𝐹𝐹𝑀  in Indian population. Therefore, an extended version of 
Janmahasatian’s 𝐹𝐹𝑀  model was developed for Indians. The extended 𝐹𝐹𝑀 
model structure includes (estimable) ethnicity specific body composition 
parameters, which can be further estimated for other relevant populations as 
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STRUCTURE OF THE THESIS 
In this thesis covariate based scaling of drug doses from standard body 
size to differently sized individuals has been assessed. Under Part I, Chapter 1 
covers an introduction of the current state of knowledge about scaling of 
maintenance doses and the importance of accurate scaling of pharmacokinetic 
(PK) parameters. In particular, the influence of body size and composition on 
between-subject variability of drug clearance and identification of the right 
covariate to quantify are discussed. 
Chapters 2 to 7 cover the assessment of key covariates, i.e. total body 
weight (𝑊𝑇) and fat-free mass (𝐹𝐹𝑀)  for the purpose of quantifying the 
influence of body size and composition on clearance. Broadly, these chapters 
are divided into three parts: Part II covers body size-based scaling, Part III 
covers body composition-based scaling, and Part IV covers scaling of clearance 
by lean liver volume (𝐿𝐿𝑉).  
Under Part II, Chapter 2 covers a stochastic simulation-estimation based 
assessment of the current methodologies of allometric scaling of clearance by 
𝑊𝑇, which has been the conventionally used descriptor of body size.  
Under Part III, methodologies associated with 𝐹𝐹𝑀  based scaling are 
discussed. 𝐹𝐹𝑀  has emerged as an alternative scaler of clearance since it 
accounts for body composition. However, 𝐹𝐹𝑀  is not a readily measurable 
characteristic and several experimental methods are available for its 
measurement. The applicability and validity of the methods in a particular 
population depend on some key assumptions. Therefore, an extensive review 
of these 𝐹𝐹𝑀 measuring methods is provided in Chapter 3 that would help 
rationalise the use of these methods. 
In practice, 𝐹𝐹𝑀  is estimated by predictive models since the 𝐹𝐹𝑀 
measuring methods are quite resource intensive. The Janmahasatian model is 
mostly used for this purpose in clinical pharmacology. However, there is 




Indians, which can be attributed to ethnicity-related differences in body 
composition. Therefore, in Chapter 4, an extension of the Janmahasatian model 
has been developed that can extend the model’s application to other 
populations. This extended model has been evaluated in a cohort of Indian 
patients. 
Although 𝐹𝐹𝑀  has been validated in a number of studies and 
recommended as the choice of scaler of clearance, the scaling relationship (i.e. 
exponent) varies across studies, and it is mostly empirical. In this context, a 
model based meta-analysis has been conducted and reported in Chapter 5 in 
order to determine the average observed value of the exponent for scaling 
clearance by 𝐹𝐹𝑀. 
Under Part IV, a new physiological variable, lean liver volume (𝐿𝐿𝑉) is 
introduced for use as a universal descriptor of functional liver size. The key 
role of 𝐿𝐿𝑉 in describing the variation in clearance is highlighted, especially in 
obese. Therefore, a predictive model of 𝐿𝐿𝑉 has been developed in Chapter 6, 
where 𝐹𝐹𝑀  is considered as the covariate. The relationship (i.e. exponent) 
between 𝐿𝐿𝑉 and 𝐹𝐹𝑀 can serve as the theoretical basis for clearance vs. 𝐹𝐹𝑀 
scaling exponent. 
Additionally, further use of the 𝐿𝐿𝑉 model, which has been developed in 
Chapter 6, is explored in Chapter 7 by evaluating its potential use as a scaler in in 
vitro-in vivo extrapolation (IVIVE) of clearance.  
Under Part V, Chapter 8 concludes the thesis with a discussion of the 
findings and an outline for future research. This is followed by appendices 
which contain additional material such as NONMEM control files, MATLAB 
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1.1. Quantitative clinical pharmacology 
The goal of quantitative clinical pharmacology is to predict the right dose 
and regimen for every patient which, helps ensure a safe and effective drug 
treatment. The required (safe and effective) dose in a patient is influenced by 
the underlying pharmacology of the administered drug. From a quantitative 
point of view, the pharmacology of a drug is defined by two distinct set of 
properties known as pharmacokinetics (PK) and pharmacodynamics (PD) [1].  
PK refers to the time course of drug concentration in a body fluids as a 
result of an administered dose of drug, whereas PD refers to the magnitude of 
drug effect in relation to its concentration in a body fluid [2]. Ideally, the effect 
of a drug is related to the concentration at the site of action [3] which is often 
impossible to measure. Therefore, it is common practice to use plasma 
concentration as the surrogate measurement, assuming the drug is in 
equilibrium between the water spaces of plasma and the tissue of interest 
where drug action takes place. In a broader framework [4], PK describes drug 
“exposure” over time ±  summary measures such as the area under the 
concentration-time curve (𝐴𝑈𝐶) and PD describes drug “effect” which can be a 
change in a pharmacological marker (e.g. TNFα/CD4+ count), an efficacy 
index (e.g. pain score), or a measure of safety (e.g. QT prolongation). The 
biological processes that govern the PK such as drug absorption, distribution, 
metabolism, and excretion (ADME) involve almost all parts of the body. On the 
other hand, the biological processes that govern the PD such as drug-target 
binding, target abundance, and turn-over primarily occur at the 
pharmacological target level. In either case, whether PK or PD, these associated 
biological processes vary widely in the population which makes the PK and the 
PD properties of a drug variable between individuals. 
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1.1.1. Pharmacokinetics (PK) 
The time course of drug in the body after an intravenous (IV) 
administration is primarily defined by two PK parameters clearance (𝐶𝐿) and 
volume of distribution (𝑉). Biologically, these two parameters are independent 
from each other within an individual. This means, if the 𝐶𝐿  values of two 
different drugs were similar, their 𝑉 values would not necessarily be similar in 
an individual. However, individual values of 𝐶𝐿  and 𝑉  of a drug are often 
correlated in the population, since they often share common biological factors 
(e.g. body size) which causes the individual parameter values to deviate from 
the population estimate.  
1.1.1.1. Volume of distribution  
Volume of distribution (𝑉) is a measure of the distribution volume of a 
drug inside the body water [5]. If a drug freely distributes into the body water 
by passive diffusion, its 𝑉 will be equal to the volume of total body water. For 
example, the reported mean 𝑉 (CV%) of antipyrine in normally hydrated adults 
is 31 L (17%) [6]. Similarly, highly polar drugs like aminoglycosides that can 
only distribute into the extra-cellular water demonstrate a 𝑉 of about 0.16 L/kg 
[7]. Some drugs exist in ionic form and thus cannot permeate beyond the plasma 
water of vascular space, so their 𝑉 is nearly equal to the plasma volume, e.g. 
heparin [8]. The range of 𝑉 across drugs varies hugely from a lower limit of 
about 0.04 L/kg (i.e. plasma volume) to several thousands of litres (e.g. 
chloroquine [9]). A higher value of 𝑉 than total body water volume indicates 
substantial binding of the drug inside tissue(s) leaving the tissue free fraction 
(𝑓𝑢,𝑡) to be lower than plasma free fraction (𝑓𝑢,𝑝). The higher the volume of 
distribution of a drug the lower will be the total concentration of the drug in 
plasma at a given time point. 
Volume of distribution depends on the drug’s physico-chemical 
properties as well as the (patho)physiological status of the patient. 
Theoretically, a more lipophilic drug (e.g. general anaesthetics) will distribute 
more into adipose tissue than a less lipophilic drug. Therefore, from PK point 
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of view, it is expected that an obese individual has a higher (absolute) 𝑉 than a 
lean individual for the former (more lipophilic) drug, e.g. phenytoin, diazepam, 
lorazepam whereas both individuals will have similar (absolute) 𝑉 for the case 
of latter (less lipophilic) drug, e.g. digoxin, antipyrine [10]. However, within the 
high lipophilic category, it is difficult to predict the magnitude of change in V 
during obesity, i.e. whether the change is proportional (e.g. lorazepam) or less 
than proportional (e.g. digoxin) or more than proportional (e.g. diazepam) to 
WT [11, 12]. Even, a highly lipophilic drug’s V can remain unaffected in obesity as 
seen in the case of propofol [13]. Similarly, 𝑉 can increase during critical illness 
(e.g. sepsis [14]) most commonly due to altered protein binding, fluid shifts, and 
changes in pH [15]. Clinically significant alteration in 𝑉 due to critical illness can 
be expected for hydrophilic drugs that have limited intra-cellular penetration 
and have low volume of distribution [15]. Therefore, variation in the 
physiological status (e.g. obesity, critical illness) between individuals in the 
population potentially causes variation in 𝑉, and thereby variation in the time 
course of the drug concentration. 
1.1.1.2. Clearance 
Clearance is a quantitative measure that quantifies the capacity of the 
body to eliminate xenobiotics (i.e. drugs). Primarily, the liver and kidneys are 
the two main organs that eliminate drugs from the body. Thus clearance of a 
drug often refers to the summation of hepatic and renal clearance where their 
individual contributions to the overall clearance vary across drugs. 
1.1.1.2.1. Hepatic clearance 
The majority of drug elimination in the liver is caused by bio-
transformation (i.e. metabolism) by intra-cellular enzymes. Bio-transformation 
leads to (chemical) conversion of drug molecules to metabolites that are 
physico-chemically different (i.e. more polar) than the parent drug molecule, 
which facilitate their excretion through the kidney and/or bile. The majority of 
the hepatic bio-transformation happens by a set of oxidative enzymes known 
as cytochrome P450 enzymes (CYPs). CYPs are membrane bound enzymes that 
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are located within the microsomes of the hepatocytes and present in several 
isoforms, e.g. CYP3A4, CYP2D6, CYP2C9. CYP mediated bio-transformation is 
commonly referred as Phase-1 metabolism. The rest of the hepatic bio-
transformation is caused by Phase-2 enzymes that are located within the 
cytosol of the hepatocytes, e.g. uridine glucuronyl transferase isoforms (UGTs).  
The hepatic (systemic) 𝐶𝐿 of a drug depends on its intrinsic clearance and 
physiological variables. These physiological variables typically include CYP 
abundance (defined as pmol of CYP enzymes per mg of microsomal protein), 
functional liver size, hepatic blood flow, and drug free-fraction in the blood. 
The intrinsic clearance of a drug is very much specific to the drug and the 
metabolising enzymes (i.e. a drug specific property). However, physiological 
variables can vary widely across individuals, based on characteristics such as 
age, body size, health status, etc. For example, individuals with different body 
sizes likely have different liver sizes, which may influence drug 𝐶𝐿 differently. 
This implies, an obese patient (with normal organ function) may have a higher 
𝐶𝐿, and a child may have a lower 𝐶𝐿, than an adult with normal body weight. 
1.1.1.2.2. Renal clearance 
Many drugs are eliminated from the body by the kidneys. Renal drug 
elimination primarily occurs through glomerular filtration and/or active 
secretion process from the distal tubular region. Similar to hepatic clearance, 
renal 𝐶𝐿 also depends on drug specific properties such as molecular weight, 
polarity, and also physiological variables such as glomerular filtration rate 
(GFR), plasma protein concentration, etc. Therefore, renal 𝐶𝐿 also varies with 
individual characteristics, due to the variation in physiological variables. For 
example, renal failure patients demonstrate lower 𝐶𝐿 than healthy patients due 
to a reduction in GFR. 
1.1.2. PK model 
The time course of drug concentration in the body (at a given dose) can be 
quantitatively described by a PK model where the PK parameters (e.g. 𝐶𝐿) are 
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used as constants. A simple one compartmental PK model has been shown in 
Eq 1.1 where the drug is administered by an intra-venous (IV) bolus dose. 
Here, the basic assumption is that the distribution equilibrium between plasma 
water and tissue water is achieved instantaneously following drug 
administration, and the drug follows a first order elimination kinetics. Under 
this assumption, the (total) drug concentrations of plasma (𝐶𝑝) and tissue(s) are 
not necessarily be the same, but tissue drug concentration proportionally 
changes with plasma concentration.   










Eq 1.1 One compartment PK model with intra-venous bolus dose 
 
In reality, the distribution kinetics of drugs across different tissues can 
vary largely depending upon the physico-chemical properties of the drug 
and/or the perfusion to the respective tissues. Typically, when distribution is 
perfusion rate limited (i.e. no active process is involved), highly perfused 
tissues such as the liver, lungs, and kidneys achieve equilibrium much faster 
than the poorly perfused tissues such as muscles and adipose tissues. In such 
situation, it is common to assume two different pools (i.e. compartments) of 
tissues in which the drug resides throughout its time course in the body. The 
former pool which instantaneously reaches equilibrium with plasma is 
considered as the central compartment, and the latter pool is considered as the 
peripheral compartment. This means (total) drug concentration of plasma (𝐶𝑝) 
proportionally changes with concentration of drug in the tissues of the central 
compartment (similar to one compartment). It is also assumed that the drug 
elimination occurs from the central compartment.  
The schematics of one compartment and two compartment PK models [16] 
have been shown in Figure 1.1 (a, b). The two compartment model has two 
clearance parameters, i.e. elimination (𝐶𝐿) and distribution (𝑄) clearance, and 
also two volume parameters, i.e. central (𝑉𝑐) and peripheral (𝑉𝑝) volume of 
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distribution. A one compartmental model would produce a straight line 
(Figure 1.1c) when concentration-time profile is plotted on a semi-logarithmic 
scale, whereas a two compartment model would produce a bi-phasic profile 
(Figure 1.1d) due to initial distributional delay in the peripheral compartment. 
Sometimes a tri-phasic profile may appear (i.e. three compartment) if the 
distribution equilibrium into certain tissue(s) is achieved much slower than the 
other peripheral compartment.     
 
 
Figure 1.1 Schematics of one (a) and two (b) compartment models and their 
signature concentration-time profiles in (c) and (d) respectively. 
𝑉𝑐  volume of central compartment, 𝑉𝑝  volume of peripheral compartment, 𝐶𝐿  elimination 
clearance, 𝑄 distribution clearance, 𝐶𝑝 drug concentration in plasma. 
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1.1.3. PD model 
In quantitative pharmacology, the key assumption is that the 
pharmacological effect of a drug is related to its concentration at the site of 
action. This means that different concentrations of the same drug would 
produce different levels of effect in a patient. A PD model mathematically 
relates the drug effect to its concentration, thereby facilitating prediction of the 
effect of a drug at a given concentration. The mathematical constants that relate 
these two variables (i.e. effect and concentration) are known as PD parameters. 
In most cases, measurement of drug concentration at the site of action is not 
feasible in clinical studies. Therefore, PD model usually relates the drug effect 
to its concentration in plasma (blood) which is an easily accessible body fluid 
[2].  
Typically, the concentration-effect relationships (defined by PD models) 
are found to be non-linear, probably due to the non-linear nature of the 
underlying biological processes (e.g. drug-receptor interaction [17]). For 
example, a general model for describing concentration-effect relationship is a 
simple 𝐸𝑚𝑎𝑥 model (Eq 1.2) where 𝐸 and 𝐶𝑝 represent the drug effect and the 
plasma concentration respectively, and the PD parameters are maximum drug 
effect (𝐸𝑚𝑎𝑥) and concentration for half-maximal effect (𝐶50). The underlying 
assumption is that the drug concentration at the site of action is in equilibrium 





Eq 1.2 Simple 𝑬 𝒂𝒙 model defining concentration-effect relationship 
 
The non-linearity of this equation is evident in the plot of drug effect (in 
percentage of 𝐸𝑚𝑎𝑥 ) against increasing values of 𝐶𝑝  (Figure 1.2a). Here, the 
higher the drug concentration (𝐶𝑝) the larger the effect is (𝐸), which eventually 
reaches an asymptote to maximal effect (𝐸𝑚𝑎𝑥). When 𝐶𝑝 varies over several 
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orders of magnitude, then a semi-logarithmic plot (Figure 1.2b) helps to 
visualise the data better.  
 
Figure 1.2 A typical concentration-effect profile simulated from a simple 
𝑬 𝒂𝒙 model demonstrating the non-linearity in the relationship with respect 
to drug concentration; (a) linear scale (b) semi-logarithmic scale. 
 
1.1.4. PK-PD model 
PK-PD model describes the time course of drug action by mathematically 
relating dose and the effect via linking dose vs. concentration time course and 
concentration vs. effect relationships [3, 18, 19]. The type of chosen (PK-PD) link 
model primarily depends on the observed time courses of plasma 
concentration and effect of the drug and rest is dependent on available 
biological information. 
When the peak effect occurs nearly at the time of peak plasma 
concentration, a direct (i.e. immediate) effect model is considered. A direct 
effect model assumes an instantaneous equilibrium between plasma and the 
site of action, which implies a proportional change in concentrations between 
plasma and site of action throughout the time course of the drug. This is the 
simplest circumstances where the PK model that describes the time course of 
𝐶𝑝 (e.g. Eq 1.1) can serve as the link model and the PK-PD model can be defined 
by Eq 1.3 (assuming an 𝐸𝑚𝑎𝑥 model for PD).  
(     )(  )
(   ) (      )
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                       𝐸(𝑡) =
𝐸𝑚𝑎𝑥 × 𝐶𝑝(𝑡)
𝐶50 + 𝐶𝑝(𝑡)




Eq 1.3 A simple direct effect PK-PD model 
In many cases, the peak effect of the drug occurs at a much later time 
point than that of the peak plasma concentration. This typically results in a 
counter-clock wise hysteresis loop when drug effects are plotted (in the Y-axis) 
against corresponding plasma concentrations (in the X-axis). Under such 
circumstances, an indirect (i.e. delayed) link model is applied to model the 
delay in drug action. A usual way of modelling such delay is to incorporate a 
link model to describe the time course of drug concentration in a hypothetical 
effect compartment (𝐶𝑒 ) [20, 21] that describes the drug distribution to the 
‘biophase’ [22]. A ‘biophase’ model assumes a non-equilibrium (or delayed 
equilibrium) distribution of drug between plasma and the effect site. For 
example, the link model for the simple one compartment PK by IV bolus 
administration (shown in Eq 1.1) can be written as Eq 1.4, where the first order 
rate constant 𝑘𝑒𝑜 determines the rate of disappearance of drug from the effect 
compartment. The rate at which the effect compartment achieves steady state is 
therefore related only to the rate constant 𝑘𝑒𝑜. The amount of drug in the effect 
compartment is assumed to be negligible and therefore distribution to the effect 
compartment does not affect the mass balance in the equation for PK. Then the 
PK-PD model can be written as Eq 1.5. 
                                  
𝑑𝐶𝑒
𝑑𝑡
= 𝑘𝑒𝑜 × (𝐶𝑝 − 𝐶𝑒)             𝑤ℎ𝑒𝑟𝑒, 𝐶𝑒(0) = 0 
Eq 1.4 Link model for hypothetical effect compartment 
 
                                        𝐸(𝑡) =
𝐸𝑚𝑎𝑥 × 𝐶𝑒(𝑡)
𝐶50 + 𝐶𝑒(𝑡)
      𝑤ℎ𝑒𝑟𝑒, 𝐸(0) = 0, 𝐶𝑒(0) = 0 
Eq 1.5 An indirect effect PK-PD model where effect is linked to the 
concentration of a hypothetical effect compartment (  ) by a simple Emax 
relationship. 
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Sometimes, the delay can be modelled by describing the influence of drug 
on the natural turn-over of a relevant biological process (e.g. prothombin 
complex activity) in the body that results in the clinical expression of ‘effect’ [2]. 
Such PK-PD model is known as turn-over model or indirect response model [23]. 
A general format of the biological turn-over process is shown in Eq 1.6. The 
zero order rate 𝑅𝑖𝑛 and the first order rate constant 𝑅𝑜𝑢𝑡 describe the natural 
production and the degradation of the biological marker which is modulated 
by the drug to elicit its effect. The drug can either stimulate or inhibit any one 
of these two physiological parameters ( 𝑅𝑖𝑛, 𝑅𝑜𝑢𝑡 ), which is modelled by 
factoring in either a stimulatory (𝑆 ) or inhibitory (𝐼 ) PD model into the 
respective parameters. The general format of the stimulatory and inhibitory PD 
models are shown in Eq 1.7 and Eq 1.8 respectively.   
                                  
𝑑𝐸
𝑑𝑡
= 𝑅𝑖𝑛 − 𝑅𝑜𝑢𝑡 × 𝐸      
Eq 1.6 A general model for describing biological turn-over processes 
 
𝑆 = 1 +
𝐸𝑚𝑎𝑥 × 𝐶𝑝(𝑡)
𝐶50 + 𝐶𝑝(𝑡)
     
Eq 1.7 Structure of the stimulatory PD model for incorporation into 
biological turn-over model 
 
𝐼 = 1 −
𝐸𝑚𝑎𝑥 × 𝐶𝑝(𝑡)
𝐶50 + 𝐶𝑝(𝑡)
     
Eq 1.8 Structure of the inhibitory PD model for incorporation into biological 
turn-over model 
 
Therefore, a delayed PK-PD model for a one compartment PK with IV 
administration where drug distribution to the site of action is instantaneous can 
be defined by one of the suitable models from Eq 1.9, Eq 1.10, Eq 1.11 and Eq 
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1.12 in addition to the PK model in Eq 1.1. Selection of the most appropriate PD 
model should be guided by prior knowledge of the drug pharmacology. 
                      𝑆𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑖𝑛𝑝𝑢𝑡:            
𝑑𝐸
𝑑𝑡
= 𝑅𝑖𝑛 × (𝑆) − 𝑅𝑜𝑢𝑡 × 𝐸      
Eq 1.9 An indirect response PK-PD model with stimulation of input 
                     𝑆𝑡𝑖𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑜𝑢𝑡𝑝𝑢𝑡:          
𝑑𝐸
𝑑𝑡
= 𝑅𝑖𝑛 − 𝑅𝑜𝑢𝑡 × (𝑆) × 𝐸      
Eq 1.10 An indirect response PK-PD model with stimulation of output 
                  𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑜𝑓 𝑖𝑛𝑝𝑢𝑡:              
𝑑𝐸
𝑑𝑡
= 𝑅𝑖𝑛 × (𝐼) − 𝑅𝑜𝑢𝑡 × 𝐸      
Eq 1.11 An indirect response PK-PD model with inhibition of input 
                𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑜𝑓 𝑜𝑢𝑡𝑝𝑢𝑡:             
𝑑𝐸
𝑑𝑡
= 𝑅𝑖𝑛 − 𝑅𝑜𝑢𝑡 × (𝐼) × 𝐸      
Eq 1.12 An indirect response PK-PD model with inhibition of output 
 
The inter-relationship between PK and PD in a quantitative framework 
has been described in Figure 1.3. Notably, both PK and PD parameters are 
inherent properties of a drug within a specific population, and thus are not 
subject to external modification, but the dose (and/or regimen) can be adjusted. 
Therefore, an optimal pharmacological response (i.e. safe and effective 
treatment) can be achieved by modifying the dose and/or dosing regimen, if 
the PK and PD of the drug have been inter-linked appropriately. The PK 
exposure that produces the desired pharmacological response is known as 
therapeutic exposure. 
The primary goal of quantitative clinical pharmacology is to predict the 
right dose and regimen for patients by quantifying the relationship between 
dose and the drug effect by developing a PK-PD model. This would help 
predict the pharmacological response within a standard individual at various 
doses and dosing regimens. However, in reality, individual patients hardly 
demonstrate standard characteristics such as body size (e.g. non-obese vs. 
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obese), age (e.g. adult vs. children), health status (e.g. normal vs. impaired 
organ function), etc. that affect the relevant physiology, and hence causes 
between-subject variation in PK and/or PD parameters. Such characteristics 
that reflect the sources of between-subject variability (BSV) of the PK and/or 
PD parameters are known as covariates. Therefore, identification of relevant 
covariates and quantification of their influence on the model parameters are 
key objectives of quantitative clinical pharmacology. Successful identification 
of covariates can help predict the right dose for the right patient, thus allowing 
dose scaling for optimal drug exposure and effect.  
 
 
Figure 1.3 A schematic representation of the PK-PD modelling concept 
within quantitative pharmacology framework. 
The PK and the PD models predict the concentration w.r.t. time and effect w.r.t. concentration.  
When connected, the PK-PD model predicts the time course of the drug effect. Both models are 
subject to inter-individual variation in their corresponding PK and PD parameters. The overall 
goal is to estimate these parameters, predict their inter-individual variations so that dose can 









(  ,  )
PK Model PD Model
+ Dose + Concentration
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1.1.5. Basis of dose scaling 
A fixed amount of dose that has proven for effectiveness in one particular 
population may not produce the desired effects in another population if 
significant variation in the PK and/or PD parameters was expected in the 
target population. Such situations are commonly encountered by the clinician 
when newly approved drugs are used in clinical practice. Due to the highly 
controlled nature of clinical trials, standard adult participants are studied 
during drug development (with few exceptions), and doses are approved based 
on observed therapeutic response in the standard adult population [24]. As a 
result, the approved doses do not necessarily produce optimal responses in 
other populations such as children, the obese, etc. This is because of the 
differences in relevant covariates (e.g. body size, age) in the target populations 
that lead to different PK exposures. In such circumstances, the dose is scaled 
according to the change in the covariate(s) from the standard population. For 
example, body weight is often a significant covariate of 𝐶𝐿  and thus body 
weight normalised doses are usually used clinically [25].  
 For dose scaling purposes, it is assumed that the exposure-response 
relationship remains unchanged between the patient groups (e.g. children vs. 
adult), and only the dose-exposure relationship changes due to the changes in 
PK parameter(s) [26]. Under this assumption, dose scaling actually simplifies to 
scaling of PK parameter(s) by the covariates in the target population. Since, 𝐶𝐿 
is the sole PK parameter that determines the maintenance dose, scaling of 𝐶𝐿 is 
needed to achieve a desired steady state drug exposure in the plasma upon 
multiple dosing.  
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1.1.6. Maintenance dose  
Under normal circumstances such as first order elimination, the rate of 
drug elimination is directly proportional to the plasma concentration (𝐶𝑝) of the 
drug assuming the drug rapidly distributes within the water space of plasma 
and the eliminating organ(s). Here, 𝐶𝐿 is the proportionality constant (Eq 1.13, 
Eq 1.14).  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝐸𝑙𝑖𝑚𝑖𝑛𝑎𝑡𝑖𝑜𝑛 ∝ 𝐶𝑝 
Eq 1.13 Drug elimination following first order kinetics 
 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝐸𝑙𝑖𝑚𝑖𝑛𝑎𝑡𝑖𝑜𝑛 = 𝐶𝐿 × 𝐶𝑝 
Eq 1.14 Quantifying rate of drug elimination following first order kinetics 
 
For chronic therapy, a constant drug exposure is desired so that the 
effectiveness of the drug is maintained. After a single administration, the drug 
exposure in the body decreases with time, and the amount of drug that is 
present at a particular time point depends on its elimination half-life (𝑡1/2). At 
completion of every half-life, 50% of the drug is eliminated from the body, 
which means that after 5 half-lives the drug will be almost completely 
eliminated from the body. Any successive dosing before completion of this 
wash-out period would cause the drug to accumulate inside body, and the 
extent of accumulation depends on the time and amount of successive dose 
administration.  For example, if the same amount of dose is repeatedly 
administered at the completion of every half-life, then approximately equal 
amount of the dose will be accumulated inside the body after 5 doses (as 50% 
of dose is accumulated at every dosing interval). Due to drug accumulation 
after every dose, both the peak (𝐶𝑝,𝑚𝑎𝑥) and trough (𝐶𝑝,𝑚𝑖𝑛)  concentrations 
would continue to increase until 5 doses, and further dosing would cause the 
plasma concentration to fluctuate between a fixed window of peak 
(𝐶𝑝,𝑠𝑠,𝑚𝑎𝑥)and trough (𝐶𝑝,𝑠𝑠,𝑚𝑖𝑛) concentrations. This state is known as steady 
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state (Figure 1.4) where the average of the peak and trough plasma 
concentrations (𝐶𝑝,𝑠𝑠,𝑎𝑣𝑔) remains constant over time and commonly termed as 
steady state plasma concentration. This reflects a steady state exposure of the 
drug that is intended to be maintained throughout the duration of chronic 
therapy, and the dose that yields this steady state exposure is known as 
maintenance dose [1]. At steady state 𝐶𝑝 in Eq 1.14 can be replaced by 𝐶𝑝,𝑠𝑠,𝑎𝑣𝑔 to 
form Eq 1.15.  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝐸𝑙𝑖𝑚𝑖𝑛𝑎𝑡𝑖𝑜𝑛 = 𝐶𝐿 × 𝐶𝑝,𝑠𝑠,𝑎𝑣𝑔 
Eq 1.15 Rate of drug elimination at steady state after multiple doses 
 
 
Figure 1.4 Achievement of steady state exposure upon repeated 
administration of a maintenance dose at every half-life. 
 
At steady state, the drug exposure becomes constant (i.e. 𝐶𝑝,𝑠𝑠,𝑎𝑣𝑔) because 
approximately equal amount of the of the maintenance dose is remained in the 
body at every dosing interval, due to accumulation. This implies that the rate of 
input (i.e. dose) is equal to the rate of output (i.e. elimination). Therefore, Eq 
1.15 can be rewritten as Eq 1.16.  
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𝑅𝑎𝑡𝑒 𝑜𝑓 𝐼𝑛𝑝𝑢𝑡 = 𝐶𝐿 × 𝐶𝑝,𝑠𝑠,𝑎𝑣𝑔 
Eq 1.16 General relationship between rate of input and clearance at steady 
state 
For a typical IV infusion, rate of input indicates the infusion rate 
(mass/unit time). But for IV bolus and oral administrations, rate of input refers 
to the amount of maintenance dose normalised to the dosing interval (𝜏). 
Therefore, Eq 1.16 can be rearranged as Eq 1.17 where 𝐹  represents 
bioavailability (not applicable for IV). 
𝑀𝑎𝑖𝑡𝑒𝑛𝑎𝑛𝑐𝑒 𝐷𝑜𝑠𝑒 =
𝜏 × 𝐶𝐿 × 𝐶𝑝,𝑠𝑠,𝑎𝑣𝑔
𝐹
 
Eq 1.17 Calculation of maintenance dose to achieve a target steady state 
concentration 
 
When 𝐶𝑝,𝑠𝑠,𝑎𝑣𝑔 is known for a desired therapeutic effect, the maintenance 
dosing regimen (i.e. dose and interval) can be adjusted according 
(proportional) to the 𝐶𝐿  of the drug. This leaves maintenance dose scaling 
equivalent to 𝐶𝐿 scaling. The time to reach the steady state depends on relative 
magnitude of 𝜏 with respect to 𝑡1/2 of the drug. The shorter the 𝜏 compared to 
the 𝑡1/2, the sooner the steady state is reached. For scaling 𝐶𝐿, the key is to 
identify its covariate(s) and how the covariate(s) influence(s) this parameter 
(parameter-covariate relationship) across the population. This is typically done 
by population pharmacokinetics (Pop-PK) modelling. 
1.1.7. Covariates  
Covariates are broadly defined as the intrinsic and extrinsic factors that 
influence the PK (and PD) parameters and thus describe the between-subject 
variability over these parameters to a significant extent. The intrinsic covariates 
are identifiable and measurable features of an individual (i.e. patient 
characteristics) that vary across the population such as body size, age, 
genotype, organ function (e.g. creatinine clearance), and patho-physiology (e.g. 
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serum albumin). The extrinsic covariates do not relate to the individual 
characteristics and can be modified externally, such as food, co-medication etc. 
Another classification of covariates (including intrinsic and extrinsic) is 
based on their distributional properties, i.e. categorical and continuous 
covariates. The entire classification has been summarised in Figure 1.5. 
Categorical covariates takes the form of discrete values which are pre-assigned 
to define specific states of the patients. On the other hand, continuous 
covariates refer to some quantifiable characteristics that are measured on a 
scale, such as body weight is measured in kilogram scale. 
 
Figure 1.5 Summary of the overall classification system of covariates [27] . 
 
1.1.8. Population pharmacokinetics modelling 
Conventional PK studies in drug development include well controlled 
clinical studies involving a homogeneous population (i.e. with similar 
characteristics) and rich drug sampling designs. This type of approach is 
helpful in estimating the PK parameters. However, such well controlled studies 
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have limited ability to identify effects of relevant covariates on the PK 
parameters, which makes it challenging to extrapolate PK to different 
sub/special population, e.g. children, obese, and patients with impaired organ 
function. In this context, population pharmacokinetics (Pop-PK) studies are 
useful.  Pop-PK studies mostly involve patients with wider range of 
characteristics such as body weight and age, with the exceptions of well 
controlled studies in early phase drug development, such as Phase 1 studies, 
where healthy adults within standard body size range are usually studied. 
Therefore Pop-PK studies are able to provide quantitative information about 
the PK variation in the respective target population(s), thereby giving the 
opportunity for dose scaling. Another advantage of Pop-PK study is that it can 
generate the required information from a sparse dataset (i.e. few samples per 
individuals).  
There are several modelling approaches to analyse population PK data [28-
31] such as the naïve pooled approach, the two stage approach, and the non-
linear mixed effects approach. The naïve pooled method assumes that all 
observations arise from a single individual and hence can be interpreted as that 
no differences exist between individuals [32]. Because of this, naïve pooled 
method lacks the ability to estimate random effects parameters and the 
influence of significant patient covariates. Furthermore, it potentially causes 
biased estimation of fixed effects parameters. In the two stage approach, first 
the data from each individual is modelled separately in stage 1. In stage 2 the 
individual parameter estimates are combined in order to calculate the mean 
and variance of each parameter. Mixed effects refer to fixed effects parameters 
(e.g. mean 𝐶𝐿  in the population) and the variances of random effects that 
explains between-subject variability (BSV) of the parameters and the residual 
error in the data. The mixed effects approach combines all observed data and 
accounts for both population average effects and individual differences 
simultaneously. 
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In pop-PK modelling, the mean values of the PK parameters that 
correspond to a standard person in the population are estimated. However, 
within the population, individual PK parameters deviate from the standard 
values due to BSV. BSV has two components: predictable (BSVP) and 
unpredictable or random (BSVR) [33]. The predictable portion of the variability 
(BSVP) can be described by relevant covariates. Therefore, the larger the extent 
of BSVP the closer will be the population predictions of PK to the individual 
level. Therefore, covariate identification is a key objective of pop-PK modelling 
which is typically done in a non-linear mixed effects (NLME) modelling 
framework. 
1.1.8.1. Non-linear mixed effects (NLME) modelling  
1.1.8.1.1. The PK model 
Pharmacokinetic model describes the rate of change of drug concentration 
(with respect to time) in the body. Under first order kinetics, the concentration 
changes exponentially with time, which is (mathematically) a non-linear 
process. Therefore, PK models are usually defined by a set of non-linear 
equations where time is the independent variable. Such non-linear equations 
that incorporate relevant PK parameters (e.g. 𝐶𝐿, 𝑉) describe the concentration-
time course of the drug in a standard individual that is representative of the 
population (i.e. population level prediction). This is known as structural model, 
which is defined by the fixed effects parameters. Fixed effects parameters also 
include covariate effects (if present) that extend the structural model 
predictions from population level to individual level by accounting for BSVP. 
However, concentration-time profiles of most individual participants in the 
study deviate from the predictions by the fixed effects parameters. In order to 
extend the model predictions to individual observations, random effects 
models are added to the structural model in a hierarchical manner [34]. 
The random effects models represent the stochastic components of the 
population PK model which usually represent a two stage hierarchy, viz., 
between-subject variability model (BSVR) and residual unexplained variability 
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(RUV) model. The BSVR model defines the distribution of the deviations of the 
individual PK parameters from their corresponding population values (after 
considering covariates). The RUV model is added which accounts for the 
differences of the predicted individual concentrations from the observations, 
i.e. intra-individual variation between the repeated measures. Such modelling 
approach is known as nonlinear mixed effects modelling (NLME) [35-37] that has 
different levels of hierarchy. Therefore, NLME modelling is basically a 
‘pharmaco-statistical’ modelling framework where the structural model 
describes the pharmacology (here PK) of the drug that is accompanied by 
additional statistical models to describe the variation in the PK and individual 
observations. This makes NLME a powerful approach in predicting drug 
response at individual level in the population, providing the opportunity to 
adjust the dose based on patients’ need.   
1.1.8.1.2. Hierarchical models 
A one compartment PK model with intravenous (IV) bolus input can be 
used for illustration purpose. The time course of the drug following 








Eq 1.18 A one compartment PK model with intravenous (IV) bolus input 
 
In two stage hierarchical modelling, this model in Eq 1.18 with two 
parameters (p = 2) is expressed as Eq 1.19 to describe the predictions by a 
function 𝑓, where ?̂?𝑖𝑗 refers to the model predicted concentration of the drug in 
the 𝑖 th individual at 𝑗 th observation, 𝝋𝒊  represents the vector (p × 1)  of 
individual PK parameters in the 𝑖th individual, and 𝒙𝒊𝒋 represents the vector of 
design variables like dose (𝐷 ) and time ( 𝑡 ) for 𝑗 th observation in the 𝑖 th 
individual. Here, a bold face notation indicates a vector or matrix.  
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?̂?𝑖𝑗 = 𝑓(𝒙𝒊𝒋, 𝝋𝒊) 
Eq 1.19 General model for individual level prediction of observations in two 
stage hierarchical modelling 
 
The observed concentrations (𝑌𝑖𝑗,𝑜𝑏𝑠) differ from the predicted ones (?̂?𝑖𝑗) 
by a residual unexplained error (RUV). The RUV model can be an additive (Eq 
1.20) or multiplicative (Eq 1.21) error model or a combined error model (Eq 
1.22). The additive error 𝜖𝑖𝑗𝑎𝑑𝑑 and the multiplicative error  𝜖𝑖𝑗𝑝𝑟𝑜𝑝 are assumed 
to be normally and log-normally distributed around a mean of zero and a 
variance-covariance matrix 𝚺 , where 𝜎𝑎𝑑𝑑  and 𝜎𝑝𝑟𝑜𝑝  represent their standard 
deviations respectively. An additive error model assumes a constant error for 
the entire range of observations. A multiplicative model assumes a constant 
coefficient of variation (CV) and implies a proportional error with respect to the 
observations. Further, combined error model assumes an additive type error in 
the lower observations but proportional error at larger values of observations. 
Typically the combined error model well suits the PK models and the additive 
errors mostly fits in the PD models [35, 38].    
𝑌𝑖𝑗,𝑜𝑏𝑠 = ?̂?𝑖𝑗 + 𝜖𝑖𝑗𝑎𝑑𝑑 
Eq 1.20 Additive residual unexplained error (RUV) model 
𝑌𝑖𝑗,𝑜𝑏𝑠 = ?̂?𝑖𝑗. 𝑒
𝜖𝑖𝑗𝑝𝑟𝑜𝑝 
Eq 1.21 Multiplicative residual unexplained error (RUV) model 
𝑌𝑖𝑗,𝑜𝑏𝑠 = ?̂?𝑖𝑗. 𝑒
𝜖𝑖𝑗𝑝𝑟𝑜𝑝 + 𝜖𝑖𝑗𝑎𝑑𝑑 
Eq 1.22 Combined residual unexplained error (RUV) model 
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In the second stage of hierarchy, the individual parameters (𝝋𝒊 ) are 
defined by a function 𝑔 Eq 1.23, where 𝜽  is a vector (p × 1) of population mean 
parameters, 𝒁𝒊 is a scaler or vector of covariate(s), and 𝜼𝒊 is a vector (p × 1) of 
random errors that represent the differences between the 𝑖 th individual’s 
parameter values 𝝋𝒊  from the population mean parameter values 𝜽 . The 
random error 𝜼𝒊 is assumed to be log-normally distributed around a mean of 
zero and a variance-covariance matrix 𝛀 , where 𝜔𝐶𝐿  and 𝜔𝑉  represent the 
standard deviations of the 𝜼𝒊  distributions for the parameters 𝐶𝐿  and 𝑉 
respectively. 
𝝋𝒊 = 𝑔(𝜽, 𝒁𝒋, 𝜼𝒊) 
Eq 1.23 General model for individual level prediction of parameters in two 
stage hierarchical modelling 







In non-linear regression, the parameters are estimated by an iterative 
process due to unavailability of analytical solutions through approximations 
[39]. The idea of using NLME modelling in clinical pharmacology was conceived 
by Dr Lewis Sheiner and Dr Stuart Beal at University of California, San 
Francisco and was implemented by developing the software NONMEM [40, 41]. 
They used a maximum likelihood estimation (MLE) based estimation method 
that used a first-order Taylor approximation to linearise the model around the 
mean value of 𝜼𝒊 [42-44]. This means during a step of search for a combination of 
parameters, all individuals have the same parameter values. This method is 
known as ‘first-order approximation’ (FO) method, which was implemented in 
the earlier versions of NONMEM. However, an advanced version of the 
approximation, i.e. ‘first-order conditional estimation’ (FOCE), has been 
successively implemented in the latter versions of NONMEM.  
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The MLE approach in FO method calculates the likelihood function of the 
𝑗 th observation in the 𝑖 th individual (𝐿𝑖𝑗 ) as shown in Eq 1.24, where 𝜎𝑗
2 
represents the variance of the 𝑗 th observation. Therefore, the likelihood (or 
probability) of all the ni number of repeated observations in the 𝑖th individual 
(𝐿𝑖) is the product of the likelihoods of the individual observations (𝐿𝑗) as per 
Eq 1.25. Further, 𝐿𝑖 can be rearranged to be represented as Eq 1.26. From there, 
























Eq 1.25 Likelihood of the 𝒊th individual 
𝐿𝑖 = ∏(2𝜋. 𝜎𝑗
2)−
1









Eq 1.26 Likelihood of the 𝒊th individual (rearranged) 









Eq 1.27 Equation for minus two times of log-likelihood (-2LL) in 𝒊 th 
individual 
Since the first term of Eq 1.27 is a constant, minimisation of the second 
term would maximise the likelihood 𝐿𝑖 in the individual. Therefore, NONMEM 
minimises the value of the second term in the right hand side of Eq 1.27, which 
is known as objective function (𝑂𝐵𝐽). Further, assuming the variance 𝜎𝑗
2  is 
constant which is denoted by 𝜎2, the 𝑂𝐵𝐽 for the 𝑖th subject (𝑂𝐵𝐽𝑖) can be written 
as Eq 1.28. The overall 𝑂𝐵𝐽 of the dataset is the summation of 𝑂𝐵𝐽𝑖 for all 𝑁 
individuals (Eq 1.29). Therefore, 𝑂𝐵𝐽 depends on the squared error ((𝑌𝑖𝑗,𝑜𝑏𝑠 −
?̂?𝑖𝑗)
2
) weighted by the inverse of the variance 𝜎2. This means that a lower value 
of the 𝑂𝐵𝐽 reflects a better model fit.   
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Eq 1.29 Calculation of overall NONMEM objective function (𝑶𝑩𝑱) in FO  
 
In FOCE method [45], NONMEM primarily estimates the population 
parameters (θ) while it also estimates the empirical Bayes estimate (EBE) of the 
random variable 𝜼𝒊 . Therefore, NONMEM has two objective functions to 
minimise under FOCE: one for the parameters (θ), and the other for the EBEs 
(𝜼𝒊). The overall objective function for the 𝑖th individual with total 𝑝 number of 
parameters ( 𝑘 = 1. . p ) is the summation of these two different objective 
functions, where 𝜃𝑖𝑘  refers to the 𝑘 th parameter in the 𝑖 th individual, 𝜃𝑘,𝑝𝑜𝑝 
refers to the population estimate of the 𝑘 th parameter and 𝜔𝑘
2  refers to the 














Eq 1.30 Calculation of individual NONMEM objective function (𝑶𝑩𝑱𝒊) in 
FOCE 
 
1.1.8.1.4. Covariate screening 
Broadly, two types of covariate selection approaches have been discussed 
in the literature, viz. manual and automated [46-48]. In the manual selection 
approach, the modeller can control the selection of covariates based on the a 
priori knowledge; however, automated process incorporates the covariate(s) 
based on an algorithm. There is no consensus among the pharmacometrics 
community regarding the best method of covariate modelling. A common way 
is to look for correlation between the empirical Bayes estimates (EBEs) of the 
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base model vs. the available patient characteristics (e.g. body weight, age) [49, 50]. 
The EBEs refer to the 𝜂𝑖  values that define the individual deviations of the 
parameter of interest. Therefore, observation of a reasonable correlation 
between EBEs of a parameter and a particular characteristic indicates a possible 
covariate effect on the parameter. This can be further confirmed if 
incorporation of the particular characteristic in the model (i.e. covariate model) 
eliminates the correlation. A more definitive way is to look for statistical 
significance followed by biological and clinical relevance [51, 52].  
1.1.8.1.4.1. Covariate identification 
A covariate needs to qualify a series of criteria to be incorporated into the 
population PK model.  
Statistical significance: Successful identification of covariate(s) significantly 
drops the 𝑂𝐵𝐽 value that should also accompany the decrease in BSV of the 
parameter of interest and should be additionally guided by other diagnostics as 
appropriate [53]. These diagnostics primarily include graphical diagnostics such 
as goodness-of-fit plots (and/or residual based plots), but may include 
simulation based diagnostics as well, such as visual predictive check (VPC) 
with appropriate stratifications (e.g. age group, BMI group) as needed, whereas 
every diagnostic tool has its own limitation [54]. For example, EBE based 
diagnostics can become misleading in uninformative datasets due to the 
presence of η_i and/or ϵ-shrinkage (>20-30%) as shown by Savic and Karlsson 
[49]. A covariate should cause significant improvement in the overall model fit. 
In NONMEM, the extent of model fit is usually assessed by the 𝑂𝐵𝐽. The lower 
the 𝑂𝐵𝐽  the better is the model fit. The statistical significance of the 
improvement in model fit is usually assessed by the likelihood ratio test. In 
likelihood ratio test, it is assumed that the decrease in 𝑂𝐵𝐽 between base model 
and the covariate model (Δ𝑂𝐵𝐽) is Chi-squared distributed. For nested models, 
it is usual to set the statistical significance criteria as >3.84 points drop in the 
Δ𝑂𝐵𝐽  (for one additional parameter in the covariate model than the base 
model). This corresponds to a statistical p-value <0.05. For non-nested models, 
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other criteria such as the Akaike Information Criteria (AIC) [55] can be applied. 
AIC was developed on the concept of K-L information (Kullback-Leibler 
information) that quantifies the “distance” between the full reality and a 
model. Akaike found a formal relationship between the relative K-L distance 
and likelihood theory. He found that the maximized log-likelihood (  ) value 
was a biased estimate of relative K-L distance, but this bias was approximately 
equal to 𝐩, the number of estimable parameters in the approximating model. 
Therefore, Akaike found an estimator of relative K-L distance is approximately 
equal to (𝐿𝐿 − 𝑝) . AIC refers to -2 times of the relative K-L distance that 
becomes equal to (𝑂𝐵𝐽 + 2p). These criteria allow non-nested models having 
different number of parameters to be compared between each other by adding 
a penalty for the number of parameters (p).  
Ribbing et al. [56] have highlighted that the main problem of choosing 
covariates based on statistical significance is selection bias. Selection bias refers 
to a higher covariate coefficient than its true value (i.e. effect size) when the 
respective covariate is statistically selected in the model. Selection bias can 
originate from two sources, viz. competition bias and stopping rule bias. 
Competition bias occurs when a covariate is selected from a pool of multiple 
correlated covariates that compete with each other for the parameter of interest. 
Although the overall contribution of competition bias on the selection bias is 
marginal, the presence of highly correlated covariates carries the risk of 
incorporating a false covariate in the model. This has been shown in the context 
of competition between total body weight and fat-free mass (highly correlated) 
as the covariate of clearance [57]. The majority of the selection bias comes from 
the stopping rule bias. Stopping rule is defined as the statistical significance 
criteria (e.g. p <0.05) that has been traditionally used to conclude the success 
(or failure) of a clinical trial based on the clinical end point. It has been 
previously shown that decisions made with such stopping rule can inflate the 
effect size of the trial [58]. Similar influence has been observed in covariate 
selection also, where the stricter the stopping rule criteria (e.g. p <0.05 vs. p 
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<0.01) the larger the selection bias would be. Stopping rule bias is particularly 
evident in low powered clinical studies.  
By classical definition, power is the probability of not getting a type-II 
error (1 − 𝛽 ). For the context of covariate modelling, power refers to the 
probability that a true covariate is selected in the model when the covariate is 
chosen based on such stopping rule. The weaker the effect of a covariate (i.e. 
small effect size) the higher is the power required to incorporate the covariate 
in the model. Therefore, under-powered studies can inflate the effect size of a 
weak covariate if a strict stopping rule is applied. Similar inflation of effect size 
can occur for latent covariates whose data-type and distribution are not known 
a priori [59]. Because of this, population PK-PD studies need to be adequately 
powered if covariate identification is done by statistical significance. 
Otherwise, a biased covariate model would be incorporated that would 
compromise the predictive performance of the model during model 
extrapolation. Therefore, covariate identification must be justified by 
supporting evidence from biological perspective. 
Biological plausibility: Apart from statistical significance, selection of a 
covariate must be justified by relevant biological information. For example, 
body size is known to directly (positively) influence drug clearance [60, 61] under 
normal body size and physiological range (obesity often confounds this 
positive influence). Therefore, the coefficient (i.e. effect size) of the covariate 
model is expected to be positive when body size descriptors are included as 
covariate; a negative estimate of the coefficient, if appeared statistically 
significant, should be rejected unless there is prior biological justification. In 
realty, clearance of many drugs may not be affected by obesity, such as 
midazolam, lidocaine, propranolol, verapamil or even, can be negatively 
influenced by obesity, such as triazolam [62]. This implies that the exponent can 
be of any value from negative to positive range (including zero); which needs 
to be appropriately justified by biology before accepting the estimated value. 
Further, the selection of the right body size descriptor (e.g. total body weight or 
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fat-free mass or body surface area) should be guided by appropriate biological 
justification. It is often hypothesised that fat-free mass is better correlated with 
clearance than total body weight [25] based on the fact that clearing organs 
increase in their size and/or capacity (that drive clearance) according to the 
change in fat-free mass. In spite of the known biology, 𝐹𝐹𝑀  may not be 
statistically selected as the covariate on clearance in competition with 𝑊𝑇, if the 
study design is not appropriate as shown by Han et al. [57]. Sometimes, 
biological plausibility can help preselect the covariates and incorporate in the 
base model from the beginning. For example, creatinine clearance is often an a 
priori covariate when modelling drugs that are renally eliminated.  
Clinical relevance: In addition to the above criteria, the selected covariate 
needs to change the parameter of interest to substantial extent which could be 
clinically relevant to necessitate a dose adjustment [63]. An arbitrarily criteria of 
more than ±20% change in the parameter value within the inter-quartile range 
of the covariate is often considered relevant for dose adjustment purpose. A 
covariate that fails to influence the parameter to alter more than 20% (from its 
standard value) across its range in the population may not be meaningful for 
incorporation in the population PK model. On the other hand, a poor study 
design (e.g. narrow range) may lead to exclusion of a clinically relevant 
covariate due to lack of statistical significance. This has been shown for the case 
of enoxaparin [52] where the extent excreted (by kidney) unchanged is known to 
be 80%. However, a few clinical studies failed to identify creatinine clearance as 
the covariate of enoxaparin clearance due to inappropriate trial design. 
1.1.9. Body size as covariate of clearance 
The most commonly identified covariate of 𝐶𝐿  is body size. This is 
because the key physiological/anatomical variables that drive 𝐶𝐿 are known to 
vary with variation in body size. These variables are typically the size [64] and 
perfusion [65, 66] of the clearing organs, i.e. liver and kidney.    
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The change in 𝐶𝐿 in an individual (from the population standard) can be 
broadly expressed by Eq 1.31 [61]. The individual clearance (𝐶𝑙𝑖) is the product 
of the population average (𝐶𝐿𝑠𝑡𝑑) and the three factors for maturation (𝐹𝑚𝑎𝑡), 
organ function (𝐹𝑓𝑢𝑛𝑐), and body size (𝐹𝑠𝑖𝑧𝑒). 
𝐶𝑙𝑖 = 𝐶𝐿𝑠𝑡𝑑 . 𝐹𝑚𝑎𝑡 . 𝐹𝑓𝑢𝑛. 𝐹𝑠𝑖𝑧𝑒 
Eq 1.31 General equation of expressing change in the individual clearance 
from the population standard 
 
The factor 𝐹𝑚𝑎𝑡  defines the maturational stage of drug elimination 
pathway(s) (i.e. ontogeny [67, 68]) in children. This is required since the 
physiological variables that are responsible for drug elimination (e.g. CYP 
expression or GFR) are not fully mature during childhood [61, 69]. So, for scaling 
for an adult the value of 𝐹𝑚𝑎𝑡 equals to 1.  
The factor 𝐹𝑓𝑢𝑛𝑐  refers to the functional status of clearing organs, i.e. 
kidney and liver. Organ function can be impaired by various pathological 
conditions that can exist within the organ (e.g. cirrhosis) or outside the organ 
(e.g. diabetes/obesity induced renal impairment) as well. Similarly, for scaling 
for an adult with a normal organ function the value of 𝐹𝑓𝑢𝑛  would be 1. 
Therefore, 𝐹𝑠𝑖𝑧𝑒 remains the sole factor that plays a key role in scaling 𝐶𝐿 in 
adults whose organs are expected to function normally. 𝐹𝑠𝑖𝑧𝑒  defines the 
influence of the change in the body size of an individual (𝑊𝑇𝑖 ) from the 
standard body size in the population (𝑊𝑇𝑠𝑡𝑑).   
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1.1.9.1. Scope of body size based dose scaling 
The common target populations that are vulnerable to body size related 
change in drug PK are obese patients and children. Therefore, these two 
populations are subject to consideration for body size based dose adjustment.  
1.1.9.1.1. Obese patients 
Obesity has reached an epidemic proportion not only in Western societies 
but also in other parts of the world [70, 71]. Obesity refers to excessive adiposity 
in the body, defined as body mass index over 30 kg /m2 [72]. Obesity co-exists 
with a range of co-morbidities which include: diabetes mellitus, cardiovascular 
disease, and hepatic and renal impairment [73]. Therefore clinicians are facing 
increasing number of obese patients in the clinic. Obese patients with no 
evidence of organ impairment often require higher maintenance drug doses 
than their non-obese counterparts. However, dosing guidelines for obese 
patients are often lacking since obese individuals are usually excluded from 
clinical trials during standard drug development [24]. Therefore, drug dose 
adjustments in obese patients are a common problem that is usually 
encountered in the post-approval stage.  
However, some therapeutic areas require obese patients to be studied 
during the drug development stages. Such drug development programmes 
either directly target obesity as the primary therapeutic indication [74] or other 
therapeutic areas that are highly associated with obesity (e.g. 
hypercholesterolaemia [75]). A recent example of the latter case is non-alcoholic 
fatty liver disease (NASH) where more than ten drug candidates are currently 
in clinical development [76]. 
NASH is an advanced fibrotic and/or inflammatory stage of non-
alcoholic fatty liver disease (NAFLD) that causes accumulation of substantial 
amount of intracellular fat in the liver (steatosis) [77, 78]. Currently, NASH 
severity is diagnosed through liver biopsy which is an invasive procedure, 
whereas liver fat measurement can be made by non-invasive imaging 
                                                                                                                                       Introduction 
32  
 
techniques such as magnetic resonance imaging (MRI) [79, 80]. It has been 
reported that more than 80% of NASH patients are obese [78]. Current FDA 
guidance [81] for NASH drug development specifically recommends not to 
conduct extensive efficacy study directly in biopsy-confirmed NASH patients; 
instead a prior proof-of-concept study (Phase-IIa) in high risk patients (i.e. 
obese) is recommended. As per the guidance, only drugs that have 
demonstrated significant reduction of liver fat in the proof-of-concept study 
should be taken in Phase-IIb, where biopsy confirmed NASH patients can be 
studied. This indicates a new scope for dose translation from standard adults 
(First-in-human) to obese patients (Phase-IIa onwards) in drug development 
programmes. 
1.1.9.1.2. Paediatric patients 
Similar to the obese population, there has been a scarcity of clinical trials 
in paediatric populations as part of routine drug development. This is mostly 
because of ethical and logistical challenges typically encountered while 
conducting clinical studies in this special population and to some extent lack of 
financial incentive among pharmaceutical companies [82]. As a result, use of 
drugs in children has largely remained ‘off-label’ [82, 83], which makes drug dose 
adjustments in children challenging. 
Maturation in the drug elimination mechanisms (i.e. ontogeny), in 
addition to body size and composition, are key considerations in paediatric 
dose selection. Failure to understand age-dependent maturation processes has 
resulted in serious adverse events in children in the past [84]. This has 
necessitated enactment of legislation in the Unites States of America (e.g. Best 
Pharmaceutical for Children Act 2002) and in Europe (Paediatric Regulation 
2007) to minimise off-label use of drugs in children, thereby ensuring safe and 
effective therapy in this vulnerable group of patients [85-87]. These new laws 
have made paediatric clinical trials mandatory for new drug development 
programmes if the targeted population of the drug includes children. 
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As a result of this paediatric research initiative, a number of paediatric 
trials have been carried out in the USA by the pharmaceutical industries and 
the National Institute of Health (NIH); a total of 778 paediatric labelling 
changes have been made from February 1998 to March, 2019 due to this 
campaign [88]. Since these legislations also have the provision for allowing 
additional market exclusivity right (6 extra months) [89], pharmaceutical 
companies are incentivised to carry out more paediatric drug development 
studies. Unlike first-in-human (FIH) studies in adults, where the primary 
concern is safety (not necessarily efficacy), the first-in-children (FIC) studies 
need to demonstrate both safety and efficacy, since healthy children are not 
studied for ethical reasons [90]. This makes the FIC dose finding challenging. 
Therefore, significant research opportunities exist in this area.   
1.1.9.2. Descriptors of body size 
Conventionally, total body weight (𝑊𝑇) has been used as the descriptor of 
body size and 𝐹𝑠𝑖𝑧𝑒 (see Eq 1.31) is calculated as the ratio of individual body 
weight (𝑊𝑇𝑖)  to standard body weight in the population ( 𝑊𝑇𝑠𝑡𝑑) . This 
corresponds to the ‘mg per kilogram’ dosing scheme that is commonly found in 
drug labels [25]. The choice of 𝑊𝑇  has become universal in clinical practice 
primarily because of its ease of measurement. However, there are other 
alternative size descriptors [91], e.g. body surface area (𝐵𝑆𝐴) , fat-free mass 
(𝐹𝐹𝑀) , ideal body weight (𝐼𝐵𝑊) , predicted normal weight (𝑃𝑁𝑊𝑇) , and 
adjusted body weight (𝐴𝐵𝑊) that may be more suitable to use in the obese. 
Among the alternative size descriptors, 𝐹𝐹𝑀 has gained considerable interest 
because of its relevance to pharmacokinetics. 
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1.1.9.2.1. Total body weight 
In the conventional ‘mg per kilogram’ system, the approved (adult) dose 
is multiplied by the ratio 𝑊𝑇𝑖/𝑊𝑇𝑠𝑡𝑑 where 𝑊𝑇𝑠𝑡𝑑 is often used as 70 kg [69]. 
This ‘mg per kilogram’ method assumes that drug clearance is proportional to 
𝑊𝑇 and the dose proportionally scales with 𝐶𝐿. However, this method tends to 
over dose obese patients that confounds the assumption.  
It is generally hypothesised that 𝐶𝐿  increases with 𝑊𝑇  less than 
proportionally. This was supported by the observed relationship between basal 
metabolic rate (BMR) and 𝑊𝑇 across multiple species. Thus a similar non-linear 
relationship has been adopted for scaling 𝐶𝐿 by 𝑊𝑇 where the population 𝐶𝐿 
(𝐶𝐿𝑠𝑡𝑑) is centred at 𝑊𝑇𝑠𝑡𝑑, and is popularly known as allometric scaling (Eq 
1.32). The underlying assumption of 𝑎𝑙𝑙𝑜𝑚𝑒𝑡𝑟𝑖𝑐 scaling is that 𝐶𝐿 (a parameter 
that describes the drug elimination capacity) is proportional to BMR. The term 
𝐸𝑥𝑝 refers to the exponent that describes the shape of the non-linearity. A value 
less than one for the exponent indicates a less than proportional scaling of 𝐶𝐿 to 
𝑊𝑇. 






Eq 1.32 Allometric scaling of clearance by total body weight 
 
Although allometric scaling has been extensively used in both inter- and 
intra-species (i.e. human population) scaling of 𝐶𝐿 there is no consensus on the 
value of the exponent. Some researchers propose use of universal fixed values 
of the exponent that were historically observed in the BMR vs. 𝑊𝑇 relationship 
across species. Those observed values were 2/3 [92] and 3/4 [93]. Scaling by 
𝑊𝑇2/3  is equivalent to scaling by 𝐵𝑆𝐴  which is commonly used in dose 
selection in oncology. For scaling by 𝑊𝑇3/4 , a theoretical framework was 
proposed by West et al. [94] by conducting a fractal analysis of the human 
vasculature from where the transport of essential materials takes place. Because 
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of this theoretical support, the use of 3/4 exponent has become ubiquitous in 
pharmacology. 
However, other researchers do not agree with the existence of a universal 
value of the exponent that scales 𝐶𝐿 to 𝑊𝑇. It is proposed that the value of the 
exponent depends on the data, i.e. empirical, hence “let the data speak” 
approach should be followed to determine the exponent [95]. Recently, It has 
been shown that the exponent can have a range of values for both inter- and 
intra-species scaling of 𝐶𝐿  [96, 97]. For intra-species scaling, the value of the 
exponent ranged from 0.5 to 1.2 [97]. A more detailed description of the origin of 
these exponent values and a brief account of the current conflict has been given 
in Chapter 2: . The presence of two different schools of thoughts around the 
value of the scaling exponent creates confusion among the 
pharmacometricians. Amidst this ongoing debate, it is currently unknown 
which method is likely to give the true exponent value.  
Determining the true exponent value is critical in covariate model 
development, since it defines the effect of the covariate on the fixed effects (e.g. 
𝐶𝐿 prediction). A falsely chosen exponent or a biased estimate of the exponent 
potentially cause bias in the estimation of 𝐶𝐿 when extrapolated outside the 
range of the population that was used to develop the model. For example, if the 
covariate model was developed in the standard adult 𝑊𝑇  range, a wrong 
exponent value (either chosen from the set of fixed values or estimated 
empirically) can result in biased 𝐶𝐿 prediction in children and obese adults 
who are the two extremes of the 𝑊𝑇 range. This has been shown in Figure 1.6 
where 𝐶𝐿 values were simulated across the range of the population from an 
arbitrarily chosen 𝐶𝐿𝑠𝑡𝑑  of 70 mL/min. Simulations were conducted 
considering the whole range of plausible exponent values (i.e. 0.5, 0.67, 0.75, 1, 
1.2) as found in the literature. It clearly demonstrates that the predictions do 
not deviate significantly around the standard body weight of 70 kg. However, 
the deviations are evident at the two extremes of 𝑊𝑇  range. As per the 
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simulation range (𝑊𝑇: 10-210 kg), the deviations can be as high as 2-fold in 
obese and 4-fold in children.  
 
 
Figure 1.6 Simulation of    using allometric model with different exponent 
values. 
 
Therefore, if the purpose of the model is extrapolation of 𝐶𝐿  (e.g. 
designing first-in-children study), choosing the right exponent is the key for 
correct dose selection in the target population. In this context, a simulation-
estimation based assessment is described in Chapter 2 in order to evaluate the 
current approaches of allometric scaling for their accuracy. This analysis would 
provide specific guidance to pharmacometricians on how to choose the right 
method in the right circumstances.   
 
1.1.9.2.2. Fat-free mass 
Fat-free mass (𝐹𝐹𝑀) describes the lean component of the body excluding 
all fat and is essentially the sum of muscle mass, bones, non-adipose 
components of internal organs, and extracellular fluid and excludes fat in 
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(𝐿𝐵𝑊 ) and used as a measure of non-fat weight. However, in the same 
individual 𝐹𝐹𝑀  takes a slightly lower value than 𝐿𝐵𝑊  (2-5%) as the latter 
includes the fat in bilayer lipid membranes, CNS, and bone marrow [98, 99]. Since 
the available body composition measurement techniques are not able to 
distinguish between these intrinsic fats from the rest of the body fat it is not 
possible to experimentally measure 𝐿𝐵𝑊. In contrast, 𝐹𝐹𝑀 can be measured 
experimentally using various techniques and is used to approximate 𝐿𝐵𝑊. 
 
1.1.9.2.2.1. FFM methods 
Various experimental methods are available to measure 𝐹𝐹𝑀, e.g. bio-
impedance analysis (BIA) , dual-energy X-ray absorptiometry [100]. These 
methods are quite cumbersome to use in regular practice. Some of the common 
issues with these methods include high cost, invasiveness, lengthy procedures, 
inadequate accessibility etc.  Therefore, predictive models are developed to 
predict 𝐹𝐹𝑀  from readily measurable patient characteristics (e.g. weight, 
height, and sex). However, these methods are useful for generating 𝐹𝐹𝑀 data 
for the model development purpose. 
Measuring 𝐹𝐹𝑀  by each of these experimental methods is based on 
particular assumption(s) which may or may not be valid within and between 
populations. Because of the non-universality of these assumption(s), a 
particular method may need to be restricted for use in one particular 
population (e.g. adults) and another method to be used for other populations. 
Therefore, a systematic understanding of the available experimental methods is 
a prerequisite for their rational use in future research. In this context, a concise 
review of these methods has been written in Chapter 3. This review gives 
special emphasis on mathematical interpretation of the assumptions (and 
limitations) of these methodologies and thereby connecting them to each other 
in a common scientific framework.   
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1.1.9.2.2.2. FFM models 
In regular practice, the use of 𝐹𝐹𝑀 mostly depends on predictive models. 
Although a number of predictive models are available in the literature most of 
them were developed empirically. Empirical model development entirely relies 
on the regression of observed 𝐹𝐹𝑀 against observable patient characteristics 
such as weight, height, and sex. Therefore, such models depend on the data 
and if used outside the population that was used for their development, can 
yield erroneous predictions of 𝐹𝐹𝑀. For example, the James model for 𝐹𝐹𝑀 (Eq 
1.33, Eq 1.34) [101] was developed empirically using a limited range of body size, 
and did not include sufficiently obese patients in their study. Because of this, 
the model yields unrealistic values of 𝐹𝐹𝑀  beyond a certain body weight, 
which causes an inverted parabola like shape to the 𝐹𝐹𝑀 vs. 𝑊𝑇 plot (Figure 
1.7).  






Eq 1.33 James model for 𝑭𝑭𝑴 prediction in males 






Eq 1.34 James model for 𝑭𝑭𝑴 prediction in females 
 
Later, Janmahasatian et al. [102] developed a 𝐹𝐹𝑀  model based on the 
biological relationship between bioimpedance (𝑍) and body mass index (𝐵𝑀𝐼). 
Bioimpedance is actually the measured resistance (𝑅) of human body that is 
exerted against the flow of an high frequency AC current through the body. 
Therefore, bioimpedance indirectly reflects the body composition, i.e. 
proportions of various biomaterials that altogether cause the resistance. Such 
models that not only describe the data but also support a mechanism are more 
reliable for extrapolation purposes. Therefore, the Janmahasatian model (Eq 
1.35, Eq 1.36), since its development has been extensively used in clinical 
pharmacology studies, and is widely recommended.   





6680 + 216 × 𝐵𝑀𝐼
 




8780 + 244 × 𝐵𝑀𝐼
 
Eq 1.36 Janmahasatian model for 𝑭𝑭𝑴 prediction in females 
 
A comparative plot of the James model and the Janmahasatian model has 
been shown in Figure 1.7 where 𝐹𝐹𝑀  values were simulated using the 
corresponding models over a range of body weights. For a given value of 
height, the James model starts falling down beyond a certain weight, whereas 
the Janmahasatian model continues to produce increasing values of 𝐹𝐹𝑀. This 
phenomenon warns about the risk of using empirical models, and the need for 
mechanism based models in practice.  
 
Figure 1.7 Simulation of 𝑭𝑭𝑴  values from James model [101]  and 
Janmahasatian model [102] at different heights of 150, 160, 170, and 180 cm. 
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However, the Janmahasatian model was developed in a population 
composed primarily of individuals with a European ancestry. The biological 
assumptions made thereof may not be valid in populations of other ethnic 
origins where a large inter-ethnic variation in body composition is expected. 
For example, it is widely reported that body composition widely varies 
between Asian Indians, Europeans, and Pacific Islanders. At a given 𝐵𝑀𝐼 , 
Asian Indians have the highest percentage of body fat, while Pacific Islanders 
have the lowest body fat, with the Europeans being at the middle of the rank 
order [104]. This indicates the need for the validation of the Janmahasatian 
model in these populations. Recently, a validation study in an Indian 
population [105] has revealed that the model over-predicts 𝐹𝐹𝑀 in Indians in 
comparison with BIA-measured 𝐹𝐹𝑀  data. Therefore, there is potentially a 
need to extend the Janmahasatian model to other populations, and hence an 
extension of this model was developed in Chapter 4.  
 
1.1.9.2.2.3. Relevance of FFM in clinical pharmacology 
From a biological perspective, drug elimination exclusively takes place 
within the 𝐹𝐹𝑀 component of the body, because the clearing organs are part of 
the 𝐹𝐹𝑀. So, variation in the size and/or capacity of the eliminating organs 
(that determine 𝐶𝐿) are expected to follow the variation in 𝐹𝐹𝑀 rather than 𝑊𝑇. 
For example, it has been shown that glomerular filtration rate (GFR), which 
reflects the size and/or capacity of kidneys to eliminate drugs, varies 
proportionally with 𝐹𝐹𝑀  rather than 𝑊𝑇  between normal and obese 
individuals [65]. Therefore, it is generally hypothesised that 𝐶𝐿  is better 
correlated with 𝐹𝐹𝑀 than 𝑊𝑇 when body composition is altered along with 
size, e.g. obesity [25]. 
In an extensive review by Green and Duffull [91], it was shown that 𝐶𝐿 was 
best described by 𝐹𝐹𝑀 as compared to other available size descriptors like 𝑊𝑇, 
BSA, and IBW. The authors recommended 𝐹𝐹𝑀 -based dose scaling of 
maintenance doses in the obese. As a result of growing interest in 𝐹𝐹𝑀, as a 
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measure of body size and composition, a few researchers have validated 𝐹𝐹𝑀 
based dose scaling by clinical studies with obese patients. Ingrande et al.  [106] 
has established that the 𝐹𝐹𝑀 based dose normalisation is the best way to scale 
the dose of propofol infusion in obese patients compared to a control group. 
Similar 𝐹𝐹𝑀  based dosing recommendations were also made for other 
anaesthetics such as remifentanil [103] and dexmedetomidine [107]. 
 
1.1.9.2.2.4. Scaling by FFM 
In spite of its biological relevance in scaling 𝐶𝐿, the exact relationship 
between 𝐶𝐿  and 𝐹𝐹𝑀  remains subject to dispute. Like 𝑊𝑇 , there is no 
consensus on the scaling exponent of 𝐹𝐹𝑀. As a result, a range of values can be 
found in the literature; some being fixed a priori (e.g. 1, 0.67, 0.75) and others 
are estimated through modelling of the data. 
A recent meta-analysis of the literature was conducted by McLeay et al. 
[60] to determine the average value of the scaling exponent. Their analysis 
included 484 pharmacokinetic studies that reported a final covariate model of 
𝐶𝐿 and body size. Since they did not have access to individual level data, they 
simulated individual CL values of all drugs across the human FFM range. The 
results suggest that 𝐹𝐹𝑀 raised to an exponent of 2/3 (0.67) best described the 
data. However, their analysis was based on a pooled dataset that covered a 
range of different categories of drug disposition, e.g. hepatic and renal 
elimination, low and high extraction drugs, etc. In drug development, the 
primary goal is to develop drugs with low-hepatic extraction in order to ensure 
less dose and dosing frequency in the clinic [108, 109]. Therefore to specifically 
determine the average value of the exponent for low-extraction drugs, a model 
based meta-analysis was conducted and described in Chapter 5 using literature 
reported individual data of 𝐶𝐿 and 𝐹𝐹𝑀.  
The average value of the exponent, either in the literature or determined 
in this thesis (Chapter 5) actually refers to an empirical value, which has a 
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theoretical justification. In this context, the theoretical value of the exponent has 
been derived in Chapter 6 via modelling a new liver size descriptor, lean liver 
volume ( 𝐿𝐿𝑉 ). 𝐿𝐿𝑉  universally represents the functional size of the liver 
(devoid of any fat) that is primarily constituted by hepatocytes where drug 
elimination takes place. On the contrary, total liver volume (𝐿𝑉), which has 
been conventionally used as the liver size descriptor, is likely to over-estimate 
functional liver size in most obese patients. This is because more than 90% of 
obese patients have non-alcoholic fatty liver disease (NAFLD) that causes 
steatosis [110, 111].  
Theoretically, 𝐿𝐿𝑉 is expected to be the main driver of the variation in 
clearance (particularly for low-extraction drugs) between differently sized 
individuals where alteration in body composition is expected, e.g. obese vs. 
normal adults. Hence the 𝐿𝐿𝑉-𝐹𝐹𝑀 relationship is expected to define the 𝐶𝐿-
𝐹𝐹𝑀  relationship. A detailed description of this theoretical assumption has 
been provided in Chapter 6. 
Finally, an additional use of the 𝐿𝐿𝑉 model was explored in Chapter 7 in 
in vitro-in vivo extrapolation (IVIVE) of 𝐶𝐿 in the obese population. IVIVE based 
extrapolation of 𝐶𝐿  in the obese has been recently recommended [112-114]. 
However the current method of IVIVE uses 𝐿𝑉 as the scaler for functional liver 
size, which is likely to over-scale the 𝐶𝐿 due to presence of substantial liver fat 
in obese patients [110, 111, 115]. Here, 𝐿𝐿𝑉 is expected to scale the 𝐶𝐿 better since it 
excludes all liver fat and more accurately describe functional liver size. A 
background on the science underlying these assumptions is provided in 
Chapter 7.    
Overall, there is lack of consensus on the right exponent for scaling 
clearance (hence maintenance dose) by commonly used body size metrices, 𝑊𝑇 
and 𝐹𝐹𝑀 in traditional top-down approach of PK prediction (i.e. population PK 
modelling). More specifically, for 𝑊𝑇 based scaling, the conflict is on whether 
to fix the exponent at a plausible value (e.g. 0.75) or to estimate the value. On 
the other hand, for 𝐹𝐹𝑀 based scaling, the current conflict is whether clearance 
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linearly scales to 𝐹𝐹𝑀 nor not. For 𝐹𝐹𝑀, an additional complexity is choosing 
the correct method or model for its measurement or prediction respectively. In 
the case of the former, a concise understanding of the scientific framework of 
the available methodologies is currently lacking in the literature; and for the 
latter, a universally applicable model is currently unavailable. On the other 
hand, an alternative bottom-up approach can be implemented for scaling 
clearance in differently sized populations, e.g. obese by using IVIVE. However, 
for obese population, the currently used metric for liver size (i.e. total liver 
volume) is likely to over-predict clearance because of prevalence of non-
alcoholic fatty liver disease (NAFLD). Therefore, lean liver volume (𝐿𝐿𝑉) would 
be a more mechanistic descriptor of ‘functional’ liver size in this target 
population. However, there is currently no predictive models available for 
prediction of 𝐿𝐿𝑉 , and no assessment has been done for its predictive 
performance in IVIVE. 
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1.2. Aims of the thesis 
The overall aim of the thesis was to assess the methodologies that are 
currently being used to scale clearance (𝐶𝐿) to populations of different body 
size. The thesis has been divided into three parts as per the following: 
 
Part II: To assess scaling by body size. This part includes scaling by total body 
weight (𝑊𝑇) and was aimed to: 
(Aim 1) Assess the influence of study design (and BSV) on choosing the 
allometric exponent (Chapter 2). 
Part III: To assess scaling by body size and composition. This part includes 
scaling by fat-free mass (𝐹𝐹𝑀) and was aimed to: 
(Aim 2) Systematically review the available methods and models for 
estimating fat-free mass ( 𝐹𝐹𝑀 ) and interlinked them in a 
common scientific framework in order to understand their 
assumptions and limitations (Chapter 3). 
(Aim 3) Develop an extended version of the Janmahasatian 𝐹𝐹𝑀 model 
to extend its applicability in other ethnicities (Chapter 4). 
(Aim 4) Estimate the average value of the exponent of 𝐹𝐹𝑀 based scaling 
of clearance by conducting a model based meta-analysis of the 
literature data (Chapter 5) 
Part IV. To assess scaling by lean liver volume (𝐿𝐿𝑉), a descriptor of functional 
liver size. This involved: 
(Aim 5) Identifying the theoretical value of the allometric exponent for 
scaling 𝐶𝐿 by 𝐹𝐹𝑀, via identifying the lean liver volume (𝐿𝐿𝑉) 
vs. 𝐹𝐹𝑀 relationship (Chapter 6). 
(Aim 6) Evaluating the potential use of the lean liver volume (𝐿𝐿𝑉 ) 
model in in vitro-in vivo extrapolation (IVIVE) of clearance 




















Chapter 2:  Choosing the allometric exponent in 











This chapter is based on the following peer-reviewed publication: 
Sinha J, Al-Sallami HS, Duffull SB. Choosing the allometric exponent in covariate 
model building. Clinical Pharmacokinetics. 2019; 58(1): 89-100. 
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2.1. Introduction  
Covariate identification is an integral part of population pharmacokinetic 
modelling in order to provide dosing recommendations for subpopulation(s) 
who might otherwise be at risk of sub-therapeutic or toxic exposure [50]. 
Successful incorporation of covariate(s) therefore facilitates an understanding 
of the predictable component of between subject variability (BSV) and hence 
improves the precision of dose selection and model predictions at the 
individual level. Body size is arguably the most important covariate of 𝐶𝐿 
because of its biological and clinical relevance [61]. Total body weight (𝑊𝑇) has 
been conventionally used as the descriptor of body size. Models that link 𝐶𝐿 to 
𝑊𝑇 have a common mathematical form as shown in Eq 2.1, which has been 
discussed in section 1.1.9.2.1 of Chapter 1: .  






Eq 2.1 Scaling of clearance by total body weight (same as Eq 1.32) 
 
As per Eq 1.32 the value of the term 𝐸𝑥𝑝 (exponent) determines whether 
the scaling of 𝐶𝐿 is linear (𝐸𝑥𝑝 = 1) or non-linear (𝐸𝑥𝑝 ≠ 1) in relation to 𝑊𝑇. 
Linear scaling is often depicted in the drug label (as ‘mg/kg’ dosing) and 
commonly practised in the clinic because of its simplicity of calculation. On the 
other hand, non-linear scaling of 𝐶𝐿 is adopted from the observed non-linear 
relationship between metabolic rate and body size across various animal 
species. 
In 1880’s, Max Rubner [92] observed that the mammalian basal metabolic 
rate (BMR) was proportional to (𝑊𝑇)
2
3  which is equivalent to scaling by body 
surface area (𝐵𝑆𝐴). The 𝐸𝑥𝑝 value of 2/3 is widely used today in relation to 
oncologics and estimating GFR where normalisation by 𝐵𝑆𝐴 is common. Later 
in 1932, Max Kleiber [116] showed that the BMR values of birds and mammalian 
species, spanning 3.7 orders of magnitude, aligned with a higher exponent of 
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𝑊𝑇  which was approximately 3/4 (actually 0.737). Kleiber’s 3/4 law was 
further supported in a wider weight range, mouse-to-elephant (~5 orders of 
magnitude) by Brody [117] and mycoplasma-to-blue whale (~27 orders of 
magnitude) by West et al. [93]. A theoretical basis of 3/4 exponent was also 
postulated by West et al. [94, 118] by introducing a general model for transport of 
essential materials via a space filling fractal network of branching tubes. The 
strong biological evidence and theoretical framework supporting 3/4 has made 
it the ubiquitous rule of biology. 
In clinical pharmacology, under the assumption of a linear relationship 
between 𝐶𝐿 and BMR, this constant (𝐸𝑥𝑝) is popularly known as the allometric 
exponent and hence is widely adopted for inter-species [119-122] and intra-species 
[61] scaling of 𝐶𝐿. Debate on the value continues with the theoretical basis of 3/4 
challenged by researchers [123, 124] who claimed that mammalian metabolic rate 
is scaled by (𝑊𝑇)
2
3  rather than (𝑊𝑇)
3
4 . At this stage there remains no 
consensus over the theoretically correct value of the exponent [96, 125]. Some 
suggest, see Calvier et al. [97], that there is no universal value for this exponent 
in the population and the plausible range is 0.5 – 1.20. Hu and Hayton [96] who 
reviewed interspecies scaling of 115 xenobiotics over 3-4 species spanning four 
orders of magnitude of body weight reported a range of exponents between 
0.29 – 1.2.  
This leaves investigators with three overall approaches to solve the 
problem of scaling (1) to choose an 𝐸𝑥𝑝 value based on their belief on the 
theoretical basis of the relation of 𝐶𝐿 to 𝑊𝑇 – in this approach 𝐶𝐿 is always 
dependent on 𝑊𝑇 to the power of a pre-defined value of 𝐸𝑥𝑝  and this is not 
tested, (2) to choose a value of 𝐸𝑥𝑝 from a set of mechanistically plausible 
values e.g. 1, 3/4 or 2/3 and include the relation between 𝐶𝐿 and 𝑊𝑇 if it is 
statistically significant (similar to method 1, 𝐶𝐿  is always considered to be 
dependent on 𝑊𝑇), or (3) to estimate the value (i.e. let the data determine the 
value that best fits) as per empiricism [95, 126]. The second and third approaches 
require the investigator to have access to data that is sufficiently informative to 
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either select the correct exponent or provide an accurate and precise estimate of 
the exponent.  Certainly, if there is no strong a priori belief in the relation 
between 𝐶𝐿 and 𝑊𝑇, the empirical approach of estimation makes logical sense. 
The first approach is not considered here further as it is unaffected by 
experimental design.  The assumption that underpins the second approach is 
that a universal exponent exists and it is contained in the set of plausible values 
(i.e. is one of the elements of {2/3, 3/4, 1}). 
The work of Anderson and Holford [69] has shown that estimation, the 
third approach, can lead to an imprecise estimate of the allometric exponent in 
a regular clinical trial setting (e.g. approx. 100 patients). In their work they 
quantified the confidence interval on the exponent that, in many cases, 
included the range of 2/3 to 1.  In addition, we also see that statistical 
significance arising from low powered studies may occur because the effect 
size, by chance, is estimated to be larger than the true effect size [56, 58].  In this 
case the value of the parameter that describes the effect size will be inflated 
leading to erroneous inference from the analysis.  This has been addressed by 
Ribbing et al. [56] for covariate selection and La Caze et al. [58] in a more general 
case.  
The overall aim of this work was to evaluate the influence of BSV and 
study design on determination of the allometric exponent (𝐸𝑥𝑝), when total 
body weight has considerable influence on 𝐶𝐿. 
2.1.1. Specific objectives 
i. Objective 1: To assess the influence of between-subject variability (BSV) 
and study design on the power to select the true exponent from a set of a 
priori values. 
ii. Objective 2: To assess the influence of between subject variability (BSV) 
and study design on the power to obtain unbiased exponent estimates.   
We do not consider the precision of the estimate in this work as this has 
been adequately covered by Anderson and Holford [69].  




2.2.1. General simulation-estimation setting 
2.2.1.1. Platform 
The studies in this paper are based on a stochastic simulation 
estimation (SSE) in a non-linear mixed effects modelling framework. All 
simulations were conducted using MATLAB and estimation using 
NONMEM (version 7.2, GNU-Fortran 95 compiler) on an AMD 
OpteronTM processor (2.30 GHz) and WfN platform. The First Order 
Conditional Estimation with interaction (FOCEI) method was used for 
all estimation runs. 
In all scenarios, the nominal value of 𝐸𝑥𝑝 used for simulation (see 
Table 2.1) was considered as the true value. The specific aims were then 
assessed by comparing the estimated parameter values against the true 
value.  Simulations were conducted based on input-output (I/O) and 
covariate distribution models. No errors in trial execution were 
considered, such as patient related (e.g. dropouts) or investigator related 
(e.g. measurement error), for the simulations. 
 
2.2.1.2. I/O Model: 
Table 2.1 shows the essential components of the I/O model used for the 
simulations. A one-compartment intravenous bolus ‘unit’ model (dose = 1, 
volume = 1, half-life = 1) with linear elimination was used.  
- Fixed effect model: 𝜃1, 𝜃2, 𝜃3 represent the standard values of 𝐶𝐿, the true 
𝐸𝑥𝑝 value and volume of distribution (𝑉) of the population respectively. 𝐶𝐿𝑖 
and 𝑉𝑖  denote the individual values of 𝐶𝐿  and 𝑉 , respectively, for the 𝑖 th 
individual. 𝑡𝑗 and 𝐶𝑖𝑗 represent the time of the 𝑗th observation and the predicted 
concentration at 𝑡𝑗  for the 𝑖 th individual. Note all individuals had the same 
sampling design (see section 2.2.1.5). The covariate model for calculating 𝑇𝑉𝐶𝐿 
was as per Eq 2.1. 
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- Random effects model: Individual PK parameters, i.e. 𝐶𝐿𝑖  and 𝑉𝑖  were 
assumed to be log-normally distributed. The between-subject differences in 𝐶𝐿𝑖 
and 𝑉𝑖  were denoted by 𝜂𝑖𝐶𝐿 , 𝜂𝑖𝑉  respectively, and were considered to be 
normally distributed with their standard deviations 𝜔𝐶𝐿 , 𝜔𝑉  (where 𝛀  is the 
variance-covariance matrix). Three different levels of BSV were used for 
simulations, i.e. 𝜔𝐶𝐿 = 𝜔𝑉 = 0.2, 0.4, and 0.6  in order to mimic low (20%), 
normal (40%), and high (60%) PK variability encountered in clinical studies that 
would affect the power to different extent [127]. 
- Residual error model: A combined residual error model was used for 
simulating observed concentrations ( 𝐶𝑜𝑏𝑠,𝑖𝑗 ), where 𝑖𝑗1, 𝑖𝑗2  represent the 
proportional and additive components, respectively. The proportional and 
additive errors were normally distributed with their standard deviations 𝜎1 
and 𝜎2 respectively. The value of 𝜎1 was assumed to be 0.1 and the value of 𝜎2 
was referenced to 10% of the population predicted average concentration (𝐶𝑎𝑣𝑔) 
and considered to be constant variance (𝚺 is the variance-covariance matrix). 
 
Table 2.1 Input-output and covariate models for simulation 
















𝜃1 = ln(2) 
𝜃2 ∈ {0.67;  0.75;  1} 
𝜃3 = 𝐷 = 1 
𝑊𝑇𝑠𝑡𝑑 = 70 
𝑊𝑇𝑖 = individual weight 
𝜔𝐶𝐿 = 𝜔𝑉 ∈ {0.2; 0.4; 0.6} 
𝜎1 = 0.1 
𝜎2 = 0.1 × 𝐶𝑎𝑣𝑔 = 0.02886 
(𝐶𝑎𝑣𝑔 = 0.2886) 
𝐶𝐿𝑖 = 𝑇𝑉𝐶𝐿 × 𝑒





𝑉𝑖 = 𝜃3 × 𝑒
𝜂𝑖𝑉  
𝑖𝑗~ 𝑁(0, 𝚺) 
𝐶𝑜𝑏𝑠,𝑖𝑗 = 𝐶𝑖𝑗 × 𝑒
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2.2.1.3. Covariate distribution model 
Two different populations of non-obese individuals A and B, i.e. 
excluding and including children respectively were generated from NHANES 
III (The Third National Health and Nutrition Examination Survey,1988-1994) 
published by the CDC (Centres for Disease Control and Prevention, USA)[128]. 
Specific inclusion-exclusion criteria as mentioned in Table 2.2 were applied for 
the respective populations. This ensured plausible sets of covariates in all 
individuals.  The demographic characteristics of the covariate distributions are 
described in  
 
Table 2.2 Inclusion-exclusion criteria for generating two populations from 
NHANES database 




Adults: age ≥18, BMI: 18-30 
Children: age 3 to <18 
Adults: 𝑊𝑇 < 35 
Children: 𝑊𝑇outside 
the 5th and 95th 






BMI = body mass index in kg/m2, 𝑊𝑇 in kg, Age in years, a growth chart published by CDC 
[129] 
 
Table 2.3 Demographic characteristics of the two different populations 
Population 
Number of individuals in 
NHANES database 
Age range (year)    range (kg) 




Adults: 18 – 90 
Children: 3 to <18 
Adults: 35.1 – 109.9 
Children: 11.95 - 88 
 
  




Virtual cohorts of various sample sizes (N = 10, 20, 50, 100, 200, 500, 1000 
subjects) were generated by non-parametric bootstrap from the individual 
subjects that meet the eligibility criteria for each of the populations A and B 
mentioned in Table 2.3, using MATLAB. Stratified sampling was performed for 
population B, with even sampling under the three predefined age groups 
(years), i.e. children (3 to 12), adolescents (>12 to <18), and adults (≥18) to 
ensure an equal proportion (about one-third) of individuals in each group. The 
three age groups were selected based on the FDA and EMA guidance [86, 130], 
with the exception of the lower bound of children, normally 2 years of age was 
changed here to 3 years of age to avoid the potential influence of ontogenic 
maturation.  
2.2.1.5. Stochastic simulation-estimation scenarios 
In Table 2.4, each group ID represents a specific simulation scenario, for 
which 1000 replicate concentration-time (C-T) datasets were simulated using 
the I/O and covariate distribution models. All virtual subjects provided 
samples at 0.25, 0.5, 1, 3 and 5 hour post-dose.  
Table 2.4 Various groups representing specific simulation scenarios 
























AN 0.2, 0.4, 0.6 AIN
1 , AIIN
1 , AIIIN
1  21 
BN 0.2, 0.4, 0.6 BIN
1 , BIIN
1 , BIIIN
1  21 
a N = 10, 20, 50, 100, 200, 500, 1000; b I, II, III refer to ω = 0.2, 0.4, 0.6 respectively 
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2.2.2. Objective 1: Assessing the choice of exponent from a set of exponents 
Three values of the exponent were considered (1, 0.67, 0.75) 
corresponding to the respective theoretical values (1, 2/3, 3/4). Each of the 
exponents was set to be the true value in turn and the other two exponents 
were false values. This yields three objective function values in NONMEM for 
the 𝑖 th replicate which were determined as 𝑂𝐵𝐽𝑡𝑟𝑢𝑒 , 𝑂𝐵𝐽𝑓𝑎𝑙𝑠𝑒1 , 𝑂𝐵𝐽𝑓𝑎𝑙𝑠𝑒2  from 
which the best model would be selected based on the AIC (Akaike Information 
Criteria) [55] value and the power computed as the proportion of time the 
correct exponent was chosen (as per Eq 2.2). The number of subjects required to 
achieve an arbitrary power of 80% (𝑁80)  was interpolated to compare the 
powers of different comparisons of exponent. 
2.2.3. Objective 2: Assessing estimation of the exponent 
The true simulation value of the exponent was 𝜃2 = 0.75 for all settings 
where the exponent was estimated. Following estimation from the 𝑖th replicate, 
the respective 𝑂𝐵𝐽 values of base and covariate model (𝑂𝐵𝐽𝑏𝑎𝑠𝑒 , 𝑂𝐵𝐽𝑐𝑜𝑣) and 
estimated value of 𝜃2 (𝜃2) were recorded.  
Covariate selection criteria: The covariate model was compared with the 
base model (i.e. model without 𝑊𝑇) using the likelihood ratio test with one 
degree of freedom. A change in 𝑂𝐵𝐽  greater than 3.84 was considered 
statistically significant. 
 Power calculation: Power was calculated as the proportion of times that 
𝑊𝑇 was found to be statistically significant out of 1000 replicates (Eq 2.2), given 
that the true model included 𝑊𝑇 as a covariate.  
Bias calculation: Bias was calculated as the difference of the median 
estimated exponent (𝜃2𝑚𝑒𝑑𝑖𝑎𝑛) from the true exponent (𝜃2 = 0.75) (Eq 2.3). The 
mean estimated exponent was calculated only from the runs in which the 
covariate model was statistically preferred over the null model. 
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The workflow of the entire SSE study is presented schematically in Figure 
2.1. The MATLAB script for programming the entire SSE and the NONMEM 
files are available in section 0 to A1.5 of Appendix 1: for interested readers. 
 
Figure 2.1 Schematic of simulation-estimation workflow including 
assessment for objective 1 and objective 2 
Schematic of simulation-estimation workflow including assessment for objective 1 and 
objective 2. 𝜃2  allometric exponent, 𝜃2𝑡𝑟𝑢𝑒  true value of 𝜃2  used (0.67 or 0.75 or 1) for 
simulation and estimation; 𝜃2𝑓𝑎𝑙𝑠𝑒1and 𝜃2𝑓𝑎𝑙𝑠𝑒2  false values of 𝜃2 used for estimation (For 
𝜃2𝑡𝑟𝑢𝑒 = 0.67 , 𝜃2𝑓𝑎𝑙𝑠𝑒1 = 0.75  and 𝜃2𝑓𝑎𝑙𝑠𝑒2 = 1 ; for 𝜃2𝑡𝑟𝑢𝑒 = 0.75 , 𝜃2𝑓𝑎𝑙𝑠𝑒1 = 0.67  and 
𝜃2𝑓𝑎𝑙𝑠𝑒2 = 1 ; for 𝜃2𝑡𝑟𝑢𝑒 = 1 , 𝜃2𝑓𝑎𝑙𝑠𝑒1 = 0.75  and 𝜃2𝑓𝑎𝑙𝑠𝑒2 = 0.67 ); 𝜃2  estimate of 𝜃2 ; 
𝑂𝐵𝐽𝑡𝑟𝑢𝑒, 𝑂𝐵𝐽𝑓𝑎𝑙𝑠𝑒1 and 𝑂𝐵𝐽𝑓𝑎𝑙𝑠𝑒2 respective objective function values of the 𝑖
th replicate when 
𝜃2  is fixed at 𝜃2𝑡𝑟𝑢𝑒 , 𝜃2𝑓𝑎𝑙𝑠𝑒1  and 𝜃2𝑓𝑎𝑙𝑠𝑒2  respectively for estimation; 𝑂𝐵𝐽𝑏𝑎𝑠𝑒 , 𝑂𝐵𝐽𝑐𝑜𝑣 
objective function values of base and covariate models respectively when 𝜃2 is estimated. 
 
 






Eq 2.2 Calculation of for simulation-estimation scenarios 
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2.3.1. Objective 1: assessing choice of the exponent from a set of exponents 
The power to detect the true value of the exponent from a range of a priori 
values for various scenarios are plotted in Figure 2.2. Power depends on 
sample size, BSV, the underlying population distribution of the covariate and 
the competing false exponent. Sample size and range of the covariate 
distribution had a positive relationship with power, whereas BSV had an 
inverse relationship. Studies with a wider range of 𝑊𝑇 distribution always had 
a higher power (i.e. population B was more powerful than population A) in 
selecting the true exponent under same setting. Similarly, and as anticipated, 
within the same 𝑊𝑇 distribution at a fixed sample size and BSV, the power was 
found to depend on the relative difference in the magnitude of the competing 
exponent. For example, in Figure 2.2a, with a true exponent of 0.67 at 40% BSV, 
200 subjects resulted in ~60% power if the competing exponent was 0.75, which 
increased to ~80% if the competing value was 1. We see the values of 𝑁80 are in 
the similar range (at least not outside the two consecutive sample sizes tested) 
when the true and false values have been exchanged all other conditions being 
equal (see Table 2.5). For example, when the true coefficient is 0.67 and the false 
is 1 and vice versa, the  𝑁80  values are 170 and 150 respectively (with BSV = 
40% and population A). Hence comparisons can be simplified to a comparison 
between the absolute differences of various sets of true and false exponents.  
The range of 𝑁80 values under a certain covariate distribution gives a hint 
of clinical plausibility of choosing the correct exponent by this approach. We 
see it is almost impossible to distinguish 0.67 from 0.75 in almost any realistic 
study design for a drug with normal to high BSV (40 - 60%), even in studies 
that span children to adults (population B).  The exception is a drug with an 
unrealistically low BSV (viz 20%) where a distinction is more likely to be able to 
be seen. In contrast, linear scaling appeared mostly distinguishable from the 
non-linear scaling based models for drugs with normal BSV. 





Figure 2.2 Power vs. sample size profiles at various BSV levels and weight 
distributions. 
First (a, b), second (c, d) and third (e, f) rows of subplots represent power profiles for 𝜃2𝑡𝑟𝑢𝑒 
= 0.67, 0.75 and 1 respectively. Sub-plots in the first (a, c, e) and second (b, d, f) columns 
represent population A (normal weight adults) and B (normal weight paediatric-adults) 
respectively. Triangles, diamonds and circles represent BSV values of 20%, 40% and 60%, 
respectively. Open ( ,  ,  ) and filled ( ,   ,  ) markers under a specific shape represents 
powers when 𝜃2𝑡𝑟𝑢𝑒 is competed by 𝜃2𝑓𝑎𝑙𝑠𝑒1 and 𝜃2𝑓𝑎𝑙𝑠𝑒2  respectively at the same BSV level. 
For 𝜃2𝑡𝑟𝑢𝑒 = 0.67, 𝜃2𝑓𝑎𝑙𝑠𝑒1 is 0.75 and 𝜃2𝑓𝑎𝑙𝑠𝑒2 is 1; for 𝜃2𝑡𝑟𝑢𝑒 = 0.75, 𝜃2𝑓𝑎𝑙𝑠𝑒1 is 0.67 and 
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20% BSV  40% BSV  60% BSV 
0.67 0.75 1 
 
0.67 0.75 1 
 


















B 90 10 370 30 830 60 
1 






B 10 10 20 40 50 80 
𝑁80 values were rounded off to nearest 10’s multiple, NA not applicable 
 
2.3.2. Objective 2:  assessing estimation of the exponent 
The objective was to evaluate the influence of study design (and BSV) on 
the bias of the allometric exponent. This objective evaluated two components, 
the power of the study to correctly determine weight as a covariate and bias in 
the estimate of the exponent when weight was included as statistically 
preferred over the base model. 
The power to correctly select weight for a given sample size and covariate 
distribution is provided in Figure 2.3. In all simulations the true value of the 
exponent was arbitrarily set to 0.75 (the middle value from objective 1). A 
similar influence of BSV (inverse relationship) and range of the 𝑊𝑇 distribution 
(positive relationship) on power was observed as seen in objective 1. Although 
𝑁80  values of objective 1 are higher than those of objective 2 under an 
equivalent scenario this is not, however, a fair comparison since in objective 1 
we are determining the power to select the correct coefficient given that 𝑊𝑇 is 
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included in the model, whereas for objective 2 we are simply assessing whether 
𝑊𝑇 would be included irrespective of the estimate of the coefficient.  Therefore, 
the power calculation in objective 2 represents the power to answer a simpler 
question.  However, even for objective 2 this difference becomes minimal as the 
range of covariate distribution increases and BSV decreases, since both 
approaches become similarly powered under these circumstances. The 𝑁80 
value in the worst case situation (i.e. normal 𝑊𝑇 adult and 60% BSV) was 
approximately 200 (from Table 2.6). Most importantly, estimation of the 
exponent risks bias in the estimate of the exponent for underpowered studies. 
This bias is explored in Figure 2.4, where underpowered designs led to bias in 
the estimate of the exponent compared to the true value. For example, 
estimation with population A (normal weight adults) resulted in an 
overestimation of the exponent with a median value of 1.61 (true value = 0.75) 
with 10 subjects for normal BSV (i.e. a design that yielded 21% power). 
However, an improvement in power (87%) by increasing the sample size to 100 
subjects led to an acceptably accurate estimate (median = 0.79) of the exponent. 
It is evident that estimation bias is linked to study power, irrespective of the 
cause of the low power whether due to sample size, range of the weight 
distribution, or BSV value of clearance.  This is shown in Figure 2.5 where the 
median estimates of the exponent (expressed as % bias) are shown for all 
simulation scenarios. We observe that bias in the estimate depends on the 
study power and no further influence is seen of any of the study factors. We 
also see that the bias reaches negligible values when the power exceeds 80%.  
  




Figure 2.3 Influence of BSV on power of estimation (𝜽  𝒓  = 0.75) in two 
different populations. 
Subplots a and b represent population A (normal weight adults) and B (normal weight 
paediatric-adult subjects). Triangles ( ), circles ( ) and diamonds ( ) represent BSV values 
of 20%, 40% and 60%, respectively represent BSV values of 20%, 40% and 60%, respectively. 
 
Table 2.6 Summary of power (%) and estimate bias (%) in the scenarios 
tested 
Population N 














10 46 39 21 115 15 193 
20 73 14 31 75 18 145 
50 98 2 63 26 35 65 
100 100 0 87 5 55 27 
200 100 1 99 1 85 7 
500 100 0 100 0 100 0 
1000 100 0 100 0 100 0 
B 
10 100 0 81 8 53 27 
20 100 0 97 0 79 9 
50 100 -1 100 -1 99 -2 
100 100 -1 100 -1 100 -2 
200 100 0 100 -1 100 -1 
500 100 0 100 0 100 0 































Figure 2.4 Estimate bias (95% confidence interval) vs. sample size profiles. 
The y-axes on all subplots is the estimated 𝜃2 (𝜃2𝑡𝑟𝑢𝑒 = 0.75) and the x-axes show the sample size. The rows represent the different populations based on the 
distribution of the covariate, with the upper row being population A and the lower row the population B. The code shown above each subplot represents the 
covariate distribution and BSV (so A20 represents population A with BSV = 20%). The median ( ), 2.5
th ( ) and 97.5th percentiles ( ) of 
estimates and true exponent ( ) are plotted for total 42 scenarios The balloons above each data point represent their respective power (%) and similar 
powers are shown with the same colour. 
 




Figure 2.5 Influence of power on estimation bias of the allometric exponent 
(𝜽  𝒓  = 0.75). 
The open circles represent the median bias (%) at that power level. Bias (%) is calculated 
from each of the median estimates of all 42 scenarios described in Table 2.4. This figure 
includes simulations from all populations A (   ) and B (   ), BSV values (20%, 40% and 60%), 




There is a lack of agreement amongst researchers in clinical pharmacology 
regarding inclusion of an allometric exponent in covariate modelling. This has 
led to an ongoing debate of ‘theory’, where a value is chosen a priori, versus 
empiricism, where the exponent is estimated from the data. In this study, we 
address the ability of the study design to support theory and empiricism. 
The main findings of this work indicate that caution needs to be taken 
while building covariate models of clearance using data from regular clinical 
pharmacology studies. We are (arbitrarily) taking regular studies to involve 
<200 patients which preferentially exclude children and the typical value of 
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refer to late phase studies from phase 2b onwards. Such studies are not 
adequately powered to distinguish between choices of linear scaling (𝜃2 = 1) 
and theory based allometric scaling (𝜃2 = 0.75), and risks selection of wrong 
exponent.  The number of subjects required to achieve a power of 80% (𝑁80) 
ranged from 260 to 310 (see Table 2.5). Recruiting a wider range of weights by 
including children in the cohort increases the power of correct selection, and 
studies with less than 100 patients will be adequate to correctly determine the 
exponent, under a balanced stratified design. Further, identification of the 
correct exponent from choices of theory based allometry (𝜃2 = 0.75) and 𝐵𝑆𝐴 
based scaling (𝜃2 = 0.67) is practically impossible with any sort of regular 
study design (𝑁80 ≥ 1000 in Table 2.5). Inclusion of paediatric patients in the 
cohort (who are 3 years of age or older and therefore avoiding ontological 
issues of maturation) improves the power, but the required number of 
participants will be as high as 800. Hence, data from regularly conducted 
clinical pharmacology studies should not be relied on to correctly choose the 
exponent from a set of a priori theoretical choices. Note that even adequately 
powered study carries the risk of incorporating an incorrect exponent, since the 
true exponent can be of any value and not necessarily be limited to the set of a 
priori values tested. 
Of importance, however, is not the value of the exponent but rather how 
this affects our prediction of 𝐶𝐿 and therefore the likely dose selection and/or 
exposure. In Figure 2.6 we show the prediction error PE (%) of 𝐶𝐿 prediction 
when various false values of the exponent are chosen from a set of plausible 
values over a weight range of normal weighted individuals from ages 3 to 
adult. It is evident that false selection between 𝐵𝑆𝐴 based scaling (exponent = 
2/3) and theory based allometry (exponent = 3/4) is insignificant over the 
range of weights (i.e. within ±20% error). However, when comparing linear 
(exponent = 1) vs nonlinear (exponent = 2/3) we see significant effects on 
clearance for individuals weighing below 40 kg (the median 𝑊𝑇 of a 12 year 
old male child as per the CDC growth chart [129]). The influence on adults is 
however negligible.  This implies that power for choosing the correct a priori 
                                                                                       Choosing the allometric exponent 
64  
 
value has little importance if the purpose is to extrapolate 𝐶𝐿 within a cohort of 
adults but is of considerable importance for scaling to children, particularly 
those less than 12 years. 
 
 
Figure 2.6  Influence of an incorrect choice of an exponent on weight on the 
value of clearance and its dependence on body weight. 
The y-axis is the prediction error (PE) of clearance and the x-axis represents the weight 
range in population B, representing normal weighted subjects. The horizontal dotted lines       
(   ) represent a ± 20% difference from the true value of clearance. The plot illustrates the 
influence of false selection of the exponent value. The red line (     ), green line (    ), dashed 
red line (     ) and dashed green line (    ) represent various combinations of true and false 
exponents, i.e. true = 0.75, false = 0.67, true = 0.67, false = 0.75, true = 1, false = 0.67, and 
true = 0.67, false = 1 respectively. 
 
The alternative method explored here involved estimation of the 
exponent (as a continuous variable). We note that bias in estimating the 
exponent is evident when the power is less than 80% and hence there is a high 
risk of overestimating the true value for all studies where N < 𝑁80.  In this 
work, we show that bias in the estimate of the exponent directly depends on 
the study power and no additional variables contribute to this relation (Figure 
2.5), either intrinsic (e.g. BSV) or extrinsic (e.g. covariate distribution, sample 
size). This direct influence of study power on the bias of the parameter 
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investigated the estimation bias for a coefficient for a covariate that enters the 
model linearly. This important work highlighted the influence of low power 
and quantified bias.  In this work, we extend this consideration to parameters 
that occur in the exponent.  We believe that these parameters are inherently 
more difficult to estimate since they enter the covariate model in a nonlinear 
manner.  In this work we have also considered covariate distributions sourced 
from a database of patients that included children and adults which we hope 
will provide a robust assessment of the ability of various designs to inform the 
value of the exponent accurately and precisely. 
 The estimation approach appeared promising for typical clinical studies 
in terms of achieving required power [131-135]. It appears that a cut-off value of 
80% power is adequate in order to restrict the bias below a reasonable tolerance 
(<10%). Clinical pharmacology studies should be designed appropriately to 
achieve this level of power, if the plan is to estimate the exponent and 
potentially extrapolate the results to other cohorts. Results of objective 2 
suggest that most regular studies involving about 100 to 200 adults (resembling 
population A) are fit for the purpose of estimating the exponent reasonably (see 
40% and 60% BSV and population A in Table 2.6). For example, a sample size of 
about 100 adults would estimate the exponent to be 0.79 (true value is 0.75) 
corresponding to 5% bias in Table 2.6 considering a normal PK variability 
(40%). This much bias in the exponent is sufficient to limit the error in 𝐶𝐿 
prediction within ±3% across the body weight range of population A (35 to 110 
kg). Therefore, a minimum sample size of about 100 to 200 is needed for 
obtaining an unbiased estimate of the exponent, if only adults are included in 
the study.  
For studies that include children (typically >2 years of age to avoid 
variability due to ontogeny) the sample size requirements can be relaxed. This 
is evident from the results with population B, where about 10 to 20 participants 
with about equal proportions of children (33%), adolescent (33%) and adults 
(34%) was found to be sufficient to obtain an unbiased estimate of the 
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exponent. For example, assuming normal PK variability (40% BSV on 𝐶𝐿), 10 
study participants consisting of 3 children, 3 adolescent and 4 adults would be 
expected to provide an estimate of the exponent within 8% of the true value 
(i.e. an estimate of 0.81 assuming a true value of 0.75) (see Table 2.6). Similar to 
population A, it is anticipated that this level of bias appears to be irrelevant in 
terms of prediction of 𝐶𝐿 (within ±10%) in the studied body weight range of 
population B (12 to 110 kg). Even though low sample sizes such as 10 is 
expected to yield an imprecise estimate of the exponent (90% CI: 0.30 – 1.18) 
which is similar to the observation made by Anderson and Holford [69], it 
depends on the purpose of the study whether this is acceptable. In case an 
unbiased and appropriate precise estimate of the exponent is required, a higher 
sample size of about 50, which resembles most of the clinical studies involving 
children and adults would be required. Overall, the estimation approach 
appeared promising for typical clinical studies conducted involving adults as 
well as children in terms of achieving required power [29-33]. However, the 
sample size requirements in Table 2.6 are not directly applicable for true values 
other than 0.75. To be precise, sample size requirement will decrease if the 
‘true’ value is greater than 0.75, but if the ‘true’ values is less than 0.75, the 
sample size requirement will be higher. However, the key finding of Objective 
2 will not change, i.e. the bias vs. power profile is universal and does not 
depend on the ‘true’ value. 
We explore the influence of bias in the estimate of the exponent on 𝐶𝐿 in 
Figure 2.7. In this plot we show prediction error (PE%) of clearance for a given 
range of study powers. We assume, for the purposes of illustration that the true 
exponent was 0.75 (note any value could be chosen and illustrate the same 
trends). We simulate the PE% at four representative weights 14 kg, 40 kg, 64 kg 
and 110 kg, representing typical values of weight for a 3 years and 12 years old 
children, adult and large frame adult, respectively. It is evident that a study 
power of > 80% results in negligible bias in all patient groups, indicating that 
extrapolation of 𝐶𝐿 for these types of study is likely to be without significant 
issues.  In addition, it is apparent that for individuals that are close to the 
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weight standard value (𝑊𝑇𝑠𝑡𝑑) used in the calculation of 𝐶𝐿, the less influence 
the power has on the value of 𝐶𝐿 via estimation of the allometric exponent.  The 
larger the difference of individual body weight from standard weight however 
caused significant bias in the value of 𝐶𝐿, which was typically obvious when 
power < 70%.  In contrast to the findings for a priori selection of the exponent 
(objective 1), where under powered studies are less likely to produce an error 
in 𝐶𝐿 for patients above 12 years, the bias of the estimate of the exponent can 
potentially influence the 𝐶𝐿 extrapolation to all age groups. The influence in the 
case where the exponent is estimated depends on how far the individual is 
from the reference value for weight. For example, the influence of the bias in 
the estimate of the exponent at 30% power is <10% error in the case of a 64 kg 
individual when the reference body weight is 70 kg. However had the 
reference body weight been 10 kg then the bias of the estimate at 30% study 
power would be >93 %. In either case the issue will be seen at the extremes of 
weight with respect to the reference rate.  




Figure 2.7 Influence of study power on the prediction error in clearance, 
based on the dependence of clearance on allometrically scaled weight, where 
the exponent is estimated as part of the analysis. 
The y-axis is the prediction error (PE) of clearance and the x-axis represents the power of the 
study scenarios under objective 2 (see Table 2.4). For each value of power, four clearance PEs 
are shown, for body weights of 14 kg ( ), 40 kg ( ), 64 kg ( ) and 110 kg ( ). 
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In this work only total body weight was considered as a covariate on 𝐶𝐿; 
age and/or obesity related (patho)physiological changes that can potentially 
influence clearance were not considered. Hence, improvement in the power by 
including children (population B) purely reflects the benefit of involving a 
wider range of normal weights of participants in the study.  This, also implies 
that involving overweight and obese adults, in spite of producing a wider 
range of weight in the study may not produce similar improvement in the 
power, as seen with population B. This is because this study does not address 
the influence of body composition related changes in (patho)physiology (e.g. 
renal damage, altered enzyme/transporter activity, altered protein binding) on 
clearance, which is not well understood. However, for readers’ interest 
additional scenarios with all-comer adult population (including obese) were 
explored and can be found in section A1.1 of Appendix 1: .  In addition, an all-
comer study involving children and adults (i.e. not stratified to the FDA/EMA 
guidelines) is also provided in this additional section. 
 
2.5. Conclusions 
This study has evaluated the influence of study design on the two current 
strategies for determining the properties of allometric scaling of clearance by 
weight; (1) the power to correctly select the exponent from a set of a priori 
values and (2) the power to obtain unbiased exponent estimates. In both cases, 
there is a risk of building a misspecified model by incorporating an incorrect 
value (either a priori or by estimation) which is particularly evident in studies 
with power <80%. Misspecification of the exponent does not affect the accuracy 
of the prediction of 𝐶𝐿 within the study population, but it will lead to potential 
issues when extrapolated to new populations, e.g. from adults to children. It 
seems that a study power of 80% or more is required for model extrapolation 
purpose and this is irrespective of the method used to determine the allometric 
exponent and the covariate distribution within the study cohort. Overall, the 
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sample size requirement to achieve 80% power when estimating the exponent 
was smaller than when the exponent was chosen from a range of a priori 
choices. Clinical studies that involve only adults with at least 100 to 200 
participants or includes children (more than 2 years of age), adolescents and 
adults in equal portions with at least 50 participants (in total) appear to provide 
adequate power and precision for estimation of the exponent. If practical or 
operational constraints, such as a limited sample size or a narrow weight range, 
hinder the ability to achieve an appropriate study power then it may be 
necessary to rely on prior information about the likely value of the exponent 
rather than letting the data speak to the value. However, this will also carry a 



















Chapter 3:  A review of the methods and 
mathematical models used in the measurement 











This chapter is based on the following peer-reviewed publication: 
Sinha J, Duffull SB, Al-Sallami HS. Review of the methods and associated 
mathematical models used in the measurement of fat-free mass. Clinical 
Pharmacokinetics. 2018; 57(7): 781–795.    
  




Body size-based drug dosing which is often found in drug labelling 
typically refers to total body weight (𝑊𝑇) as the size measure. However, the 
emphasis on 𝐹𝐹𝑀 as an alternative size descriptor for dose scaling is increasing 
[24, 25, 91, 126, 136-138]. Various experimental methods are available to measure 𝐹𝐹𝑀. 
These measurements can be used to develop mathematical models to predict 
𝐹𝐹𝑀 from readily measurable patient characteristics (e.g. weight, height, and 
sex). However, measuring 𝐹𝐹𝑀 by each of these experimental methods is based 
on particular assumption(s) which may or may not be valid within and 
between populations. Because of the non-universality of these assumption(s), a 
particular method may need to be restricted for use in one particular 
population (e.g. adults) and another method used for other populations. 
Therefore, a systematic understanding of the available experimental methods is 
a prerequisite for their rational use in future research. Compared to the reviews 
already published on this topic [100, 139-143], the current review presents the 
mathematical underpinnings and assumptions associated with 𝐹𝐹𝑀 
measurement methods and the clinical implications of such assumptions. 
Therefore, the aim of this review is to provide a scientific framework for 
𝐹𝐹𝑀 determination by various measurement methods with special emphasis 
on mathematical interpretation, and to illustrate how they differ and relate to 
each other in terms of their assumptions and limitations. 
3.2. Methods for body composition analysis 
There are six distinct methods (sections 3.2.1 to 3.2.6) of body composition 
analysis which are widely used in various populations. They are densitometry, 
hydrometry, bio-impedance analysis, whole body counting, dual-energy X-ray 
absorptiometry, and medical imaging. These are built on different physical 
and/or biological principles (e.g. body density, X-ray attenuation) and 
simplified based on some key assumptions. This section describes the 
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From a body composition perspective, the human body can be divided 
into two components: fat mass (𝐹𝑀) and fat-free mass (𝐹𝐹𝑀) and thus total 
body mass (𝐵𝑀) can be expressed by Eq 3.1. 
𝐵𝑀 = 𝐹𝑀 + 𝐹𝐹𝑀  
Eq 3.1 Components of human body from body composition perspective 
 
The major portion of 𝐹𝐹𝑀 constitutes of water in addition to proteins, 
carbohydrate and minerals. Thus 𝐹𝑀  and 𝐹𝐹𝑀  are assumed to be two 
immiscible phases in the body (see Figure A2.1 in Appendix 2: ) which allows 
the volume to be summed as Eq 3.2 similar to mass in Eq 3.1. 
𝑉𝐵 = 𝑉𝐹 + 𝑉𝐹𝐹 
Eq 3.2 Components of body volume 
𝑉𝐵  denotes total body volume and 𝑉𝐹 and 𝑉𝐹𝐹  represent the volumes of fat and fat free 
components, respectively.  
 
Since volume can be expressed as mass divided by density, Eq 3.2 can be 
rewritten as Eq 3.3 below, where 𝜌BM, 𝜌FM,  and 𝜌FFM represent densities of 𝐵𝑀, 










Eq 3.3 Body volume in terms of mass and density  
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Further rearrangement of Eq 3.3 and incorporating fractional fat mass 
(𝑓FM) and fractional fat-free mass (𝑓FFM) result in Eq 3.6 below (detail derivation 
is shown in section A2.1 of Appendix 2: ). 
𝐵𝑀
𝜌𝐵𝑀
 =  
𝐵𝑀 × 𝑓𝐹𝑀
𝜌𝐹𝑀




Eq 3.4 Body volume in terms of mass, fractional mass and density 
1
𝜌𝐵𝑀
 =  
𝑓𝐹𝑀
𝜌𝐹𝑀












Eq 3.6 Equation for fractional fat mass 
 
The densities of 𝐹𝑀 and 𝐹𝐹𝑀 were derived from adipose tissue samples 
during surgery and by chemical analysis of human cadavers. Mean values were 
𝜌FM = 0.90 g/mL [144], 𝜌FFM = 1.10 g/mL [145] (detailed calculations are shown in 
sections A2.2.1 and A2.2.3 of Appendix 2: ). Using these values, Eq 3.6 can be 





 − 4.5) 
Eq 3.7 Siri's equation of body composition 
Often, body mass ( 𝐵𝑀 ) is referred to as total body weight (𝑊𝑇 ). 
Therefore, 𝐹𝐹𝑀 can be derived by measuring 𝑊𝑇 using Eq 3.8 and Eq 3.9. 
𝐹𝑀 = 𝑊𝑇 × 𝑓𝐹𝑀 
Eq 3.8 Calculation of fat mass 
 
𝐹𝐹𝑀 = 𝑊𝑇 − 𝐹𝑀 
Eq 3.9 Calculation of fat-free mass  




Using an a priori known values of 𝜌FM and 𝜌FFM, 𝐹𝐹𝑀 can be calculated by 
Eq 3.6, Eq 3.8 and Eq 3.9 if the total body density (𝜌BM) is known. Total body 
density can be determined by the ratio of 𝑊𝑇 and 𝑉𝐵 . 𝑊𝑇 can be measured 
easily using a weight machine whereas the measurement of 𝑉𝐵  is more 
involved (sections 3.2.1.2.1 and 3.2.1.2.2). Alternatively, 𝜌BM  can be directly 
predicted by anthropometric measurements as described in 3.2.1.2.3. 
3.2.1.2.1. Hydrostatic weighing 
The experimental system consists of a tank of water and a weight scale. 
The subject’s weight is taken first outside water (𝑊𝑇𝑎𝑖𝑟) followed by weighing 
under water ( 𝑊𝑇𝑤𝑎𝑡𝑒𝑟) . For 𝑊𝑇𝑤𝑎𝑡𝑒𝑟  determination, the subject exhales 
maximally, submerges completely in the water, and body weight is recorded 
on the scale. The reduction in the weight (Δ𝑊𝑇) due to underwater weighing is 
calculated by Eq 3.10.  
∆𝑊𝑇 =  𝑊𝑇𝑎𝑖𝑟 − 𝑊𝑇𝑤𝑎𝑡𝑒𝑟 
Eq 3.10 Reduction in the weight due to underwater weighing 
 
According to Archimedes' principle, Δ𝑊𝑇 is equal to the upward buoyant 
force which is exerted on the subject’s body while immersed inside the water 
and this is equal to the weight of the water displaced by the subjects’ body. 
Since the displaced water volume is equal to the total body volume of the 
subject, Δ𝑊𝑇 is equal to 𝑉𝐵 at 4
°C, the temperature at which water density is 1 
g/mL. Since, under-water weighing is carried out in water at 30°C, a water 
density correction needs to be considered at this temperature to obtain 𝜌BM (Eq 
3.11). The density of water at 30°C is 0.9957 g/mL.Residual air (𝑉𝑅) trapped in 
the lung is a significant source of error for 𝜌BM measurement by hydrostatic 
weighing and needs to be accounted for by subtracting it from the calculated 
body volume [147]. Closed circuit oxygen dilution technique is commonly used 
for measuring 𝑉𝑅. 
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Eq 3.11 Calculation of body density by underwater weighing 
 
 Hydrodensitometry can be used to measure body density with good 
precision provided that the operators are well trained. In spite of the 
consistency in body density measurement, hydrostatic weighing is not 
preferred in children, elderly, disabled and other special populations due to its 
experimental difficulties [147]. 
 
3.2.1.2.2. Air displacement plethysmography  
A relatively recent technique of air displacement plethysmography for 
measurement of body density obviates the need for underwater weighing. BOD 
POD® [148] differs from underwater weighing in that it uses air instead of water 
to measure body volume, based on the physical relationship between pressure 
and volume change in a thermally insulated system (Eq 3.12). This relationship 










Eq 3.12 Physical relationship between pressure and volume 
𝑉1 and 𝑉2 represent the respective volumes of a gas at two different pressures of 𝑃1 and 𝑃2 and 
𝛾 is a gas specific constant whose value is 1.4 for air [149] 
 
The BOD POD® device is comprised of a ‘test’ chamber and a ‘reference’ 
chamber, which are separated by a diaphragm [149]. The subject is seated in the 
test chamber and the diaphragm oscillates to produce a slight change in 
volume and, consequently, pressure in each chamber. The subject's volume is 
obtained by the difference in pressure in the presence and absence of the 
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subject in the test chamber. When the volume is increased in one of the 
chambers, it is decreased by the same amount in the other chamber, and vice 
versa. The pressure in each of the two chambers changes accordingly, and the 
magnitude of the pressure change indicates the relative size of each of the 
chambers. The pressure change is roughly ± 0.005 m H20, and is rarely 
noticeable to the subject (comparable to the change in pressure while moving 
from the first floor to the second floor in an elevator). In this method the BOD 
POD® measures the pressure change and then under ideal gas properties as per 
Eq 3.12 is able to compute the respective apparent volumes of each chamber. 
Unlike hydrostatic weighing, the subject breathes normally inside the 
instrument during experiment. But the air inside the lung (lung volume) and in 
contact with hair, clothing, and skin surface closely follows isothermal 
processes and thus is more compressible than in the rest of the test chamber 
under adiabatic condition. This leads to error in 𝑉𝐵 measurement and needs to 
be corrected for. The body density is calculated by using Eq 3.13 [149]: 
𝜌𝐵𝑀 =
𝑊𝑇
𝑉𝐵 + 0.40 × 𝑉𝐿 − 𝛿 × 𝐵𝑆𝐴
 
Eq 3.13 Calculation of body density by BOD POD 
 
Due to isothermal compression, the lung volume (𝑉𝐿) appears 40% larger 
than it is, and consequently underestimation of 𝑉𝐵  occurs by 40% of 𝑉𝐿  and 
hence added to the measured 𝑉𝐵. For this reason, 𝑉𝐿 is also determined in the 
BOD POD®. 𝑉𝐿 is determined as per usual  pulmonary function tests  [150]. The 
effect of clothing and hair is handled by wearing minimal clothing (e.g. bathing 
suit) and swim cap respectively. The effect of surface area causes 
overestimation of 𝑉𝐵  and therefore corrected by subtracting a factor called 
surface area artefact (SAA). SAA is calculated automatically by the instrument 
by multiplying subject’s body surface area (BSA, calculated by Dubois formula 
[151]) with an instrument specific constant ‘𝛿’ (L/m2). This technique overcomes 
the difficulties associated with underwater weighing. 
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3.2.1.2.3. Anthropometry (Skinfold Thickness): 
Skinfold thickness has been explored to predict body density. This 
approach is based upon two assumptions: the thickness of the subcutaneous 
adipose tissue reflects a constant proportion of total body fat and the sites 
selected for measurement represent the average thickness of the body’s 
subcutaneous adipose tissue [139]. The measurement of skinfold thickness is 
made by grasping the skin and adjacent subcutaneous tissue between the 
thumb and forefinger, shaking it gently to exclude underlying muscle, and 
pulling it away from the body just far enough to allow the jaws of the calliper 
to impinge on the skin. Multiple readings are made at each site to improve the 
accuracy and the reproducibility of the measurements. 
Jackson et al. [152, 153] proposed a generalised regression equation for males 
and females. In their work, they used a quadratic regression model over the 
sum of seven skinfold measures (chest, axilla, triceps, sub-scapula, abdomen, 
supra-iliac and front thigh) and incorporated age, waist, forearm 
circumference, and gluteal circumference as additional independent variables. 
Their predictive models are shown in Eq 3.14 and Eq 3.15. 
𝜌BM = 11010 × 10
−4 − 4.115 × 10−4 × 𝑋1 + 0.0069 × 10
−4 × (𝑋1)
2 − 2.2631
× 10−4 × 𝑋2 − 59.239 × 10
−4 × 𝑋3 + 190.632 × 10
−4 × 𝑋4 
Eq 3.14 Jackson's model for body density for males 
 
𝜌BM = 11470 × 10
−4 − 4.293 × 10−4 × 𝑋1 + 0.0065 × 10
−4 × (𝑋1)
2 − 0.9975
× 10−4 × 𝑋2 − 6.2415 × 10
−4 × 𝑋5 
Eq 3.15 Jackson's model for body density for females 
𝑋1= sum of seven skinfolds, 𝑋2= age, 𝑋3= waist circumference, 𝑋4= fore arm circumference, 
𝑋5 = gluteal circumference.  
  





In the hydrometry setting, water is assumed to constitute a constant 
fraction of 𝐹𝐹𝑀. It is, therefore, possible to estimate 𝐹𝐹𝑀 if total body water 
can be measured experimentally. Total body water (𝑇𝐵𝑊) can be measured 
either by measuring the dilution space of an isotope labelled water or of a non-
aqueous compound which freely distributes in body water. Knowing 𝑇𝐵𝑊, 
𝐹𝐹𝑀  can be calculated by Eq 3.16 using a standard value of 𝑅water/FFM =
0.73, based on the reported experimental value of 𝐹𝐹𝑀 hydration using human 
cadavers [154]. Detailed calculation of cadaver analysis is shown in section 
A2.2.2 of Appendix 2: . 




Eq 3.16 Relationship between total body water and fat-free mass 
   
3.2.2.2. Methodology: 
Various methods have been proposed to approximate 𝑇𝐵𝑊. These are 
discussed in sections 3.2.2.2.1 and 3.2.2.2.2 and calculated by Eq 3.17-Eq 3.21. 
3.2.2.2.1. Isotope dilution 
The tracers used for determination of 𝑇𝐵𝑊  are either tritiated water 
(3H2O), deuterated water (2H2O), or stable 18O-labelled water (H218O). The 
tracer is administered orally or by intravenous (IV) injection and allowed to 
equilibrate for 2-6 h depending on the tracer used and the health status of the 
subject. After equilibration a single fluid sample is taken (typically blood or 
saliva) for analysis and the urine is also collected and analysed for calibration 
purposes. The underpinning assumption is that different isotopes of water are 
indistinguishable to the body.  
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Selection of bioanalysis technique of the tracer depends upon the tracer 
used in the experiment. Tritium (3H) estimation is very easy in the biological 
sample by using scintillation counting but it emits radiation which limits its use 
particularly in children and women during pregnancy or during child bearing 
age. In contrast, non-radioactive isotopes such as 2H and 18O are safer in this 
context, but their analysis usually involves mass spectrometry (LC-MS) which 
often limits their use in clinical practice. Upon measurement of the 
concentration of tracer, the 𝑇𝐵𝑊 is then calculated using Eq 3.17, based on the 
dilution space of the tracer. 
𝑇𝐵𝑊 = 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑡𝑟𝑎𝑐𝑒𝑟 𝑖𝑛𝑔𝑒𝑠𝑡𝑒𝑑 − 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑡𝑟𝑎𝑐𝑒𝑟 𝑖𝑛 𝑢𝑟𝑖𝑛𝑒
[𝑡𝑟𝑎𝑐𝑒𝑟]𝑏𝑙𝑜𝑜𝑑 
 
Eq 3.17 Calculation of total body water by isotope dilution 
N.B. For tritium dilution, the amounts and concentration in Eq 3.17 would be replaced by radio 
activity 
 
Isotope dilution is a relatively lengthy process requiring the time to reach 
steady state, which can vary across subjects leading to potential errors. 
Typically multiple samples are taken to avoid these issues.  
3.2.2.2.2. Non-aqueous compound dilution 
𝑇𝐵𝑊 can be indirectly measured by separately measuring extracellular 
water (𝐸𝐶𝑊) and intracellular water (𝐼𝐶𝑊) and by Eq 3.18.  
𝑇𝐵𝑊 =  𝐸𝐶𝑊 +  𝐼𝐶𝑊 
Eq 3.18 Components of total body water 
 
Bromide (𝐵𝑟−) and chloride (𝐶𝑙−) are distributed primarily in the 𝐸𝐶𝑊. 
Therefore, 𝐸𝐶𝑊  is typically measured either using dilution of 𝐵𝑟−  or by 
measuring chloride space (volume of distribution). Essentially both of these 
techniques use the estimated volume of distribution of the species in question 
as the value for 𝐸𝐶𝑊. 
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𝐵𝑟− is usually administered in the form of sodium bromide (NaBr) orally 
or as an IV injection in isotonic saline. A blood sample is collected post-
equilibrium, 3-4 h later. Since 𝐵𝑟− has a long biological half-life of ~12 days, 
very insignificant amount is lost by the time of collection and hence no 
correction for the amount excreted is required. Eq 3.19 can be used to calculate 
the volume of 𝐸𝐶𝑊  ( 𝐸𝐶𝑊𝐵𝑟) using the corrected 𝐵𝑟
− dilution space. No 
correction for bioavailability is required for oral administration because of its 




× 𝛽1 × 𝛽2 × 𝛽3 
Eq 3.19 Calculation of extra-cellular water volume by bromide space 
 
The correction factors 𝛽1, 𝛽2 and 𝛽3 are fixed constants.  𝛽1 accounts for 
the limited distribution of administered 𝐵𝑟− into non-extracellular space 
(primarily erythrocytes), 𝛽2 denotes the water content (~94% ) in serum [156, 157] 
and 𝛽3 is the ratio of [𝐵𝑟
−]𝑠𝑒𝑟𝑢𝑚 to [𝐵𝑟
−]𝐸𝐶𝑊. The ratio 𝛽3 is used to correct for 
the equilibrium shift caused by the presence of charged plasma proteins in the 
intra-vascular space and was found to be similar for both 𝐵𝑟− and 𝐶𝑙−. The 
values of 𝛽1, 𝛽2 and 𝛽3 used in literature are 0.90, 0.94 and 0.95 respectively [156-
159]. 
Total body 𝐶𝑙−content (𝑇𝐵𝐶𝑙) is estimated by delayed 𝛾-neutron activation 
in order to measure the chloride space. In delayed 𝛾  -neutron activation, 
placing a subject within a neutron beam from an external source produces 
short-lived radionuclides of 𝐶𝑙−atoms in the body, which decay during the next 
~5-20 minutes by releasing a characteristic 𝛾 -ray. The count is measured by 
using thallium-doped sodium iodide (NaI[TI]) scintillator which has adequate 
energy resolution. The measured count is converted to the absolute 𝑇𝐵𝐶𝑙 
amount using calibration curve of absolute amount vs. measured count, 
prepared with prior standards having known amount of 𝐶𝑙− [100]. Eq 3.20 is 
used to calculate the 𝐸𝐶𝑊 using corrected 𝐶𝑙− space (𝐸𝐶𝑊𝐶𝑙) , which uses the 
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same correction factors as in Eq 3.19, since 𝐶𝑙− shares similar non-extracellular 




× 𝛽1 × 𝛽2 × 𝛽3 
Eq 3.20 Calculation of extra-cellular water volume by chloride space 
 
𝐼𝐶𝑊  can be quantified and distinguished from 𝐸𝐶𝑊  on the basis of 
compartment specific cation/anion patterns. Since, potassium (𝐾+) is mostly 
restricted to the intracellular space (~97%), its dilution space can give good 
approximation of 𝐼𝐶𝑊. Total body potassium (𝑇𝐵𝐾) can be measured by 40K 
whole body counting (Eq 3.28 in section 3.2.4) and 𝐼𝐶𝑊 can be estimated by 
dividing 𝑇𝐵𝐾  with intracellular 𝐾+  concentration ([𝐾+]𝑖)  using Eq 3.21. The 






Eq 3.21 Calculation of intra-cellular water volume by total body potassium 
 
3.2.3. Bio-impedance Analysis (BIA) 
3.2.3.1. Principle: 
For a solid conductor, the resistance (𝑅) is a measure of the extent to 
which the solid element opposes the flow of electrons. Body fluids are rich in 
electrolyte ions (Na+, K+ etc.), which conduct electricity and impose resistance 
(𝑅) opposite to the current flow. A direct current (DC), when applied to the 
body, only passes through the 𝐸𝐶𝑊 because of the lipid based cell membrane 
barrier which acts as insulator. In contrast, if an alternating current (AC) is 
applied, the cell membrane acts as capacitor in an electrical circuit, which 
accumulates then discharges electrical charge with each cycle of the AC 
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current. The resistance produced by the capacitor is known as reactance (𝑋𝑐) 
and is defined by Eq 3.22. 
𝑅𝑒𝑎𝑐𝑡𝑎𝑛𝑐𝑒 (𝑂ℎ𝑚) =
1
2𝜋 × 𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 (𝐻𝑧) × 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑎𝑛𝑐𝑒 (𝐹𝑎𝑟𝑎𝑑𝑠)
 
Eq 3.22 Relationship between reactance, capacitance and frequency 
 
The magnitude of reactance (𝑋𝑐) depends inversely on the frequency of 
the applied AC current, whereas resistance (𝑅) is constant across frequencies. 
The overall resistance to current flow through our body, which is known as 
(bio)-impedance (𝑍), has two components 𝑅 and 𝑋𝑐 and is defined by Eq 3.23 
[163] 
𝑍2 = 𝑅2 + 𝑋𝑐
2 
Eq 3.23 Relationship between bio-impedance, resistance and reactance 
 
At lower frequency (<5 kHz), the magnitude of 𝑋𝑐  is high and thus it 
opposes the current flow through the 𝐼𝐶𝑊. But, at higher frequency range (50-
100 kHz), the reactive component (𝑋𝑐 ) becomes negligible and thus the 
impedance (𝑍) is mainly due to the resistance (𝑍 ≈ 𝑅), which allows the current 
to flow through 𝐼𝐶𝑊 as well (Figure A2.2 of Appendix 2: ) 
 
3.2.3.2. Methodology: 
Single frequency BIA is carried out to determine 𝑇𝐵𝑊 and 𝐹𝐹𝑀, where a 
high frequency (typically 50 kHz) AC current (800 µA) is applied to a subject’s 
body by a tetra-polar BIA instrument (Figure A2.3 of Appendix 2: ). Two source 
electrodes are placed for applying current and two detection electrodes are 
placed to record the voltage drop due to impedance, a function of both 𝑅 and 
𝑋𝑐 [163-166]. Typically BIA electrodes are placed as per hand-to-foot arrangement 
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as shown in Figure A2.3, but some BIA instruments use hand-to-hand or foot-
to-foot electrode placement as well [167].  
For a cylindrical conductor (Figure 3.1) with specific resistivity 𝜑 (ohm-
cm), length 𝐿 (cm), cross-sectional area 𝐴𝑐 (cm2) and volume 𝑉𝑐 (mL), the 𝑍 or 𝑅 
are defined by Eq 3.24, from where Eq 3.25 can be derived for the solution of 𝑉𝑐.  










Eq 3.24 Resistance of a cylindrical conductor 




Eq 3.25 Calculation of volume of a conductor from its resistance 
 
 
Figure 3.1 Representation of electric current flow through cylindrical 
conductor against the resistance or impedance. 
𝐿 length, 𝐴𝑐 cross-sectional area, 𝑍 impedance, 𝑅 resistance 
 
𝑉𝑐 and 𝐿 can be imagined as the volume of 𝑇𝐵𝑊 or 𝐹𝐹𝑀 through which 
current flows exclusively and height (𝐻𝑡 ) of an individual, respectively. 
Therefore it follows that if the value of 𝑅 or 𝑍 can be determined by BIA then 
the volume of 𝑇𝐵𝑊 or 𝐹𝐹𝑀 can be estimated. If 𝑇𝐵𝑊 is estimated instead of 
𝐹𝐹𝑀, it can be used to predict 𝐹𝐹𝑀 indirectly by previously described Eq 3.16. 
Since human body does not represent a series of cylinders, an equation needs 
to be developed that links experimentally determined bio-impedance to 𝑇𝐵𝑊 
or 𝐹𝐹𝑀. This is typically accomplished by from 𝐻𝑡
2
𝑅  or 
𝐻𝑡2
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point with additional anthropometric characteristics included as required. Eq 
3.26 represents the general format of the equations for predicting 𝑇𝐵𝑊 or 𝐹𝐹𝑀 
reported commonly in the literature [163, 167, 168], where the coefficients (𝜃1,𝜃2, 𝜃3, 
𝜃4 ) and intercept ( 𝜃5 ) values are estimated. The value of a particular 
coefficient(s) could be zero if poor correlation is demonstrated.  
TBW = 𝜃1 × [
Ht2
𝑅 or 𝑍
] + 𝜃2 × [Sex] + 𝜃3 × [WT] + 𝜃4 × [Age] + 𝜃5 
Eq 3.26 General format of the equations for predicting total body water from 
bioimpedance 
 
Janmahasatian et al. [102] developed a mathematical model (Eq 3.27) for 
predicting 𝐹𝐹𝑀  directly from measured 𝑍  which obviates the need of 
predicting 𝑇𝐵𝑊. They first developed a model for predicting bio-impedance 
(?̂?) from 𝑊𝑇 and 𝐻𝑡. In the next step, they developed 𝐹𝐹𝑀 prediction model 
using the model predicted ?̂? estimates using mechanistic basis. Their model can 
be used for predicting 𝐹𝐹𝑀 directly from BIA derived 𝑍 value or from 𝑊𝑇 and 
𝐻𝑡 without BIA data. 




Eq 3.27 Janmahasatian's equation for predicting 𝑭𝑭𝑴 from bioimpedance 
𝐹𝐹𝑀 is in kg, 𝐻𝑡 is in metres and 𝑍 is in ohms.   
 
3.2.4. Whole Body Counting  
3.2.4.1. Principle: 
The whole body scans obtained from whole body radioactivity counters 
installed at nuclear plants and laboratories were found to have natural 
background signal from the body. With the development of scintillation 
detectors with adequate energy resolution, one of the naturally emitted signals 
was identified as potassium (40K). Naturally-occurring potassium contains 
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three isotopes among which the 40K isotope is radioactive and constitutes a 
very small constant proportion of potassium (93.1% 39K, 6.9% 41K, 0.0118% 40K). 
Therefore, total body potassium (𝑇𝐵𝐾) can be determined by measuring the 40K 
content in the body (Eq 3.28). A whole body scan takes 5-20 minutes using 
detectors with high energy resolution to selectively record 𝛾-rays of 1.46 MeV 
energy emitted from 40K. 
𝑇𝐵𝐾 (𝑚𝑚𝑜𝑙) =
 𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑒 𝐾 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 (𝑚𝑔)
0.000118 × 39.102 (𝑚𝑔/𝑚𝑚𝑜𝑙)
 
Eq 3.28 Measurement of total body potassium from whole body counting 
0.000118 is the mass fraction of radioactive 40K and 39.102 is the molecular weight of 
potassium. Of note here, the value of 𝑇𝐵𝐾  determined by Eq 3.28 is used in Eq 3.21 to 
calculate 𝐼𝐶𝑊. 
  
Potassium is mostly (97%) restricted to intra-cellular space which is 
exclusively present within the 𝐹𝐹𝑀 portion of the body, and therefore the 𝑇𝐵𝐾 
value can be used to estimate 𝐹𝐹𝑀 (Eq 3.29) assuming that 𝑇𝐵𝐾 constitutes a 
constant proportion of 𝐹𝐹𝑀. The standard 𝑇𝐵𝐾 to 𝐹𝐹𝑀 ratio (𝑅TBK / FFM) used in 
body composition research is 68.1 mmol/kg of 𝐹𝐹𝑀 used for both sexes [140]. 
This value was determined from human cadaver studies and discussed further 





Eq 3.29 Measurement of fat-free mass from whole body counting data 
 
𝐹𝐹𝑀 values extrapolated from 𝑇𝐵𝐾 data depend on the ratio; 𝑅TBK / FFM. 
Variations in this ratio were reported in the literature (discussed in detail in 
section A2.4 of Appendix 2: ) which suggests that this ratio is not constant 
across populations. Therefore, 𝐹𝐹𝑀 extrapolated from 𝑇𝐵𝐾 data might become 
erroneous if a universal value of 𝑅TBK / FFM is used. 
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3.2.4.2. Methodology of counting: 
The subject is placed in a supine position on the table, and scanning is 
performed through radioactivity detectors placed at anterior and posterior 
sides of the subject. The detector possesses high quality energy resolution to 
discriminate the 𝛾-rays emitted from 40K and from other naturally occurring 
radioisotopes inside body. Thallium-doped sodium iodide (NaI[TI]) scintillator 
is best suited for this purpose [169]. The counting takes 5-20 minutes depending 
upon number of detectors used. 
 
3.2.5. Dual-energy X-ray absorptiometry (DXA): 
3.2.5.1. Principle: 
The underlying concept of DXA is similar to that of the regular diagnostic 
X-ray radiography, which states that X-ray absorption in vivo is a function of 
tissue composition and X-ray wavelength. DXA employs two monochromatic 
X-ray beams i.e. a low (40 keV) and a high (70 keV) energy beam and it 
employs a photo-detector with electronic transmission to record the attenuation 
of beam intensities (Figure 3.2). DXA divides the whole human body into 
several thousands of small squares (usually 1 mm× 1 mm), known as pixel 
(about 21,000 pixels) and records the respective attenuation ratios (denoted as 
‘𝑟’ later in this section) of low to high energy beams for each of the pixels.  The 
primary objective of DXA is to solve the fractional mass of lean tissue out of the 
attenuation data from all the pixels by using mathematical approximation. The 
effective radiation dose used in DXA is about 5 times lower than that used in a 
regular diagnostic chest X-ray radiography [170] which makes it a safer way of 
studying body composition in special populations (e.g. children). This 
corresponds to an average radiation exposure that a person receives in 1-2 days 
from natural sources [171].  
 




Figure 3.2 Schematic of a pixel composed of mixture of tissue components. 
Two monochromatic X-ray beams passes through the pixel. (𝐼0)𝐿  and (𝐼0)𝐻  denote the 
intensities of low and high energy incident beams respectively. (𝐼)𝐿 𝑎𝑛𝑑 (𝐼)𝐻  denote the 
intensities of  low and high energy transmitted beams. Every pixel represents fractional masses 
and masses of a individual components, i.e. lean, fat and bone mineral 
 
 Using DXA, one assumes that the body is composed of three major 
constituents, i.e. fat, lean tissue and bone mineral, where fat and lean together 
constitute the soft tissue. Each of these tissues, being distinct in terms of 
composition, possesses a characteristic attenuation ratio (𝑟) of the 40 keV to 70 
keV intensity beams, which are known a priori. These ratios are denoted here as 
𝑟𝑓𝑎𝑡 , 𝑟𝑙𝑒𝑎𝑛 and 𝑟𝑏𝑜𝑛𝑒  for fat, lean and bone mineral respectively. Their known 
theoretical values are 1.21, 1.36 and 2.86 respectively, which were calculated by 
Pietrobelli et al. [172] using the elemental composition (e.g. C, H, O, N) of 
respective tissues and the known attenuation of each of the elements. The 
authors further estimated 𝑟𝑓𝑎𝑡 and 𝑟𝑙𝑒𝑎𝑛 to be 1.20 and 1.40 experimentally by 
using animal tissues. The observed 𝑟 values of the pixels from a DXA scan 
differs from these standard values because they are mixture of two or three of 
these standard tissues with (almost) infinite sets of fractional compositions. For 
example, if a pixel is composed of fat and lean tissue its 𝑟 value would be 
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would fall between 1.36 and 2.86. Moreover, because of infinite sets of possible 
compositions, 𝑟 values can hold any number within the specific range. 
DXA involves a two stage process (Figure 3.3). In the first stage, pixels 
related to bone mineral are separated from the non-bone pixels of a whole body 
scan. This is performed based on a threshold value of ‘𝑟’, below which non-
bone or soft tissue pixels appear. The soft tissue pixels are a two-component 
system of lean and fat tissue. The fractional mass of lean tissue in each (𝑖th) soft 
tissue pixel (𝑓𝑙𝑒𝑎𝑛𝑖) is derived from the measured 𝑟 values (𝑟ST𝑖) using Eq 3.30 
(for derivation, refer to section A2.3 of Appendix 2: ). The average fraction of 
lean tissue in the whole body’s soft tissue mass, i.e. 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇) is then determined 
by dividing the sum of all 𝑓𝑙𝑒𝑎𝑛𝑖 values by the total number (𝑁ST) of soft tissue 
pixels (Eq 3.31). 
  




Figure 3.3 Summary of DXA workflow covering various steps from whole 
body scan to FFM estimation. 
The total number of pixels generated in the whole body DXA scan is equal to the sum of 𝑁𝑆𝑇 
and 𝑁𝐵𝑀. 𝑟𝑖 attenuation ratio of the 𝑖
th pixel, 𝑟𝑆𝑇 approximated attenuation ratio of soft tissue in 
the bone mineral pixels, 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇) average fraction of lean tissue in the whole body’s soft tissue 






Eq 3.30 Calculation of fractional mass of lean tissue in soft tissue pixel in 
DXA 
  
   
Soft tissue pixels
(   )
Bone mineral pixels
( 𝑩𝑴)
Lean fraction of soft 
tissue    𝒂 𝒊
   𝒂  (  )
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Eq 3.31 Calculation of average fraction of lean tissue in the whole body’s soft 
tissue mass in DXA 
 
In the second stage, bone mineral content (𝐵𝑀𝐶) is calculated by Eq 3.32 
(for derivation, refer to section A2.3 of Appendix 2: ) using attenuations from 
the bone mineral containing pixels which remained above the threshold ‘𝑟’ 
value.  
𝐵𝑀𝐶 (𝑔)  = ∑ 𝑀𝐵𝑀𝑖(𝑔/𝑐𝑚





Eq 3.32 Calculation of bone mineral content in DXA 
𝑀𝐵𝑀𝑖 and 𝑁𝐵𝑀 represent the bone mineral areal density (g/cm
2) of the 𝑖th  pixel and the total 
number of bone mineral pixels. 
 
The bone containing pixels usually constitutes 40-45% of the total 21000 pixels 
recorded in a typical whole body DXA scan [173]. Once the 𝐵𝑀𝐶  mass is 
determined, the weight of soft tissue (𝑊𝑇𝑆𝑇) and 𝐹𝐹𝑀 can be calculated by Eq 
3.33 and Eq 3.34 respectively. 
𝑊𝑇𝑆𝑇 (𝑔) = (𝑊𝑇 − 𝐵𝑀𝐶) 
Eq 3.33 Calculation of weight of soft tissue in DXA 
 
𝐹𝐹𝑀 (𝑘𝑔) = 𝑊𝑇𝑆𝑇 (𝑘𝑔) × 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇) + 𝐵𝑀𝐶 (𝑘𝑔) 
Eq 3.34 Calculation of fat-free mass in DXA 
 
3.2.5.2. Methodology of scanning: 
For a whole body scan, the subject lies in a supine position in the centre of 
the scanning table. The X-ray source, located at the posterior position of the 
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subject emits radiation which passes through the subject’s body and is captured 
by the detector placed anteriorly. A whole body scan requires 5-30 minutes 
depending upon the instrument used. The subject must avoid movement 
during the scan.  
3.2.6. Medical Imaging 
Medical imaging is also a very useful tool in body composition research. 
Computed tomography (CT) and magnetic resonance imaging (MRI) are the 
two radiological techniques primarily used for this purpose. 
 
Principle of CT: 
The working principle of CT is similar with that of DXA, as both measure 
the differential attenuation (tissue dependent) of X-ray as it passes through the 
body. The difference lies with the effective dose of the applied radiation and 
the methods used for image detection and analysis. CT effective dose is many 
fold higher than regular X-ray radiographic doses and thus significantly higher 
than DXA. This imposes potential risk to the patient, particularly upon 
repeated exposure. A DXA-generated pixel represents an infinite depth of a 
tissue mixture (therefore volume cannot be determined), whereas CT-derived 
pixels correspond to a specific depth (known a priori) from where volume can 
be calculated. This is accomplished by dividing the whole body into hundreds 
of axial slices and assigns distinct pixels on every slice to reconstruct high 
resolution images of a particular tissue on every slice. Therefore in CT, every 
pixel represents a 3D voxel which corresponds to the slice thickness (usually 10 
mm) and inter-slice distance, whereas DXA works with 2D pixel. Tissue 
volume is then calculated by adding up the volumes of that tissue on every 
slice and the interpolated inter-slice volumes (discussed later under 3.2.6.2). In 
contrast to DXA, CT is based on estimating the volume of adipose tissue rather 
than bone mineral mass and fractional lean mass.  DXA and CT derive the mass 
of tissues in exactly opposite ways. DXA determines the (areal) density (g/cm2) 
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of bone mineral first, which is then multiplied by a known geometric variable, 
i.e. pixel area (cm2) to estimate the mass of bone mineral (g). On the contrary, 
CT determines the geometric variable i.e. volume of adipose tissue (cm3) first, 
which is then multiplied by the known (a priori) value of adipose tissue density 
(g/cm3) in order to derive the adipose tissue mass (g). Also, unlike DXA CT is 
not strictly dependent on two particular monochromatic X-ray beams of 
specific energy.  
 
3.2.6.1. Principle of MRI: 
MRI has been proposed as an alternative technique which avoids the 
health risk associated with ionising radiation. This technique is based on the 
interaction between hydrogen nuclei (protons) and the magnetic field 
generated by the MRI instrument. The MRI induces a strong magnetic field that 
is about 50,000 times stronger than earth’s magnetic field (1.5 Tesla vs 3.2 x 10-5 
Tesla), whereby the spin of all hydrogen nuclei aligns with the applied 
magnetic field. Once the magnetic alignment is achieved, a pulse radio 
frequency (RF) is applied which is well absorbed by the protons and upon 
cessation of the RF pulse, the excited protons return to their original position 
by releasing energy in the RF range. This radiating energy travels through the 
tissue and gets attenuated before it is captured by the detector placed in the 
MRI scanner. The extent of signal attenuation is tissue specific. Therefore the 
MRI system is able to distinguish various types of tissues by constructing 
images based on variable signal attenuation.   
 
3.2.6.2. Methodology of image analysis: 
Images are generated during the scan by dividing the subject’s body into 
several axial slices along the longitudinal axis. Once image acquisition is 
completed, both CT and MRI images can be analysed using a common method. 
The attenuation is expressed as CT number (measured in Housenfield units 
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[HU]), which is a measure of attenuation relative to water, defined as 0 HU. 
The image is constructed by many pixels (usually 1 mm × 1mm) which have a 
defined CT number based on a grey scale which gives contrast to the image. 
Every pixel represents a voxel element with a specified depth. The extent of 
attenuation is dependent on the physical density of a particular tissue; with 
lower density represented by lower CT numbers, relative to water (HU=0). For 
example, pixels of adipose tissue range from -190 to -30 HU and for skeletal 
muscle from 30 to 100 HU. Each pixel is then segregated based on the CT 
number using interactive image analysis software that utilises image 
segmentation algorithms like ‘histogram analysis’ or ‘edge detection’ [174]. Once 
the edges of different tissues have been identified and demarcation lines are 
drawn, the analyser applies colour coding to provide visual differentiation of 
regions of tissues and thereby, to calculate the surface area contributed by a 
particular tissue on that image. 
Acquisition and analysis of contiguous images of whole body scan is time 
consuming and expensive. Therefore in actual practice, axial images are 
typically collected along with inter-slice gaps (e.g. space between the upper 
surface of one image and lower surface of adjacent image) ranging from 20 to 
40 mm as described in Figure 3.4. Image𝑖  and Image𝑖+1  are two consecutive 
image slices with an inter-slice distance (𝑙) of 40 mm and image thickness (t) of 
10 mm. The surface areas (cm2) of the adipose tissue (shown in grey colour) on 
two images are Area𝑖  and Area𝑖+1 respectively (Area𝑖>Area𝑖+1), 𝑁𝑠  is the total 
number of image slices generated and 𝑉AT is the total volume (cm3) of adipose 
tissue in the body. 𝑉AT is then calculated from the areas of adipose tissue on 
consecutive images and the inter-slice distance. Three different geometrical 
models are in place for volume calculation, which mainly differ in their 
assumptions of the inter-slice volume interpolation [174]. However, all models 
assume that the change in cross-sectional area of adipose tissue between two 
consecutive images is linear. The parallel trapezium model (Eq 3.35) [175] is one 
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of the geometrical models used for this purpose. It assumes that the irregular 








Eq 3.35 Calculation of adipose tissue volume by medical imaging 
 
 
Figure 3.4 Schematic representation of CT/MRI image slices 
(a) Schematic representation of two consecutive CT/MRI image slices and areas covered by 
adipose tissue (𝐴𝑟𝑒𝑎𝑖, 𝐴𝑟𝑒𝑎𝑖+1) and non-adipose tissue. (b) Total volume of adipose tissue 
(dark shaded) contributed by two slices (𝑡 slice thickness) and the inter-slice gap (𝑙) assuming 
a linear interpolation (dotted line). The tissues in each slices are geometrically irregular, 
which are approximated by various assumptions made in the mathematical models for volume 
calculation 
 
The 𝐹𝑀  weight can be calculated by Eq 3.36 by knowing the adipose 
tissue density (𝜌AT) and fractional fat content (𝑓AT) and finally the 𝐹𝐹𝑀  by 
using Eq 3.9. Apart from fat, adipose tissue also contains water, protein, 
minerals and thus holds a slightly higher density than 𝜌FM. A density of 0.95 
g/mL and 80% fat content (𝑓AT = 0.80) of adipose tissue is usually assumed in 
the literature for calculating its volume from imaging studies [99, 176, 177]. 
FM = 𝑉AT × 𝜌AT × 𝑓AT 
Eq 3.36 Calculation of fat-mass by medical imaging  
Non Adipose Tissue Adipose Tissue
 
     𝒊      𝒊+ 
 
(b)(a)
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3.3. An overarching framework to quantify FFM 
Although each method of 𝐹𝐹𝑀 measurement is distinct with respect to its 
working principle and operation, their interim outcomes are interrelated. We 
provide an overarching scheme of how the methods interrelate in Figure 3.5 
and the interlinks between parameters of various methods through specific 
Equation numbers in Figure 3.6. Examples of their use in calculations of 𝐹𝐹𝑀 
using standard values are summarised in Table A2.5 of Appendix 2: . Each of 
the physiological variables measured by most of the methods discussed here 
i.e. fat mass (𝐹𝑀), total body water (𝑇𝐵𝑊) and total body potassium (𝑇𝐵𝐾) 
links multiple methods. For example, both densitometry based methods 
(hydrostatic weighing, BOD POD®, skinfold thickness) and imaging based 
methods (CT, MRI) determine the same physiological estimate i.e. fat mass, 
which is subtracted from total body weight (𝑊𝑇) to calculate 𝐹𝐹𝑀. Similarly, 
total body water is the common outcome determined by hydrometry based 
methods (isotope dilution, 𝐼𝐶𝑊  and 𝐸𝐶𝑊  measurement) and bioimpedance 
analysis (BIA) from which 𝐹𝐹𝑀 is calculated using the ratio 𝑅water/FFM. Again, 
the intracellular water is measured from the total body potassium 
measurement, which is a part of whole body counting, another 𝐹𝐹𝑀 measuring 
method.  In whole body counting, 𝐹𝐹𝑀 can be directly calculated from 𝑇𝐵𝐾 
using the ratio 𝑅TBK/FFM without the need of estimating 𝑇𝐵𝑊. On the other 
hand, DXA measures unique variables i.e. 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇)  and 𝐵𝑀𝐶  which are not 
shared by any other methods. The 𝐹𝐹𝑀 model by Janmahasatian et al. appears 
in the framework (Figure 3.5) because it involved the development of a BIA 
prediction model which was subsequently used to develop a 𝐹𝐹𝑀 prediction 
model. 
 




Figure 3.5 Summary of various body composition measurement methods and 
how they contribute to understanding of 𝑭𝑭𝑴. 
The circles surrounding 𝐹𝐹𝑀  (darker shade) in the centre represent the parameters from 
which 𝐹𝐹𝑀  can be directly calculated.  Smaller circles towards peripheri (lighter shade) 
represent the parameters required to derive the parameters within the darker circles. A 
continuous arrow represents a direct calculation, but a dashed arrow represents an indirect 
derivation based on assumption(s) and/or a predictive equation.Unlike other methods each of 
which derives a single outcome, DXA derives two parameters, i.e. 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇) and 𝐵𝑀𝐶, in order 
to derive 𝐹𝐹𝑀. Each of the numbers from [1] to [13] against the dashed arrows represents the 
specific basis of the calculation related to that indirect step: [1] based on population specific 
regression equation; [2] based on assumed value of 𝜌𝐹𝑀 and 𝜌𝐹𝐹𝑀; [3] based on the model 
developed by Janmahasatian et al. which can predict 𝑍 (bioimpedance) using body weight and 
height; [4, 5] based on population specific regression equation [6] 𝐵𝑟−/ 𝐶𝑙−dilution space is 
an approximation of 𝐸𝐶𝑊; [7] 𝐾+ space is used as an approximation of 𝐼𝐶𝑊 with an assumed 
value of [𝐾+]𝒊; [8] value of 𝑅𝑤𝑎𝑡𝑒𝑟/𝐹𝐹𝑀 needs to be assumed; [9] assumed value of 𝑅𝑇𝐵𝐾/𝐹𝐹𝑀; 
[10] 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇)  estimation is dependent on assumed/measured values of 𝑟𝑓𝑎𝑡  and 𝑟𝑙𝑒𝑎𝑛 ; [11] 
approximation of 𝑟𝑆𝑇 value needs to be made for determining 𝐵𝑀𝐶; [12] based on assumption 
   
   
BMC
+
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for interslice volume interpolation of adipose tissue; [13] depends on assumed values of 𝑓𝐴𝑇 
and 𝜌𝐴𝑇. 𝐸𝐶𝑊 extracellular water, 𝐼𝐶𝑊 intracellular water, 𝑇𝐵𝑊 total body water, 𝑇𝐵𝐾 total 
body potassium, 𝑍 impedance, 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇) average fraction of lean tissue in the whole body’s soft 
tissue mass, 𝐵𝑀𝐶 bone mineral content, 𝐹𝐹𝑀 fat-free mass, 𝐹𝑀 fat mass, 𝑉𝐴𝑇 total volume of 
adipose tissue in body, 𝜌𝐵𝑀  total body density, DXA dual-energy X-ray absorptiometry, CT 
computed tomography, MRI magnetic resonance imaging, BIA bio-impedance analysis, and 
BOD POD® represents air displacement plethysmography. 
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𝜌BM Eq 3.6 and Eq 3.8 
𝐹𝑀 Eq 3.9 
𝑭𝑭𝑴 





CT/MRI Eq 3.35 𝑉𝐴𝑇 Eq 3.36 





























𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇) + 𝐵𝑀𝐶  
Eq 3.33, 
Eq 3.34 
a Eq 3.14 and Eq 3.15 are for men and women respectively; b Not applicable since 𝑍 is directly read 
from BIA instrument; c Eq 3.19 and Eq 3.20 are for 𝐸𝐶𝑊𝐵𝑟  and 𝐸𝐶𝑊𝐶𝑙 respectively; 
d Eq 3.31 and Eq 
3.32 are for 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇) and 𝐵𝑀𝐶 respectively. 
Figure 3.6 Interconnections between various methods through specific 
equations. 
Shaded outcomes represent the outcomes required to calculate 𝐹𝐹𝑀 as described in Figure 
3.5. The non-shaded boxes represent the equations that link the methods or outcomes. The 
equation numbers represent those from the text. 𝐸𝐶𝑊 extracellular water, 𝐼𝐶𝑊 intracellular 
water, 𝑇𝐵𝑊  total body water, 𝑇𝐵𝐾  total body potassium, 𝑍  impedance, 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇)  average 
fraction of lean tissue in the whole body’s soft tissue mass, BMC bone mineral content, 𝐹𝐹𝑀 
fat-free mass, 𝐹𝑀 fat mass, 𝑉𝐴𝑇 total volume of adipose tissue in body, 𝜌𝐵𝑀 total body density, 
DXA dual-energy X-ray absorptiometry, CT computed tomography, MRI magnetic resonance 
imaging, BIA bio-impedance analysis 
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3.4. Prediction Models for FFM 
Another way of determining 𝐹𝐹𝑀  is by the use of predictive models 
which have been extensively published in the literature [101, 102, 178-185]. These 
models utilise measurable patient characteristics (e.g. 𝑊𝑇 , 𝐻𝑡 , age, sex) to 
predict 𝐹𝐹𝑀  and thus preferred for determining individual 𝐹𝐹𝑀  in 
pharmacokinetic analyses and in clinical practice. However, the mathematical 
relationship between 𝐹𝐹𝑀  and such patient characteristics were mostly 
empirically derived based on regression analysis of measured 𝐹𝐹𝑀 (e.g. using 
DXA or BIA) in relation to patient characteristics such as 𝑊𝑇, 𝐻𝑡, and age. 
Empirical models are mostly data-driven which hinders their use in new 
populations. For instance, the model by James et al. [101] results in under 
prediction of 𝐹𝐹𝑀 once a certain value of 𝑊𝑇 is exceeded, which can lead to 
under-dosing in obese patients [25, 103]. This is because the range of 𝑊𝑇 that was 
used during model development was narrow, mostly excluding obese and 
there was no biological mechanism supporting the mathematical relationship 
used in the model. Later, Janmahasatian et al. [102] developed a model in adults 
with a wide range of age (18-82 years), body weight (40.7-216.5 kg), 𝐵𝑀𝐼 (17.1-
69.9 kg.m2) and assumed a more mechanistic relationship between 𝐹𝐹𝑀 and 
other size variables. Janmahasatian’s model has been used commonly for 𝐹𝐹𝑀 
calculation in pharmacokinetic analyses. More recently, Al-Sallami et al. [185] 
extended Janmahasatian’s adult 𝐹𝐹𝑀 model to include children of 3 years and 
above by introducing a maturation model. This model might help in predicting 
the body composition driven change in clearance in children. A list of various 
published 𝐹𝐹𝑀 models is in Table A2.6 of Appendix 2: .  
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3.5. Limitations of assumptions and operations and their clinical 
implications 
It is important to use a particular 𝐹𝐹𝑀 measuring method in situation(s) 
where its assumption(s) and operational requirement(s) are largely met. In this 
section, a discussion of the methods in terms of assumptions and operational 
challenges is provided. This is intended to provide a guide for the choice of 
method when measuring 𝐹𝐹𝑀 experimentally and subsequent application to 
pharmacokinetic studies. 
 Of note, none of the existing methods measures 𝐹𝐹𝑀 directly. Instead, 
𝐹𝐹𝑀  is derived indirectly from an experimental measurement (e.g. 𝜌BM) by 
factoring in certain parameters. Although the typical values used for these 
parameters (e.g. 𝜌FFM=1.10 g/mL) are the key assumptions for 𝐹𝐹𝑀 derivation 
they may not be constant across the populations. Their values can deviate from 
the standard values as a result of (patho)physiological changes (e.g. structural 
maturation or abnormal hydration) caused by age [154, 186, 187], pregnancy, 
disease [159, 188, 189] and even by therapeutic intervention [190, 191]. A detailed 
discussion about deviations in the assumed constants can be found in section 
A2.4 of Appendix 2: . Therefore, caution must be used while selecting a 
particular method in a particular population, where alteration in the required 
parameter values are suspected. Parameter values can also differ within a 
population. This natural variability can potentially cause measurement errors 
in certain methods, e.g. at least 4% error in 𝐹𝑀 estimation by densitometry[98]. 
On the other hand, variation in the level of body hydration within the natural 
range is not expected to cause significant variation in DXA-derived 𝐹𝐹𝑀 
measurement [173].      
Further to the biological variation between and within populations, the 
use of these methods may be impacted by operational challenges. These 
include practical and safety aspects of use and are discussed in detail in section 
A2.5 and Table A2.7 of Appendix 2: . In this context, anthropometry, BOD 
POD, BIA, and DXA appear reasonably acceptable for most situations due to 
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their relative safety and ease of use. However, anthropometry and BOD POD® 
may not be the method of choice where a biological variation in 𝜌FFM  is 
expected e.g. children. Similarly, BIA is not recommended if abnormal 
hydration is suspected, e.g. younger children, pregnant women, and critically 
ill patients. Use of DXA is more acceptable in this regard since it is least 
susceptible to biological variation in hydration. Therefore, DXA has been 
indicated as the standard method for assessing body composition in most 
patient groups [173].  
  Alternatively,𝐹𝐹𝑀  prediction models are available and are used in 
certain situations in clinical practice. Models in current use include the adult 
𝐹𝐹𝑀 model developed by Janmahasatian et al. [102] which was based on 𝐹𝐹𝑀 
measurements using BIA and DXA. The paediatric 𝐹𝐹𝑀 model developed by 
Al-Sallami et al. [185] was based on 𝐹𝐹𝑀 measuremenst using DXA. Of note, 
neither of these models extends to patients at the extremes of age (under 3 
years or over 82 years). 
3.6. Relevance of FFM in clinical pharmacology 
Most size-based dosing recommendations stipulate total body weight 
(𝑊𝑇) as a scaler on a ‘dose per kilogram’ basis. This is because 𝑊𝑇 is relatively 
easy to measure and often correlates well with drug clearance especially in 
subjects with normal weight. Clearance ( 𝐶𝐿 ) depends on the intrinsic 
elimination capacity of the various eliminating organ(s) and their perfusion 
which often correlates well with 𝑊𝑇 in normal weighted individuals. However, 
excess fat mass does not contribute to drug elimination hence scaling drug 
clearance based on 𝑊𝑇 in the obese can potentially result in over-prediction of 
the maintenance dose. Obese subjects are often excluded from the various 
stages of drug development [24], despite the increasing prevalence of obesity 
worldwide [70, 192]. This has necessitated the development of alternative 
descriptors of size including 𝐹𝐹𝑀 which is expected to correlate better with 
drug 𝐶𝐿 [24, 25, 91, 126, 136-138]. Of note, at least empirically, 𝐹𝐹𝑀 has shown non-
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linear correlation with 𝐶𝐿 according to a recent review by McLeay et al. [60] in 
which various body size descriptors were analysed as covariates on 𝐶𝐿 . 
Findings of this study (Figure 3.7) suggest that 𝐹𝐹𝑀 raised to the power of 2/3 
best described the overall increase in 𝐶𝐿 with body size compared to other 
established size metrics. Although 𝐿𝐵𝑊  and 𝐹𝐹𝑀  continue to be used 
interchangeably in the literature 𝐿𝐵𝑊 can not be measured experimentally and 
is approximated by 𝐹𝐹𝑀. Bedside determination of 𝐹𝐹𝑀 in the clinic is possible 
through the use of either BIA or 𝐹𝐹𝑀 prediction models. 
Along with 𝐶𝐿 , volume of distribution (𝑉 ) also plays a key role in 
determining loading dose and scaling of 𝑉  is also important for dose 
optimisation in obese patients. Conventionally, 𝑉 is scaled linearly with 𝑊𝑇 
irrespective of body size. However, the absolute 𝑉  (in Litres) of low to 
moderately lipophilic drugs (e.g. non-depolarising neuromuscular blockers) 
are less likely to be affected by obesity and hence suggested for 𝐹𝐹𝑀 based 
scaling [138]. Clinically, 𝐹𝐹𝑀 -based dosing has been demonstrated for 
daptomycin [193], propofol [106], remifentanil [103] and dexmedetomidine [107] in 
morbidly obese patients. Therefore, 𝐹𝐹𝑀  based dosing is increasingly being 
adopted in clinical pharmacology and accurate prediction of individual 𝐹𝐹𝑀 is 
of utmost importance.  
 
  




Figure 3.7 Meta-analysis result of relationship between various size metrics 
with    
Mean scaled 𝐶𝐿 values (normalised to the centred 𝐶𝐿) across the 𝑊𝑇 range from 121 studies 
(which reported various size metrics as covariate of 𝐶𝐿 in adults) are plotted on the y-axis 
(thick dark line). Various other size metrics scaled across the 𝑊𝑇 range are also overlaid. 
𝐿𝐵𝑊 refers to 𝐹𝐹𝑀 and 𝑇𝐵𝑊 refers to 𝑊𝑇 in the context of this thesis. (Centring: TBW= 59 
kg, 𝐿𝐵𝑊= 50.45 kg, 𝐵𝑆𝐴= 1.72m2). 𝑊𝑇  total body weight (𝑇𝐵𝑊  represents 𝑊𝑇  in this 
figure), 𝐿𝐵𝑊  lean body weight, 𝐵𝑆𝐴  body surface area. Modified with permission from 
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3.7. Discussion and Conclusion 
Body size is one of the most important covariates to describe drug 
pharmacokinetics. 𝑊𝑇 is an appropriate size descriptor if body composition 
remains constant over all sizes. However, body composition is not constant 
over the 𝑊𝑇  range thus 𝑊𝑇-based dosing regimens are not appropriate for 
obese patients. 𝐹𝐹𝑀 has been gaining popularity in clinical pharmacology as it 
describes body size without the excess fat mass which is not thought to 
contribute to drug metabolism and excretion. However, unlike 𝑊𝑇, 𝐹𝐹𝑀 is not 
a directly measurable characteristic, hence accurate 𝐹𝐹𝑀  measurement is 
required. There are numerous methods for measuring 𝐹𝐹𝑀 which are highly 
variable in terms of their working principles and assumptions. These are 
thoroughly discussed in this review with special emphasis on their 
interrelationship on a physiological framework and will help rationalising their 
use. These methods can then be used to develop predictive mathematical 
models that can predict 𝐹𝐹𝑀 from readily measurable patient variables. 
 
Although predictive models for 𝐹𝐹𝑀 are used in population PK analyses 
and size-based dose recommendations, these models can not be extrapolated to 
special populations such as infants or patients suffering from cachexia. 
Extrapolating 𝐹𝐹𝑀 to these populations using the available models may result 
in prediction bias. In such situations, where the available models do not appear 
suitable, new models need to be developed. Future model development 
processes need to measure 𝐹𝐹𝑀  experimentally and hence the choice of 
method should be determined based on proper scientific justification. The 
technical details described in this review will help researchers in selecting fit-
for-purpose methods to determine 𝐹𝐹𝑀 in order to develop predictive models 
for relevant patient populations. 
 








Chapter 4:  An extended framework of 
Janmahasatian’s fat-free mass model for universal 



















As discussed in Chapter 3, measurement of 𝐹𝐹𝑀  involves methodologies 
which are often too cumbersome to be implemented in regular practice. The use of 
𝐹𝐹𝑀  is therefore based on the availability of predictive equations. Among the 
available 𝐹𝐹𝑀 models, the model developed by Janmahasatian et al. [102] has been 
widely recommended and used extensively. The semi-mechanistic model (for adults) 
is shown in Eq 1.35 and Eq 1.36 in Chapter 1: . Janmahasatian’s model has recently 
been extended to predict 𝐹𝐹𝑀 in children to 3 years of age [185].   
Janmahasatian’s model was built from healthy volunteers whose ancestry 
predominantly originated from Europe. A key assumption in this model is a linear 
relationship between bioimpedance (𝑍)  and body mass index (𝐵𝑀𝐼)  which was 
supported in their study population. It is unknown whether this relationship will 
hold true for all ethnic groups. Rush et al. [104] have reported that the percent fat 
mass and 𝐵𝑀𝐼  have a curvilinear (not linear) relationship, and moreover the 
relationship varies between populations of different ethnic origins. This implies that 
percent fat mass values are different in different ethnic populations once normalised 
to 𝐵𝑀𝐼. In particular it was shown in their work that people from India had on 
average 7.6% (95% CI: 5% – 10.2%) higher fat mass component than Europeans for a 
given 𝐵𝑀𝐼 value and in contrast that people from the South Pacific (e.g. Samoa) had 
about 3.8% (95% CI: 1.4% – 6.1%) lower fat mass component than Europeans. This 
implies that Asian Indians have lower 𝐹𝐹𝑀  compared to European adults at an 
equivalent 𝐵𝑀𝐼. We anticipate therefore that people of other ethnicities (e.g. India) 
may challenge the linear assumption seen in the original (Janmahasatian) 𝐹𝐹𝑀 
model. Therefore, 𝐹𝐹𝑀𝐽𝑎𝑛 which follows the European body composition pattern is 
expected to over-estimate 𝐹𝐹𝑀 in Indians. A recent study by Srigiripura et al. [105] 
evaluated the Janmahasatian model which resulted in bias in 𝐹𝐹𝑀 predictions for 
Indian people (Figure 4.1). Their work reported over-estimation of 𝐹𝐹𝑀 in the Indian 
population by Janmahasatian model when compared to the BIA measured values 
(𝐹𝐹𝑀𝐵𝐼𝐴). However, the authors did not mention which regression equation was 
used to extrapolate 𝐹𝐹𝑀 from the BIA measured 𝑍 data, and the equation’s validity 




in the study population. The mean error [95% CI] of the prediction (𝐹𝐹𝑀𝐵𝐼𝐴 −
𝐹𝐹𝑀𝐽𝑎𝑛) was -3.76 [(-7.96) – (0.44)] kg. This could be due to the non-universality of 
the body composition vs. 𝐵𝑀𝐼 relationship which was not considered in the 𝐹𝐹𝑀𝐽𝑎𝑛 




Figure 4.1 Bias in 𝑭𝑭𝑴  prediction by Janmahasatian’s model in Indian 
population 
The difference in 𝐹𝐹𝑀 prediction by Janmahasatian’s model compared to the BIA measured 
𝐹𝐹𝑀 values are plotted in y-axis and the average of corresponding model predicted and 
measured 𝐹𝐹𝑀 values are plotted in x-axis. The figure has been reproduced from the report 




















In the current work we describe an extension of the Janmahasatian equation 
that relaxes the linearity assumption in the use of bioimpedance to provide an 
equation that is universal across populations. The revised model was termed an 
extended 𝐹𝐹𝑀 model (𝐹𝐹𝑀𝐸𝑥𝑡).  
Objective-1: To derive an extended version of 𝐹𝐹𝑀 model structure (𝐹𝐹𝑀𝐸𝑥𝑡) 
that would incorporate estimable ethnicity specific parameter(s). 
Objective-2: To estimate the ethnic specific parameters from the extended 𝐹𝐹𝑀 
equation to describe an Indian population. 
  





4.2.1. Objective-1: Extension of the 𝑭𝑭𝑴 equation to include ethnic specific 
parameters 
For this objective, one of the biological assumptions that underpinned 
Janmahasatian’s model development was revisited. From here, the original 
assumption of linearity was relaxed to accommodate ethnic differences and provide 
specific parameters that can be estimated in future studies. This objective yields the 
extended 𝐹𝐹𝑀 equation (𝐹𝐹𝑀𝐸𝑥𝑡). 
 
4.2.1.1. Bioimpedance and Janmahasatian’s assumption 
The body is comprised of both conducting (e.g. charged ions) and non-
conducting materials (e.g. fat). When an AC current flows through the body, it 
experiences two types of opposition to its flow, i.e. resistance (𝑅) produced by the 
conducting materials and reactance (𝑋𝑐) produced the non-conducting materials. 
Bioimpedance (𝑍) refers to the overall inhibition against the AC current flow which 
depends on both 𝑅 and 𝑋𝑐 (Eq 4.1). Reactance (𝑋𝑐) is inversely proportional to the 
capacitance (of the non-conducting material) and also, to the frequency of the AC 
current. At high frequency range as in BIA (typically, 50 kHz), 𝑋𝑐  becomes 
negligible, thus 𝑍 becomes approximately equal to 𝑅. Therefore BIA in this setting 
reflects the resistance (𝑅) of the body. The magnitude of the electrical resistance 
produced by different bio-materials is different and hence the total resistance to a 
flow of current provides an indication of the composition for a given size. Therefore, 
𝑍 (essentially a measure of resistance) is an indirect measure of body composition.  
The assumption that the fat type or content, for a given composition based on 𝐵𝑀𝐼, 
is similar across ethnic groups is predicated in the use of Janmahasatian’s model. 
𝑍 = √𝑅2 + 𝑋𝑐
2 
Eq 4.1 Relationship between bioimpedance, resistance and reactance (same as Eq 
3.23)   




For a cylindrical conductor 𝑅 is a function of specific resistivity (𝜑), length (𝐿) 
and cross-sectional area (𝐴) as in Eq 4.2. Every conductor has a distinct 𝜑 value.  
𝑅 (≈ 𝑍) =
𝜑 × 𝐿 
𝐴
 
Eq 4.2 Electrical resistance of a cylindrical conductor 
 
When Janmahasatian et al. applied this principle to the human body, it was 
assumed that the body was approximated by a series of cylinders with total 𝐿 is 
equivalent to height (𝐻𝑡). Eq 4.4 was derived from Eq 4.2. (where, 𝑉 is body volume, 
𝑊𝑇 is total body weight and 𝜌𝐵𝑀 is body density).  The intermediary step (Eq 4.3) is 
shown here.  
𝑍 ≈ 𝑅 =
























Eq 4.4 Relationship between bioimpedance and 𝑩𝑴  
 
As per Eq 4.4, if (and only if) 𝜑 and 𝜌𝐵𝑀 (or their product) are constant across 
the human body size range (i.e. 𝐵𝑀𝐼  range), then Eq 4.5 holds. This was a 
fundamental assumption in Janmahasatian’s model and one that proved reasonable 
in the population that they studied. 
𝑍𝐽𝑎𝑛 ∝ 𝐵𝑀𝐼
−1 
Eq 4.5 The key assumption of Janmahasatian's model: proportional relationship 
between bioimpedance and 𝑩𝑴  
  




From Eq 4.5, Janmahasatian et al. derived the structure of the 𝑍𝐽𝑎𝑛’s model as 
Eq 4.6, where 𝜃1  and 𝜃2  are the intercept and proportionality constant. In this 
expression both 𝜃1 and 𝜃2 are functions of 𝜑 and/or 𝜌𝐵𝑀.  
𝑍𝐽𝑎𝑛 = 𝜃1 + 𝜃2 × 𝐵𝑀𝐼
−1 
Eq 4.6 Janmahasatian's linear model structure for bioimpedance 
 
By regressing observed 𝑍  values against 𝐵𝑀𝐼 , estimates of 𝜃1  (male: 216, 
female: 244) and 𝜃2  (male: 6680, female: 8780) were obtained. In the next step, 
observed 𝐹𝐹𝑀  was estimated as proportional to  𝐻𝑡
2
𝑍𝐽𝑎𝑛
  with the estimated 
proportionality constant 𝜃3 (Eq 4.7). Then, 𝑍𝐽𝑎𝑛 from Eq 4.6 was substituted into the 
Eq 4.7, which depicts a previously accepted relationship, to develop the final 𝐹𝐹𝑀𝐽𝑎𝑛 
model (Eq 4.10). Note Eq 4.10 can be expressed as Eq 1.35 and Eq 1.36 of Chapter 1: .  









𝜃1 + 𝜃2 × 𝐵𝑀𝐼−1
 





𝜃1 × 𝐵𝑀𝐼 + 𝜃2
 





𝜃2 + 𝜃1 × 𝐵𝑀𝐼
 
Eq 4.10 Janmahasatian's model structure for fat-free mass with respect to BMI and 
WT 




4.2.1.2. Extended assumption 
The composition of the human body (i.e. proportions of various conducting 
materials.) changes as body size changes. This also results in changes to fat content 
(composition or amount), which across ethnic groups does not support a universal 
constant 𝜑 and 𝜌𝐵𝑀  (i.e. body density) for a given value of 𝐵𝑀𝐼  in humans. This 
implies, that the electrical impedance theory needs accommodate the potential 
(special) case of ‘biodiversity’-impedance. This can be accommodated by relaxing the 
assumption of proportionality between 𝑍 and 𝐵𝑀𝐼−1  (of Eq 4.6) as shown in Eq 4.11. 
This would also enable the extended 𝐹𝐹𝑀 model (𝐹𝐹𝑀𝐸𝑥𝑡) to account for ethnicity 
specific differences in the non-linearity (should they exist) by estimating the set of 
additional composition factors Ψ {𝜓1;  𝜓2;  𝜓3}.  
 
𝑍𝐸𝑥𝑡 = 𝜓1 × 𝜃1 + 𝜓2 × 𝜃2 × 𝐵𝑀𝐼
(−𝜓3) 
Eq 4.11 Extended non-linear model structure for bioimpedance 
 
In this work, of development of the 𝐹𝐹𝑀𝐸𝑥𝑡 model, it was also assumed that the 
𝐹𝐹𝑀 to  𝑍 relationship was universal (Eq 4.12), as used by Janmahasatian et al. (Eq 
4.7).  
4.2.1.3. Derivation of FFM𝐸𝑥𝑡 model 
 




Eq 4.12 Extended model structure for fat-free mass 
  








𝜓1 × 𝜃1 + 𝜓2 × 𝜃2 × 𝐵𝑀𝐼(−𝜓3)
 
Eq 4.13 Extended rearranged model structure for fat-free mass  





[𝜓1 × 𝜃1 +𝜓2 × 𝜃2 × 𝐵𝑀𝐼(−𝜓3)] × 𝐵𝑀𝐼
 




𝜓1 × 𝜃1 × 𝐵𝑀𝐼 + 𝜓2 × 𝜃2 × 𝐵𝑀𝐼(1−𝜓3)
 
Eq 4.15 Extended rearranged model structure for fat-free mass with respect to 𝑩𝑴  
and   
The extended 𝐹𝐹𝑀 model was derived as Eq 4.16.  
 
𝑭𝑭𝑴𝑬𝒙 =
𝜽𝟑 ×  
[𝝍 × 𝜽 × 𝑩𝑴 𝜓3 +𝝍 × 𝜽 ] × 𝑩𝑴 ( −𝜓3)
 
Eq 4.16 Final extended rearranged model structure for fat-free mass 
 
If Ψ {𝜓1, 𝜓2, 𝜓3} = 1  (i.e. no change in composition) then 𝐹𝐹𝑀𝐸𝑥𝑡  model (Eq 
4.16) simplifies to  𝐹𝐹𝑀𝐽𝑎𝑛  model (Eq 4.10). Otherwise, for other populations, 
ethnicity specific estimated values of  𝜓1, 𝜓2 𝑎𝑛𝑑 𝜓3 can be estimated. 
  




4.2.2. Objective-2: Application of the extended 𝑭𝑭𝑴 model in Indians 
Here, the ethnicity specific composition parameters, the vector Ψ  were 
incorporated in the 𝐹𝐹𝑀𝐸𝑥𝑡  model structure and were estimated for an Indian 
population, providing an extended 𝐹𝐹𝑀 model for Indians 𝐹𝐹𝑀𝐸𝑥𝑡(𝐼𝑛𝑑).  
For objective-2, a reference model to describe the 𝐹𝐹𝑀 in the Indian population 
was identified.  Simulations from this model were used to calibrate the Ψ parameters 
from the 𝐹𝐹𝑀𝐸𝑥𝑡 model using nonlinear regression for their estimation. 
 
4.2.2.1. The reference FFM model for the Indian population 
Derivation of an extension to the 𝐹𝐹𝑀𝐽𝑎𝑛  model was developed based on a 
reference equation that has been shown to provide acceptably accurate estimates of 
𝐹𝐹𝑀  in the Indian population. The reference equation was based on the model 
developed by Kulkarni et al. [194]. Kulkarni’s model (𝐹𝐹𝑀𝐾𝑢𝑙) was developed and 
validated in a large cohort (N=2200, 36% female) of healthy Indian adults (age: 18 - 
79 years) covering a wide range of 𝐵𝑀𝐼 (14 - 44 kg/m2). 
Briefly, in their study [194], the participants were randomly assigned to the 
prediction and the validation group which comprised of 60% and 40% of the sample 
size respectively. The data of the prediction group was used for model development, 
which was done by simple linear regression analysis of dual energy X-ray 
absorptiometry (DXA) measured 𝐹𝐹𝑀  data (single measurements) against simple 
anthropometric variables 𝑊𝑇, 𝐻𝑡 and age. The model equations are shown in Eq 4.17 
and Eq 4.18 for males and females respectively. The mean error of prediction 
(standard deviation) of these models, when applied to their validation dataset were 
0.28 (1.96) kg and 0.02 (1.64) kg for males and females respectively.  
  




Later, the Kulkarni model for males (Eq 4.17) was externally validated in the 
study by Srigiripura et al. [105], where they assessed the predictive performances of 
the model in 72 Indian male patients (age: 40 - 74 years, BMI: 13.67 – 33.12 kg/m2) 
against the BIA measured 𝐹𝐹𝑀  data. They found that the mean error (standard 
deviation) of prediction by the Kulkarni model was 0.33 (2.35) kg in the dataset, 
which was similar to Kulkarni’s validation result (0.28 kg) as mentioned above. 
Based on these findings, the Kulkarni’s model (𝐹𝐹𝑀𝐾𝑢𝑙) was used as the reference 
model on the assumption that 𝐹𝐹𝑀𝐾𝑢𝑙  reasonably approximates the true 𝐹𝐹𝑀  in 
Indian adults (among the available models).  
𝐹𝐹𝑀𝐾𝑢𝑙 (𝑚𝑎𝑙𝑒) = −15.605 − (0.032 × 𝐴𝑔𝑒) + (0.192 × 𝐻𝑡) + (0.502 ×𝑊𝑇) 
Eq 4.17 Kulkarni’s fat-free mass model for Indian males 
 
𝐹𝐹𝑀𝐾𝑢𝑙 (𝑓𝑒𝑚𝑎𝑙𝑒) = −13.034 − (0.018 × 𝐴𝑔𝑒) + (0.165 × 𝐻𝑡) + (0.409 ×𝑊𝑇) 
Eq 4.18 Kulkarni’s fat-free mass model for Indian females 
 
4.2.2.2. Simulation of 𝐹𝐹𝑀 data from the reference model 
The reference equations (Eq 4.17 & Eq 4.18) were used to simulate 𝐹𝐹𝑀 
measurements (without error) to provide a calibration for the composition 
parameters of the 𝐹𝐹𝑀𝐸𝑥𝑡 model. The simulation data was based on a database of 
N=100 patient volunteers (demographics are summarised in Table 4.1) that arose 
from a retrospective study described briefly here and reported elsewhere [195]. The 
primary objective of this study was to measure liver fat by computerised 
tomography (CT). Patient characteristics including sex, 𝐻𝑡, 𝑊𝑇, age were collected 
for one hundred adult Indian patients consisting of 30 females and 70 males aged 18-
60 years. The study was conducted at the PSG Hospital, Coimbatore, India. All 
subjects had normal liver or kidney function tests, and were not undergoing any 
treatment for a medical condition related to the liver or kidney, not pregnant, and 
not breastfeeding.  




In this study a single 𝐹𝐹𝑀 value was simulated per subject and each subject 
was included in the simulated data once only. The data that were generated from 
this simulation were denoted 𝐹𝐹𝑀𝐾𝑢𝑙. 
 







Age (year) 37 (23 - 59) 39 (18 - 66) 
Height (cm) 155 (143 - 170) 166 (148 - 197) 
Weight (kg) 70.4 (46 - 118) 79.3 (45 - 128) 
𝐵𝑀𝐼 (kg/m2) 29.6 (18 - 43.9) 28.5 (16.9 - 51.8) 
𝐹𝐹𝑀𝐾𝑢𝑙 (kg) 40.0 (29.6 - 61.6) 56.1 (34.7 - 81.2) 
𝐹𝐹𝑀𝐽𝑎𝑛 (kg) 40.8 (30.8 – 56.1) 57.1 (38.0 – 75.5) 
𝐹𝐹𝑀  fat-free mass, 𝐵𝑀𝐼  body mass index, 𝐹𝐹𝑀𝐾𝑢𝑙  fat-free mass calculated by Kulkarni’s 
model [194], 𝐹𝐹𝑀𝐽𝑎𝑛  fat-free mass calculated by Janmahasatian’s model [102], These patients 
characteristics were part of a retrospective study that was reported elsewhere [195] 
 
4.2.2.3. Model development 
 
The 𝐹𝐹𝑀𝐾𝑢𝑙 data were modelled within a nonlinear regression framework. The 
first-order approximation method (FO) in NONMEM was used (version 7.3). As 
indicated in section 4.2.2.2, there were no repeated measures in this data set. Model 
selection was based on Akaike Information Criteria (AIC) [55], where a lower AIC 
value was indicative of a better description of the data. Model evaluation as done by 
goodness-of-fit (GoF) plots of observed vs. predicted values of 𝐹𝐹𝑀.  
 




The model for 𝐹𝐹𝑀𝐸𝑥𝑡(𝐼𝑛𝑑) estimation is shown in Eq 4.19 (adapted from Eq 
4.16). The subscript ‘𝑖’ denotes the 𝑖th individual’s value. The sex specific values of 
𝜃1, 𝜃2, 𝜃3 were fixed as per Janmahasatian’s model (see Eq 4.10 and the values in Eq 
1.35 and Eq 1.36). The three composition (aka ethnicity) parameters 𝜓1, 𝜓2, 𝜓3 were 
estimated for Indians, along with the variance parameter of the residual error model. 
Sex was tested as covariate for Ψ  parameters, which is similar to the original 
Janmahasatian model. Finally an additive error model was considered where the 








Eq 4.19 Structure of fat-free mass model in Indians 
 
4.3. Results 
The 𝐹𝐹𝑀𝐽𝑎𝑛 was demonstrated to deviate from the 𝐹𝐹𝑀𝐾𝑢𝑙 as shown in Figure 
4.2. Overall, 𝐹𝐹𝑀𝐽𝑎𝑛 estimates were higher than the 𝐹𝐹𝑀𝐾𝑢𝑙 estimates, particularly in 
males as shown in Table 4.2. 
 
Figure 4.2 Deviation in 𝑭𝑭𝑴 prediction in Indian males (a) and females (b) by 
Janmahasatian's model and Kulkarni's model.  
The solid line and the dotted line represent the line of unity and the linear regression line 
respectively. 
  




Table 4.2 Bias (ME) and precision (RMSE) of Janmahasatian’s 𝑭𝑭𝑴  model in 
Indian patients 
Sex 




Male -1.9 [(-2.6) – (-1.2)] 3.0 
Female 0.3 [(-0.2) – 0.9] 1.6 
ME mean error, RMSE root mean squared error 
 
A summary of model selection is shown in Table 4.3. When, sex was considered 
as a covariate on 𝜓1 (Model-2), it caused massive drop (about 141 unit) in the AIC 
value compared to the base model (Model-1). Further, considering sex as a covariate 
on 𝜓2 (Model-3) significantly improved the model fit. However, considering sex on 
𝜓3 (Model-4) did not further improve the model fit (as AIC was increased), thus 
keeping Model-3 as the current best choice. Since, the estimates of 𝜓1 in Model-3 
were negligible, these were fixed to 0 (Model-5), which further lowered the AIC 
value by about 7 unit and produced similar estimates as compared to Model-3. 
Therefore, Model-5 was considered as the final model. Summary of the parameter 
estimates of the final model is shown in Table 4.4. GoF plots of the final model are 
shown in Figure 4.3.   




Table 4.3 Summary of extended 𝑭𝑭𝑴 model selection for Indians. 
Model 
No. 
Covariate on 𝚿 AIC ∆AIC 𝝍  𝝍  𝝍𝟑 𝝈 (kg) 
1 - 154.06 - 0.87 2.34 1.21 1.26 
2 Sex on 𝜓1 12.97 -141.09 0.20 0.02 0.86 0.78 0.62 
3 Sex on 𝜓1 and 𝜓2 -37.96 -50.93 0.02 0.02 0.78 0.71 0.72 0.47 




















𝐹𝐹𝑀𝐸𝑥𝑡(𝐼𝑛𝑑) extended fat-free mass in Indians; 𝜃1, 𝜃1 and 𝜃3 are Janmahasatian’s model parameters (fixed), 𝑊𝑇 total body weight; 𝐵𝑀𝐼 body mass 
index; Ψ {𝜓1, 𝜓2, 𝜓3} ethnicity specific body composition parameters; AIC Alaike Information Criteria; 𝜎 standard deviation of additive error;  a 
(Model 5 – Model 3); ∆AIC represents the difference between the two consecutive models unless otherwise stated; the drop and gain in AIC values 
(compared to the previous model) is represented by negative and positive signs respectively 
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Table 4.4 Parameter estimates (%RSE) of the final 𝑭𝑭𝑴𝑬𝒙 (  𝒅) model 




0.72 (1.3) 0.47 (12.4) 
female 0.70 (3.3) 
 
The (final) extended models for 𝐹𝐹𝑀 prediction in Indians can be written 
as Eq 4.20 and Eq 4.21 respectively. Here we preserve the previous 
Janmahasatian parameter values in order to allow comparisons. 
 
 
Figure 4.3 GoF plots of model fit of the final 𝑭𝑭𝑴𝑬𝒙 (  𝒅)model in Indian 
males (a) and females (b). 




0.77 × 6680 × 𝐵𝑀𝐼0.28
 




0.70 × 8780 × 𝐵𝑀𝐼0.28
 
Eq 4.21 Final extended fat-free mass model for Indian females  




In this work, we have revisited the basic assumption of Janmahasatian’s 
𝐹𝐹𝑀  model structure, and extended it to accommodate ethnicity specific 
correction factors (i.e. parameters), which are estimable when 𝐹𝐹𝑀  data is 
available for a new population. We further showed an application of the 
extended 𝐹𝐹𝑀  model structure (𝐹𝐹𝑀𝐸𝑥𝑡)  by developing the extended 𝐹𝐹𝑀 
model for the Indian population (𝐹𝐹𝑀𝐸𝑥𝑡(𝐼𝑛𝑑)).   
Janmahasatian et al. assumed a linear (i.e. proportional) relationship 
between bioimpedance (𝑍 ) and 𝐵𝑀𝐼  (Eq 4.6), on which their 𝐹𝐹𝑀  model 
(𝐹𝐹𝑀𝐽𝑎𝑛) was subsequently built. In this work, this assumption was relaxed to 
accommodate a potential non-linear relationship (Eq 4.11), since the constancy 
of specific resistivity (𝜑) and body density (𝜌𝐵𝑀) over the body size range for all 
ethnic groups is unlikely. Changes in 𝜑 and/or 𝜌𝐵𝑀  with changes in 𝐵𝑀𝐼 are 
likely to be due to altered proportions of various bio-materials (e.g. fat, 
proteins, minerals), i.e. change in body composition for a given reference size. 
This extended assumption of non-linear relationship is further supported by 
the observation made by Rush et al. [104, 196, 197] and Deurenberg et al. [198] in their 
multiple studies. These authors quantified human adult body composition of 
different ethnicities by standard body composition analysis methods such as 
BIA and DXA, and consistently found that it follows a curvilinear relationship 
with 𝐵𝑀𝐼. Most importantly, the key conclusion of their studies was that the 
body composition vs. 𝐵𝑀𝐼  relationships differed widely across a range of 
different ethnic populations, i.e. European (Caucasian), Asian Indian, Māori 
and Pacific Islander (or Polynesian). In general, at a fixed 𝐵𝑀𝐼, the degree of 
adiposity was found to be the highest in Asian Indians, and the lowest in 
Pacific Islanders, while the Europeans fell in the middle of the rank order. This 
was partly explained by the difference in muscularity and fat distribution 
among the populations. For example, it is reported that Asian Indians have 
more abdominal fat deposition than their European and Pacific Island 
counterparts.  
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Based on apparent interethnic differences in body composition, given a 
reference size it is highly unlikely that the estimated relationship of 𝑍 with 𝐵𝑀𝐼 
in European population (Eq 4.6) as adopted in 𝐹𝐹𝑀𝐽𝑎𝑛 model, would remain 
universal. The extended 𝐹𝐹𝑀  model structure (𝐹𝐹𝑀𝐸𝑥𝑡) , in this regard will 
provide a useful extension to the scope of Janmahasatian’s model. This is 
because the 𝐹𝐹𝑀𝐸𝑥𝑡  model not only aligns with the mechanistic features of 
Janmahasatia’s model but also incorporates the potential non-linear body 
composition patterns respectively by incorporating estimable parameters 
Ψ {𝜓1, 𝜓2, 𝜓3}. 
This work was based on the use of a reference model, Kulkarni’s model 
(𝐹𝐹𝑀𝐾𝑢𝑙) [194], to calibrate the current 𝐹𝐹𝑀𝐸𝑥𝑡 model. The reference model has 
been previously evaluated, both internally and externally [105] and shown to 
perform well in Indians. However, the 𝐹𝐹𝑀𝐾𝑢𝑙  model was developed 
empirically by simple linear regression without accounting for any underlying 
mechanism, and hence may not be advisable for extrapolation to a broader 
population range. Therefore, the extension of Janmahasatian’s model, 
incorporates both the predictive performance of the 𝐹𝐹𝑀𝐾𝑢𝑙 model and due to 
its mechanistic nature the ability to extrapolate to other populations.   
The final 𝐹𝐹𝑀𝐸𝑥𝑡(𝐼𝑛𝑑)  model estimates (Table 4.4) indicate a non-linear 
body composition vs. 𝐵𝑀𝐼  relationship in Indians (i.e. 𝜓3 = 0.72 ) that is 
different than the (assumed) linear one in Europeans (i.e. 𝜓3 = 1), whereas the 
extent of non-linearity between males and females are similar. The final model 
significantly improved the individual predictions (𝐹𝐹𝑀𝐸𝑥𝑡,𝐼𝑛𝑑 ) close to the 
reference model (Figure 4.3) when compared with 𝐹𝐹𝑀𝐽𝑎𝑛 predictions (Figure 
4.2). Further, 3D plots (Figure 4.4) of the final 𝐹𝐹𝑀𝐸𝑥𝑡(𝐼𝑛𝑑) model (Eq 4.20, Eq 
4.21) and the 𝐹𝐹𝑀𝐽𝑎𝑛 model (Eq 1.35, Eq 1.36 of Chapter 1: ) were generated to 
understand how they are likely to deviate from each other over a range of 
values of 𝑊𝑇 and 𝐻𝑡 that extend outside the current study population (Table 
4.1). Overall there was a trend of larger 𝐹𝐹𝑀𝐽𝑎𝑛  estimates than 𝐹𝐹𝑀𝐸𝑥𝑡(𝐼𝑛𝑑) 
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(more in males than females) in low to moderate 𝐵𝑀𝐼 zone, whereas the trend 
flipped over at higher 𝐵𝑀𝐼 zone. 
 
 
Figure 4.4 3D plots of the final 𝑭𝑭𝑴𝑬𝒙 (  𝒅)  model and 𝑭𝑭𝑴𝑱𝒂  model in 
Indian males (a) and females (b). 
The black arrows represent the directions of low to high BMI zones. 
 
So, further analysis was aimed to identify the deflection point on the 𝐵𝑀𝐼 
axis. As per the model, the deviation in 𝐹𝐹𝑀 prediction between these two 
models is actually caused by the difference in their predicted bioimpedance 
estimates (i.e. 𝑍𝐽𝑎𝑛  vs. 𝑍𝐸𝑥𝑡 ). Therefore, 𝑍𝐽𝑎𝑛  and 𝑍𝐸𝑥𝑡  values were simulated 
over a range of 𝐵𝑀𝐼 values (Figure 4.5) using Eq 4.6 and Eq 4.11. The points of 
deflection were identified to be 32 and 28 kg/m2 for males and females 
respectively, which were close to the standard 𝐵𝑀𝐼 cut-off for obesity, i.e. 30 
kg/m2. This implies, 𝐹𝐹𝑀𝐽𝑎𝑛 model is likely to over-estimate 𝐹𝐹𝑀 in non-obese 
Indians, whereas it is likely to under-estimate in obese. This is in line with the 
validation study by Srigiripura et al. who observed over-estimation of 𝐹𝐹𝑀 by 
Janmahasatian model where the 𝐵𝑀𝐼 of their study population ranged from 14 
– 33 kg/m2. Future validation studies involving obese Indians are required to 
confirm the validity of these models.  Once the extended 𝐹𝐹𝑀 model has been 
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Figure 4.5 Predicted bio-impedance (𝒁 ) vs. 𝑩𝑴  plots in males (a) and 
females (b). 
The blue and the black lines represent the predictions by Janmahasatian’s model (𝑍𝐽𝑎𝑛) and 
extended model (𝑍𝐸𝑥𝑡)  respectively. 
 
The advantage of the extended model is that it obviates the need of 
measuring 𝐹𝐹𝑀  for future 𝐹𝐹𝑀  model development. This is because the 
extended model corrects the Janmahasatian model at the root cause level, i.e. 
difference in body composition pattern, which (if uncorrected) can eventually 
cause model misspecification in the original model, if is used outside the 
European population, as seen with Indians. Therefore, future 𝐹𝐹𝑀  model 
development in other ethnicities would only need to have the BIA data (i.e. 𝑍) 
and estimate the body composition parameters Ψ thereof, by simply doing a 
non-linear regression analysis using the equation: 𝑍𝐸𝑥𝑡 = 𝜓1 × 𝜃1 + 𝜓2 × 𝜃2 ×
𝐵𝑀𝐼(−𝜓3)  (Eq 4.11). Then, the extended 𝐹𝐹𝑀  model can be derived simply 
plugging in the 𝑍𝐸𝑥𝑡 equation in Eq 4.12, as shown in section 4.2.1.2. Therefore, 
the proposed 𝐹𝐹𝑀𝐸𝑥𝑡 model would be a highly clinically relevant approach for 
the future body composition research. This would enable the researchers 
develop 𝐹𝐹𝑀  models with only BIA data in hand, which is a much easier 
procedure to carry out than the cumbersome 𝐹𝐹𝑀  measuring methods like 
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DXA. Even, the ease and portability of BIA has made it the choice of method 
for large epidemiological surveys.  
4.5. Conclusion 
In conclusion, the original assumption of 𝐹𝐹𝑀𝐽𝑎𝑛 model was extended to 
accommodate ethnicity driven variation in body composition, and an extended 
model structure (𝐹𝐹𝑀𝐸𝑥𝑡) was derived. The 𝐹𝐹𝑀𝐸𝑥𝑡 model structure was used 
to develop an extended 𝐹𝐹𝑀  model for Indians (𝐹𝐹𝑀𝐸𝑥𝑡(𝐼𝑛𝑑)) . The 𝐹𝐹𝑀𝐸𝑥𝑡 
model structure can be applied to develop extended 𝐹𝐹𝑀  models in other 
relevant populations once 𝐹𝐹𝑀  data or bioimpedance (𝑍)  data become 
available. 







Chapter 5:  Identifying the average relationship 

















Fat-free mass (𝐹𝐹𝑀) has been proposed as an alternative dose scalar to 
body weight (𝑊𝑇) [24, 91, 103, 106, 107, 126, 136-138] as it accounts for the change in body 
size and composition in contrast with 𝑊𝑇 which only accounts for body size. 
Dose scaling by 𝐹𝐹𝑀 actually simplifies to scaling of 𝐶𝐿 by 𝐹𝐹𝑀 when drug 
response links to exposure. However, the nature of the scaling relationship 
between 𝐶𝐿 and 𝐹𝐹𝑀 is not universal in the literature. 
There is a general belief that 𝐶𝐿  proportionally scales to 𝐹𝐹𝑀 . A 
proportional relationship has been speculated [25] probably due to the fact that 
drug eliminating organs are exclusive parts of the lean portion of the body; 
hence changes in organ size and/or capacity would occur according to the 
change in 𝐹𝐹𝑀. However, there is limited theory to impute proportionality in 
the 𝐶𝐿 vs. 𝐹𝐹𝑀 relationship. 
McLeay et al. [60] have empirically determined the average value of the 
allometric scaling exponent to be 2/3 which suggests a less than proportional 
scaling of 𝐶𝐿 by 𝐹𝐹𝑀.  A non-linear (i.e. less than proportional) scaling of 𝐶𝐿 by 
𝐹𝐹𝑀 in the obese has been justified by some researchers [126, 199] on the ground 
that it is equivalent to the theoretical allometric scaling (by 𝑊𝑇 ) with an 
additional correction for body composition. This is presumably, because 
allometric scaling estimation was made on normal physiological considerations 
which do not include obesity. 
On the other hand, the empirical value (i.e. 2/3) was determined by 
pooling data from drugs with different (hepatic and renal) elimination 
pathways, which might have confounded the result (i.e. the empirical estimate 
of the exponent). For example, it is likely to be confounded by including renally 
cleared drugs as glomerular filtration rate (GFR) is known to scale to body 
surface area (𝐵𝑆𝐴 ) which is equivalent to scaling by 𝑊𝑇2/3 . Additionally, 
within the hepatic elimination category, drugs under low and high extraction 
sub-categories may scale differently to the same body size metric, since their 
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clearances are rate limited to different physiological variables (i.e. hepatic 
intrinsic clearance and blood flow respectively). For the high extraction 
category, it is not clear whether clearance scales with body size or not. Several 
high extraction drugs have been found to have no influence of increase in body 
size on their clearance, such as propranolol, lidocaine, verapamil, sufentanil, 
and paclitaxel. It has been hypothesised that liver blood flow does not increase 
with obesity (in spite of increase in cardiac output) due to increased peripheral 
resistance and/or narrowing of hepatic sinusoids due to fatty infiltration (see 
section page 175 of section 8.1 for a detail discussion). Therefore, pooling data 
from high extraction compounds also might have confounded the empirical 
estimate of the exponent (as stated above for renally cleared drugs). On the 
other hand, drugs under low extraction category, have an obvious influence of 
body size on their clearance. This is because, their clearance approximates to 
the intrinsic clearance (𝐶𝐿𝑖𝑛𝑡,𝑢𝐻) or the metabolic capacity of the liver, which 
has a direct influence of liver size (see Eq 6.1 and 6.14 in Chapter 6). Since liver 
size increases with obesity, it is expected that clearance of low extraction drugs 
would have an influence of body size. In obesity, since 𝐹𝐹𝑀 more accurately 
describes the body size (than 𝑊𝑇) from where drug elimination occurs, the 
relationship between clearance of low extraction drugs and 𝐹𝐹𝑀 needs to be 
identified. Further to it, in drug development, a key goal is to develop drugs 
with low-hepatic extraction in order to ensure less dose and dosing frequency 
in the clinic. This necessitates re-determination of the empirical value of the 
allometric exponent by further sub-group analyses, and thereby explore 
whether the elimination pathway has implications on selection of the allometric 
exponent for scaling 𝐶𝐿 by 𝐹𝐹𝑀. 
  Therefore, the objective of this work is to estimate the scaling 
relationship between 𝐶𝐿  and 𝐹𝐹𝑀  by a model based meta-analysis for low 
clearance drugs that are hepatically cleared.    
    




5.2.1. Data  
This work was based on a thorough review of the literature non-
systematic review (i.e. not at par with PRISMA guideline) using an appropriate 
search strategy followed by a model based meta-analysis.  
The literature search was carried out using MEDLINE to identify reports 
of individual 𝐶𝐿 and 𝐹𝐹𝑀 data using the specified keywords below. Further, 
inclusion and exclusion criteria were applied identify relevant publications. 
Note the data were not predicated on the requirement that a statistically 
significant relationship was or was not found between 𝐹𝐹𝑀 and 𝐶𝐿 and hence 
the risk of publication bias is expected to be minimal. The data that were 
required for this analysis was either individual tabulated data of FFM values 
(or covariates weight, height and sex in order to compute 𝐹𝐹𝑀) and 𝐶𝐿 values 
or a plot of 𝐶𝐿 versus 𝐹𝐹𝑀 from which data pairs could be extracted digitally. 
Search keywords: “((NONMEM OR ((population AND (model* OR analys*)) OR 
(non AND linear AND mixed AND effect*))) AND ((fat AND free AND 
(weight OR mass)) OR (lean AND body AND (weight OR mass))) AND (PK 
OR pharmacokinetic* OR clearance)”  
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5.2.1.1. Inclusion criteria:  
- Full text articles only 
- Only human studies,  
- Only reports in English 
- Only adult participants (i.e. >18 years of age)  
- Reports that provide individual values of 𝐶𝐿 and 𝐹𝐹𝑀 or where 𝐹𝐹𝑀 
could be calculated at the individual level (using sex, body weight, 
and height) 
5.2.1.2. Exclusion criteria:  
- Drugs that are significantly eliminated by kidney (>20%) and/or by 
other extra-hepatic mechanism such as plasma instability; non-specific 
metabolism (e.g. carboxyl esterase, protease); and target mediated 
drug disposition (TMDD). 
- Drugs that are known to demonstrate non-linear and/or time varying 
elimination due to auto-inhibition and induction of metabolic 
enzyme(s) respectively.  
- Drugs that have a high systemic clearance above 30 L/hr and/or are 
substrates of polymorphic enzymes such as CYP2D6.  
Articles which reported individual 𝐶𝐿  and 𝐹𝐹𝑀  data (either in tabular or 
graphical format) were selected. Where a graphical format was provided, 
individual level data were extracted using the software programme Plot 
Digitizer (version 2.5). The data were then collated for analysis. 
Individual data of all the drugs were pooled to form a single dataset for 
analysis. In the input data file (.csv), each drug was assigned an ID, and the 𝐶𝐿 
values under each drug was considered as the repeated dependent variable 
measures and 𝐹𝐹𝑀 the explanatory variable. For drug(s) where 𝐶𝐿 values of 
multiple metabolic pathways (e.g. acetaminophen) were separately reported, 
each pathway was considered as a distinct ID in the data file. If sufficient multi-
pathway data were available then an additional level of between-occasion 
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variability would be considered. For each drug, the average 𝐶𝐿 value (𝐶𝐿𝑚𝑒𝑎𝑛) 
was calculated and recorded in the dataset, which was used as an a priori drug 
specific normalising constant during the modelling step. The hierarchical 
model for the data is described below (Eq 5.1, Eq 5.2 and Eq 5.3)  
Individual level model: 
𝑌𝑖𝑘𝑗 = 𝑓(𝜽𝒊𝒌, 𝑥𝑖𝑘𝑗 , 𝐶𝐿𝑚𝑒𝑎𝑛𝑖) + 𝑖𝑘𝑗 
Eq 5.1 Individual level model of    and 𝑭𝑭𝑴 
𝑌𝑖𝑘𝑗: 𝐶𝐿 of the 𝑖
th drug in the 𝑘th occasion (i.e. article) at the 𝑗th observation (i.e. patient), 𝜽𝒊𝒌: 
Vector of individual level parameters for the 𝑖th drug in the 𝑘th occasion, 𝑥𝑖𝑘𝑗: Represents 𝐹𝐹𝑀 
for the 𝑖th drug in the 𝑘th occasion at the 𝑗th observation, 𝐶𝐿𝑚𝑒𝑎𝑛𝑖𝑘: Represents the calculated 
average clearance of the 𝑖th drug (considered as a normalising constant) in the 𝑘th occasion, 
𝑖𝑘𝑗 : Residual error between the predicted and 𝑗
th observation of the 𝑖 th drug in the 𝑘 th 
occasion. 
 
Between-occasion variability (BOV) model: 
𝜽𝒊𝒌~𝑁(𝜽𝒊, 𝚱) 
Eq 5.2 BOV model for    and 𝑭𝑭𝑴 
𝜽𝒊: Vector of individual level parameters for the 𝑖
th drug (average of 𝑘 occasions),𝜥: Variance-
covariance matrix of inter-occasion variability of 𝜃𝑖  parameters, BOV model was only 
applicable if data of the same drug comes from multiples sources (i.e. articles).  
 
Between-subject variability (BSV) model: 
𝜽𝒊~𝑁(𝜽,𝛀) 
Eq 5.3 BSV model for    and 𝑭𝑭𝑴 
𝜽: Vector of population level parameters [𝜃1, 𝜃2, 𝜃3]. Their descriptions are given in section 
5.2.2.1 and in Table 5.1,𝜴: Variance-covariance matrix of between-subject variability of 𝜽 
parameters. 
5.2.2. Model development 
The data were analysed in a nonlinear mixed effects modelling 
framework due to the presence of repeated measures and the model may incur 
inclusion of statistical nonlinearity. Modelling was performed using NONMEM 
(version 7.3) and a three stage hierarchical modelling framework. An input-
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output (I/O) model was used to scale individual clearance with 𝐹𝐹𝑀 (𝑥𝑖𝑘𝑗) by 
using the individual level parameters (𝜽𝒊𝒌) as in Eq 5.1. A combined error 
model (proportional + additive) was applied to quantify the residual 
unexplained variability (RUV) over the observations, i.e. intra-individual 
variability. A BOV model was assumed to obtain the individual level 
parameters at the 𝑘th occasion (𝜽𝒊𝒌) from the average of all the occasions (𝜽𝒊) as 
shown in Eq 5.2. The average individual parameters were obtained from the 
population parameter (𝜽) by assuming a between-subject variability (BSV) 
model (Eq 5.3). The first-order conditional estimation with interaction (FOCEI) 
method was used for parameter estimation. Here, a model for BOV would be 
considered if individual 𝐶𝐿 and 𝐹𝐹𝑀 data for a particular drug (i.e. ID) came 
from multiple sources (i.e. articles).  
5.2.2.1. Model description 
A summary of the general model equations are shown in Table 5.1. In the 
absence of multiple references for the same drug then BOV would be omitted. 
Three population level parameters (fixed effects) were considered, i.e. 𝜃1, 𝜃2, 
and 𝜃3. Here, 𝜃1 refers to the ratio between standard population 𝐶𝐿 (unknown) 
and 𝐶𝐿𝑚𝑒𝑎𝑛𝑖𝑘  (known) for a drug; e.g. 𝜃1  will be 1 if the observed 𝐶𝐿𝑚𝑒𝑎𝑛𝑖𝑘 
equals to population 𝐶𝐿 . The parameters 𝜃2  and 𝜃3  represent the scaling 
exponent and the intercept of clearance with respect to 𝐹𝐹𝑀 at the population 
level. For all fixed effects parameters 𝜃1, 𝜃2, and 𝜃3, BSV models were applied 
to account for the random inter-individual differences by which drug specific 
parameters 𝜃1𝑖 , 𝜃2𝑖 , and 𝜃3𝑖  were obtained respectively. A BOV model was 
assumed to discern the drug specific parameter values for the for the 𝑘 th 
publication (if exists), i.e. 𝜃1𝑖𝑘 , 𝜃2𝑖𝑘 , and 𝜃3𝑖𝑘  respectively. Proportional error 
models were used to account for BSV, where 𝜂𝑖1, 𝜂𝑖2, and 𝜂𝑖3 were the random 
errors of 𝜃1 , 𝜃2 , and 𝜃3  respectively, and were log-normally distributed. The 
distributions of 𝜂𝑖1, 𝜂𝑖2, and 𝜂𝑖3 were defined by the variance-covariance matrix 
𝛀, where 𝜔1, 𝜔2, and 𝜔3 refer to their respective standard deviations from a 
mean zero. Similarly, proportional error models were used to account for BOV, 
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where 𝜂𝑘1, 𝜂𝑘2, and 𝜂𝑘3 were the random errors of 𝜃1𝑖, 𝜃2𝑖, and 𝜃3𝑖 respectively, 
and were log-normally distributed. The distributions of 𝜂𝑘1, 𝜂𝑘2, and 𝜂𝑘3 were 
defined by the variance-covariance matrix 𝚱, where 𝜅1, 𝜅2, and 𝜅3 refer to their 
respective standard deviations from a mean zero. At the individual level (i.e. 
for 𝑖th drug at 𝑘th occasion), an I/O model was used to describe the expectations 
of repeated measurements of clearance at the 𝑗th observation of 𝐹𝐹𝑀 (𝐶𝐿𝑖𝑘𝑗).  
The I/O model consisted of a coefficient term and an exponent (non-linear) 
term with and without an intercept term 𝜃3 . Finally, the RUV model was 
considered to describe the intra-individual variations of the observations 
(𝐶𝐿𝑖𝑘𝑗,𝑜𝑏𝑠) from the I/O model expectations (𝐶𝐿𝑖𝑘𝑗). For RUV, both additive and 
combined error model was used where 𝜖𝑖𝑘𝑗1 and 𝜖𝑖𝑘𝑗2 refer to the additive and 
the proportional errors respectively. The distribution of 𝜖𝑖𝑘𝑗1  and 𝜖𝑖𝑘𝑗2  was 
defined by the variance-covariance matrix 𝚺 , where 𝜎1  and 𝜎2  refer to their 
respective standard deviations with a mean zero. Additionally, a drug specific 
proportional error (𝜂𝑖4) was also tried which was distributed with standard 
deviation 𝜔4 and mean zero.  
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Table 5.1 Model equations for the meta-analysis 
Fixed Effects Parameters: 𝜽 ,  𝜽 , 𝜽𝟑 (population level) 
BSV Model 
𝜃1𝑖 = 𝜃1 × 𝑒
𝜂𝑖1   
𝜃2𝑖 = 𝜃2 × 𝑒
𝜂𝑖2      
𝜃3𝑖 = 𝜃2 × 𝑒
𝜂𝑖3               






]    
BOV Model (if applicable) 
𝜃1𝑖𝑘 = 𝜃1𝑖 × 𝑒
𝜂𝑘1   
𝜃2𝑖𝑘 = 𝜃2𝑖 × 𝑒
𝜂𝑘2   
𝜃3𝑖𝑘 = 𝜃3𝑖 × 𝑒
𝜂𝑘3 







]    
I/O model (Individual level) 







𝐶𝐿𝑖𝑘𝑗,𝑜𝑏𝑠 = 𝐶𝐿𝑖𝑘𝑗 × 𝑒
𝜖𝑖𝑘𝑗2 + 𝜖𝑖𝑘𝑗1  
𝐶𝐿𝑖𝑘𝑗,𝑜𝑏𝑠 = 𝐶𝐿𝑖𝑘𝑗 + 𝜖𝑖𝑘𝑗1 × 𝑒
𝜂𝑖4 , where variance of 𝜂𝑖4 is 𝜔4
2 (defined in 𝛀) 




2]    
 
5.2.2.2. Model selection and evaluation 
Various fixed effects models (e.g. fixing or estimating parameter) and 
random effects models (e.g. with or without BSV on 𝜃2 , additive or 
combination RUV models) were tested. Model selection was done based on log-
likelihood ratio test (LRT), where a decrease in the NONMEM objective 
function (Δ𝑂𝐵𝐽) > 3.84 was considered statistically significant (p-Value <0.05) 
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for one parameter difference. The final model was evaluated by the observed 
vs. the predicted (i.e. the goodness-of-fit) plots.  
5.3. Results 
5.3.1. Data 
The flow chart of the article screening process is shown in Figure 5.1. The 
initial search resulted in 221 articles. Out of these 221 articles, 88 articles were 
retained after applying the inclusion/exclusion criteria. Upon manually 
screening those 88 articles, 15 articles were found to contain individual level 
data for 𝐶𝐿 and 𝐹𝐹𝑀. Further applying the criteria to exclude significant extra-
hepatic elimination and high clearance drugs resulted in 7 articles, which were 
eligible for analysis.  
 
Figure 5.1 Summary of article screening following MEDLINE search 
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A summary of the chosen articles is provided in Table 5.2. None of the 
drugs were found from multiple articles. For acetaminophen, separate values 
of 𝐶𝐿  for three different metabolic pathways, i.e. glucuronidation (major), 
sulfation (minor) and CYP2E1 mediated oxidation (minor) were available for 
each patient. Since no drug data were sourced from more than 1 study then the 
BOV terms were dropped from the modelling.  In addition, only 1 drug had 
repeated pathways unmeasured and therefore an additional level of BOV was 
not considered. The, 𝐶𝐿  values from each pathway of acetaminophen were 
assigned to a different ID in NONMEM input data file. Also, carabamazepine 
data were excluded from the modelling dataset because of its known property 
of enzyme induction. Hence, altogether 8 different IDs and 521 repeated 
measures were used in the NONMEM data set. Visualisation of individual 𝐶𝐿 
vs. 𝐹𝐹𝑀 data for all the 8 IDs is shown in Figure A3.1 of Appendix 3: . 
  








   (L/hr) 
Reference 





Antipyrine PO 17 32.0 – 62.0 1.6 [60] 
Efavirenz PO 71 35.6 – 75.0 6.6 [201] 
Theophylline PO 12 44.8 - 67.6 33.2 [202] 
Ribavirin PO 321 40.6 - 91.3 19.7 [203] 
Moxifloxacin IV 12 49.4 - 94.8 9.6 [204] 
a 𝐶𝐿  for three metabolic pathways were separately reported for each patient, b 
glucuronidation, c sulfation, d oxidation, e excluded from modelling dataset  
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5.3.2. Model development 
A summary of the model selection is given in Table 5.3. Additional 
models were tested and are summarised in Table 5.4. All modelling was 
considered within a two-stage hierarchical modelling. Initially, an intercept 
model (M1) was tried where the intercept 𝜃3 was estimated. The estimate of 𝜃3 
was negligible and also, the associated estimate of CV% (𝜔3) was 152% which 
appeared to be unrealistic. Moreover, excluding the 𝜃3 parameter (and 𝜔3) did 
not significantly worse the model fit in M2. Therefore, successive modelling 
(M2 onwards) excluded 𝜃3. Initially, an additive error was used to describe 
RUV (M1, M2); however inclusion of a combined error model (M3) 
significantly improved the fit. In M4, the BSV on parameter 𝜃2 was fixed to zero 
which significantly worsened the model fit as 𝑂𝐵𝐽 was increase by 25.53 points 
compared to M3. When an ETA-EPS error model was considered, i.e. using 
BSV in the residual error (𝜖 × 𝑒𝜂 ), the fit of model M5 was significantly 
improved compared to M3 (Δ𝑂𝐵𝐽 = −62.78). The estimated exponent of M5 
was 0.68 with a 45% BSV on it. Further, fixing the BSV of 𝜃2 to zero (M6) and 
considering correlation between 𝜔2, 𝜔3  (M7) did not improve the model fit 
compared to M5. The final model was therefore M5. 
A sub-group analysis was done (Table 5.4) by excluding certain drugs 
based on their metabolic pathways to rule out if any particular pathway is 
influential towards the estimate of the exponent. First, oxidation pathway of 
acetaminophen was excluded (S1) since it has minute contribution on the 
overall elimination of the drug. In the next stage, its glucuronidation was 
excluded (S2) given the fact that a type of enzyme (i.e. cytosolic) isoform is 
involved in the process (aka phase-2) which is different that the regular 
microsomal metabolism by CYPs (aka phase-1). Exclusion of moxifloxacin was 
also tested (S4) since it is metabolised by phase-2 enzymes. Further, exclusion 
of both acetaminophen glucuronidation and moxifloxacin data (S5) and 
exclusion of all pathways of acetaminophen were also tried (S3). Irrespective of 
the exclusion of specific metabolic pathway or drug, the estimate of exponent 
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varied from 0.52 to 0.76. In subgroup analyses 𝑂𝐵𝐽 values were not compared 
as the number of records varied in different datasets.  
The goodness-of-fit plot and the residual plot of M5 appeared reasonable 
(Figure 5.2). Therefore, M5 was considered as the final model. The signature 
profile of the 𝐶𝐿 𝑣𝑠. 𝐹𝐹𝑀 relationship has been shown in Figure 5.3. 
 
Table 5.3 Summary of model selection in meta-analysis 









M1a 1150.98 - 0.99 0.64 4% 38% 1.8 - 
M2 1151.17 0.19 0.99 0.64 4% 38% 1.8 - 
M3 1130.35 -20.63 b 1.00 0.65 5% 35% 1.4 8% 













M5 1067.57 -62.78 c 0.99 0.68 3% 45% 0.67 1.1 




M7 1066.61 -0.96 d 0.99 0.71 3% 42% e 0.67e 1.1 
a Estimates of intercept 𝜃3 = 0.02 and its BSV 𝜔3 = 1.52 , b Calculated as (M1 – M3), c 
Calculated as (M3 – M5), d Calculated as (M5 – M7), e Correlation between 𝜔2 and 𝜔3 was 
estimated to be -0.42, ∆𝑂𝐵𝐽 represents the difference between the two consecutive models 
unless otherwise stated; the drop and gain in 𝑂𝐵𝐽 values (compared to the previous model) is 
represented by negative and positive signs respectively. 
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Table 5.4 Summary of sub-group analyses. 









S1 1087.33 1.00 0.61 4% 35% 1.4 51% 
S2 978.49 1.00 0.61 4% 43% 1.01 64% 
S3 962.08 1.01 0.52 5% 1% 1.3 53% 
S4 1034.85 1.00 0.76 4% 39% 1.0 69% 
S5 945.52 1.01 0.70 5% 37% 0.90 63% 
S1 excluded acetamenophen-oxidation; S2 excluded acetamenophen -glucuronidation; S3 
excluded all pathways of acetamenophen metabolism, S4 excluded moxifloxacin; S5 excluded 




Figure 5.2 (a) Goodness-of-fit plot and (b) residual vs. IPRED plot of the final 
model (M5) 
The solid black line represents the line of unity and the dotted line represents the zero residual. 
 
 




Figure 5.3 Normalised clearance (PRED/    𝒂 ) vs. normalised fat-free mass 
(𝑭𝑭𝑴/𝑭𝑭𝑴  𝒅) plots 
The solid black lines represent the line of unity. 
 
5.4. Discussion 
In this work, the average relationship between clearance (𝐶𝐿) and fat-free 
mass (𝐹𝐹𝑀) was estimated from the literature data using a model-based meta-
analysis (MBMA) method within the framework of non-linear mixed effects 
(NLME) modelling.  
In clinical pharmacology, the traditional meta-analysis refers to the 
statistical analysis of a large collection of data from multiple pharmacokinetic 
(PK)-pharmacodynamic (PD) studies for the purpose of integrating the findings 
[205]. Model-based meta-analysis (MBMA) builds on traditional meta-analysis 
by further incorporating NLME models into it in order to describe the average 
findings, e.g. PK parameters and the variability. Meta-analyses can be based on 
either individual patient data (e.g. individual concentration-time course) or 
aggregate data (e.g. mean response or treatment effect). While individual 
patient data based meta-analyses are considered the gold standard [206], 
literature based meta-analyses are more often based on aggregate data due to 
limited accessibility to individual level data. Pooling data from multiple studies 
makes the analyses more informative in nature, increasing the precision of the 
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parameter estimates and also the statistical power to accurately identify the 
sources of variability (i.e. covariates) in the parameters of interest [207]. Overall, 
MBMA has been extensively applied in clinical pharmacology to address a 
range of questions. For example, new covariates of 𝐶𝐿 (that were not identified 
retrospectively) were identified for efavirenz [208] and docetaxel [209] from 
pooled phase-1 and phase-2 studies; a parent-metabolite PK model for vitamin 
D3 and its active metabolite 25-hydroxy vitamin D3 was developed [210]; and a 
guidance to optimally design phase-1 studies for therapeutic antibodies [211] 
using MBMA has also been proposed.  
There was an a priori expectation that 𝐶𝐿 would vary in proportion to 
𝐹𝐹𝑀 (i.e. linear scaling) since drug elimination occurs in the lean portion of the 
body. The finding of Chapter 6: (next chapter) aligns with such expectation of 
linear scaling of clearance by 𝐹𝐹𝑀. However, the result of this analysis suggests 
that 𝐶𝐿 is scaled by 𝐹𝐹𝑀 with an estimated exponent of 0.68 which indicates a 
less than proportional scaling. This estimate includes scaling of 𝐶𝐿  by 2/3 
power of body size which is a well-known scaling method in total body weight 
based scaling [123, 124].  
The finding of this study aligns with the literature based meta-analysis 
reported by McLeay et al. [60]. Their meta-analysis derived the average scaling 
exponent to be 2/3 (i.e. 0.67) when 𝐶𝐿 is scaled by 𝐹𝐹𝑀. It is noteworthy that 
their meta-analysis involved pooling drugs from a range of mechanisms (i.e. 
renal, hepatic, and mixed) and extents (i.e. low and high liver extraction ratios) 
of elimination, whereas this work particularly analysed the data coming from 
low-clearance drugs that are solely eliminated by liver and in the subgroup 
analysis only those that were eliminated by phase-1 metabolism (S5 in Table 
5.4). Therefore, there is little theoretical explanation behind the similarity in 
these findings. While looking at the individual 𝐶𝐿 vs. 𝐹𝐹𝑀 profiles (Figure A3.1 
in Appendix 3: ), a range of exponents were found among the drugs. This can 
be explained by 45% BSV over the estimate of the exponent (𝜃2). The cause of 
this variation could not be understood by the current analysis. 
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The major limitation of this work was limited sample size, i.e. 8 IDs (N=8) 
out of 6 drugs were available for modelling. Such a small sized study is less 
likely to have adequate power to estimate the true parameter-covariate 
relationship as demonstrated by Ribbing et al. [56] and also covered under 
Chapter 2:  [212] Therefore, the estimated exponent 0.68 should be interpreted 
and implemented cautiously, as it may not represent the true 𝐶𝐿  vs. 𝐹𝐹𝑀 
relationship across a wider range of drugs, unless validated by a larger meta-
analyses in the future. Future studies are advised to include an a priori power 
analysis and increase the sample size accordingly in order to ensure adequate 
(>80%) power. In addition, the current study covered limited pathways of CYP 
metabolism (e.g. CYP2E1: acetaminophen, CYP2B6/2A6: efavirenz, CYP1A2: 
theophylline), and phase-2 metabolism (e.g. acetaminophen, moxifloxacin). 
Therefore, the current study provide limited support to extend the use of 2/3 
as the value of exponent for drugs that are metabolised by phase-1 and/or 
phase-2 metabolism in general. Thus future analyses should ideally include 
sufficient data covering other common pathways of drug metabolism (e.g. CYP 
2D6, 2C9, 2C19), and possibly drug efflux (i.e. transporter mediated biliary 
secretion). Hence, in the absence of knowledge about the true relationship 
between 𝐶𝐿 and 𝐹𝐹𝑀, it will be prudent to estimate the exponent with the data 
empirically. However, if the study is under-powered (due to limited sample 
size and/or covariate range), estimation may lead to biased exponent as shown 
in Chapter 2:  [212].  Under such circumstances, assuming the theoretical linear 
relationship (derived in Chapter 6: ) or a value of 2/3 might be a reasonable 
alternative. In this context, a theoretical basis of 𝐶𝐿 vs. 𝐹𝐹𝑀 scaling exponent 




















Chapter 6:  Evaluating the relationship between 
















The global prevalence of obesity and its related co-morbidities are rising 
[192, 213]. As a result, clinicians are faced with an increasing number of obese 
patients in their day to day practice [24]. Obesity is known to influence drug 
clearance (𝐶𝐿) due to changes in body size and composition, and hence alters 
the maintenance dose rate requirements [183, 214, 215]. However, quantification of 
dose requirements in the obese is rarely formally explored as obese subjects are 
often excluded from clinical trials during drug development.  
Fat-free mass (𝐹𝐹𝑀) has been proposed as an alternative dose scaler to 
body weight (𝑊𝑇) [25, 91, 103, 106, 107, 126, 136-138] as it accounts for the change in body 
size and composition in contrast with 𝑊𝑇 which only accounts for size. Dose 
scaling by 𝐹𝐹𝑀  is underpinned by the scaling of 𝐶𝐿  by 𝐹𝐹𝑀 , based on the 
assumption that dose and 𝐶𝐿  follow a proportional relationship; however, 
limited theory is available to impute linearity. Moreover, the nature of the 
scaling relationship is not universally proportional in the literature, and an 
empirical value of 0.67 was derived by McLeay et al. [60]. In line with the 
literature, the empirically estimated value of the exponent particularly for the 
low extraction drugs was 0.68 in Chapter 5, which again does not support a 
linear scaling of CL by FFM. Therefore, it is necessary to understand whether 
the empirically determined values can be supported by a theory. 𝐹𝐹𝑀 based 
scaling is underpinned by the assumption that drug eliminating organs are 
constituents of 𝐹𝐹𝑀 and their capacity to metabolise and/or excrete drugs (as 
determinant of 𝐶𝐿) vary according to the variation in 𝐹𝐹𝑀  across lean and 
obese individuals [136]. When the eliminating organ is the liver, 𝐶𝐿  of low 
clearance drugs approximates to the hepatic intrinsic clearance, i.e. 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻 
(assuming a well-stirred model), which is believed to be proportional to 
𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 (Eq 6.1) under certain assumption (see section 6.4 and Eq 6.14). Since 
𝐶𝐿 ∝ 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒, then the 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 vs. 𝐹𝐹𝑀 relationship that is denoted by a 
mathematical function 𝑓 in Eq 6.2 would determine the theoretical relationship 
between  𝐶𝐿 and 𝐹𝐹𝑀, described by function 𝑔 in Eq 6.3 (i.e. 𝑓 = 𝑔). Therefore, 
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the theoretical scaling relationship between 𝐶𝐿 and 𝐹𝐹𝑀 (i.e. 𝑔), whether linear 
(i.e. proportional) or non-linear, can be deduced by finding the relationship 
between 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 and 𝐹𝐹𝑀 (i.e. 𝑓).  
 
𝐶𝐿 (≈ 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻) ∝ 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 
Eq 6.1 Relationship between clearance and liver size 
 
𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 = 𝑓(𝐹𝐹𝑀) 
Eq 6.2 Liver size as a function of fat-free mass. 
 
𝐶𝐿 = 𝑔(𝐹𝐹𝑀) 
Eq 6.3 Clearance as a function of fat-free mass. 
 
Traditionally, total liver volume (𝐿𝑉) is used as descriptor of 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒. 
However, it is unclear if 𝐿𝑉 accurately describes the ‘functional’  𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 in 
the obese. Here, we define ‘functional’ 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 as the volume of liver from 
which drug elimination occurs. From a biological point of view, 𝐿𝑉 represents 
the summation of lean liver volume (𝐿𝐿𝑉) and liver fat (𝐿𝐹𝐴𝑇) as shown in Eq 
6.4. The lean portion of the liver primarily consists of metabolically active 
parenchymal tissue that almost exclusively contributes to drug elimination. In 
healthy livers, the presence of liver fat is negligible (<2% of 𝐿𝑉) [216, 217] and thus 
𝐿𝑉  is a sufficient approximation of ‘functional’ 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 . However, nearly 
90% of obese patients have steatosis [110, 111], a pathological condition where 
liver fat is above 5% of 𝐿𝑉  and reported to be as high as 50% [79, 115, 218]. 
Therefore, we hypothesise that scaling of 𝐶𝐿 by 𝐹𝐹𝑀 actually simplifies to the 
scaling of 𝐿𝐿𝑉 by 𝐹𝐹𝑀.  
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𝐿𝑉 = 𝐿𝐿𝑉 + 𝐿𝐹𝐴𝑇 
Eq 6.4 Components of total liver volume. 
 
The aim of this work was to investigate the relationship between LLV and 
𝐹𝐹𝑀 and therefore to identify the form of Eq 6.2.  
6.2. Method 
6.2.1. Data 
One hundred adult Indian (Caucasian) patients consisting of 30 females 
and 70 males aged 18-60 years and scheduled to undergo a computerised 
tomography (CT) scan of the abdomen or neighbouring anatomical region were 
recruited in this study. The study was conducted at the PSG Hospital, 
Coimbatore, India and described by McLeay et al. elsewhere [195]. Subjects were 
stratified into three groups according to body mass index ( 𝐵𝑀𝐼 ) with 
approximately equal number of subjects per group: normal (<25 kg/m2), 
overweight (25-30 kg/m2), and obese (>30 kg /m2). Single measurements of 
lean liver volume (𝐿𝐿𝑉) per patient were available from this study, along with 
patient characteristics such as sex, height (𝐻𝑡), weight (𝑊𝑇), age, and clinical 
chemistry such as blood glucose and lipid profiles and liver and kidney 
functions. The 𝐿𝐿𝑉 data was derived from the total liver volume (𝐿𝑉) and liver 
fat (𝐿𝐹𝐴𝑇) data, measured by a CT-based method which has been described in 
detail by McLeay et al. [195]. All subjects underwent ultrasonography screening 
of the abdomen prior to recruitment and were excluded if there was evidence 
of hepatic structural abnormality. Subjects were also excluded if they had 
abnormal liver or kidney function tests, were undergoing current treatment for 
a medical condition related to the liver or kidney, were pregnant, or were 
breastfeeding. Patient characteristics used for modelling are summarised in 
Table 6.1. Individual 𝐹𝐹𝑀 was calculated from the patients’ characteristics by 
using the equations developed by Janmahasatian et al. (Eq 6.5 and Eq 6.6) [102] 
and Kulkarni et al. (Eq 6.7 and Eq 6.8) [194]. However, 𝐹𝐹𝑀 by Kulkarni’s model 
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was used throughout the modelling work based on the assumption that it 
reasonably approximates the true 𝐹𝐹𝑀  in Indian subjects [105] (discussed in 




6680 + 216 × 𝐵𝑀𝐼
 




8780 + 244 × 𝐵𝑀𝐼
 
Eq 6.6 Janmahasatian's model for fat-free mass in females (same as Eq 1.36 
 
 
𝐹𝐹𝑀𝐾𝑢𝑙 (𝑚𝑎𝑙𝑒) = −15.605 − (0.032 × 𝐴𝑔𝑒) + (0.192 × 𝐻𝑡) + (0.502 ×𝑊𝑇) 
Eq 6.7 Kulkarni's model for fat-free mass in males 
 
𝐹𝐹𝑀𝐾𝑢𝑙 (𝑓𝑒𝑚𝑎𝑙𝑒) = −13.034 − (0.018 × 𝐴𝑔𝑒) + (0.165 × 𝐻𝑡) + (0.409 ×𝑊𝑇) 
Eq 6.8 Kulkarni's model for fat-free mass in females 
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Table 6.1 Summary of patient characteristics in the study 
BMI strata 
Normal 
( = 𝟑 ) 
Over weight 
( = 𝟑 ) 
Obese 
( = 𝟑𝟗) 







































































𝐹𝐹𝑀 fat-free mass, 𝐵𝑀𝐼 body mass index, 𝐵𝑆𝐴 body surface area, 𝐿𝑉 total liver volume, 𝐿𝐹𝐴𝑇 
liver fat, 𝐿𝐿𝑉  lean liver volume, a calculated by Kulkarni’s model [194], b calculated by 
Janmahasatian’s model [102]   
 
6.2.2. Model development 
Lean liver volume was modelled within a nonlinear regression 
framework using the first-order approximation method (FO) in NONMEM 
(version 7.3). Note there were no repeated measures in this data set. Covariates 
were selected based on the Akaike Information Criteria (AIC) [55], where a 
lower AIC value was indicative of a better description of the data. In the first 
stage, both allometric scaling (Eq 6.9) and linear scaling (𝜃𝑠𝑖𝑧𝑒 fixed to 1) was 
used to identify the best size descriptor among 𝑊𝑇, 𝐵𝑆𝐴, and 𝐹𝐹𝑀, with and 
without including sex. We define allometric here as any relationship that is not 
isometric, that is any nonlinear relationship between 𝐿𝐿𝑉  and a measure of 
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body size. This was followed by testing clinical chemistry markers by linear 
models (Eq 6.10) using stepwise covariate modelling which involved forward 
selection (p value <0.05) followed by backward deletion (p value <0.01) steps. An 
additive residual error model (Eq 6.11) was used for modelling the data. 
Finally, biological plausibility was used to justify the selection of the final 
model.  






Eq 6.9 Allometric scaling model for lean liver volume. 
 









Eq 6.10 Linear model for lean liver volume. 
 
𝐿𝐿𝑉𝑖,𝑜𝑏𝑠 = 𝐿𝐿𝑉𝑖 + 𝜖𝑖      [where 𝜖𝑖 ∼ 𝑁(0, 𝜎
2)] 
Eq 6.11 Error model for lean liver volume 
 
6.2.3. Model evaluation 
Goodness-of-fit (GoF) plots were used for preliminary evaluation of the 
models. A marginal visual predictive check (VPC) plot was created to assess 
the predictive performance of the final model. The model estimated fixed 
effects and the distribution of the residual error were used to (parametrically) 
generate 1000 simulated 𝐿𝐿𝑉 values for each subject in the dataset that was 
used for modelling. The 5th, 50th, and 95th prediction percentiles along with 
their 95% confidence intervals (CI) from the simulated 𝐿𝐿𝑉 data were plotted 
with the observed data (5th, 50th, and 95th percentiles) superimposed.  
In addition, non-parametric bootstrap analysis of the final model was 
performed with 1000 replicates from the dataset and the mean of the parameter 
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estimates along with the boundaries of their interquartile range (IQR) and 
relative standard error (RSE) were reported. 
 
6.3. Results  
𝐹𝐹𝑀  data predicted by Janmahasatian’s model (𝐹𝐹𝑀𝐽𝑎𝑛)  demonstrated 
deviation from the 𝐹𝐹𝑀 data that was predicted by Kulkarni’s model (𝐹𝐹𝑀𝐾𝑢𝑙) 
[194], (see Figure 4.2 of Chapter 4: ). Overall, 𝐹𝐹𝑀𝐽𝑎𝑛 estimates were higher than 
the 𝐹𝐹𝑀𝐾𝑢𝑙 estimates, particularly in males, and the mean difference [95%CI] 
was -1.9 [(-2.6) – (-1.2)] kg with a standard deviation of 3 kg (see Table 4.2 of 
Chapter 4: ).  
All size descriptors (i.e. 𝑊𝑇, 𝐵𝑆𝐴, and 𝐹𝐹𝑀) were found to be statistically 
significant covariates of 𝐿𝐿𝑉 irrespective of whether scaled linearly (i.e. fixed 
exponent 1) or allometrically (i.e. exponent is estimated) (Table 6.2: M2 to M11 
performed better than M1). The allometric models (M3, M6, M9) performed 
better than their linear counterparts (M2, M5, M8), in terms of AIC reduction, 
although this improvement was marginal for 𝐹𝐹𝑀 + 𝑠𝑒𝑥 . Notably, the 𝐵𝑆𝐴 
model (M6) was most preferred (statistically) among the allometric models 
tested. However, including sex in the 𝐹𝐹𝑀 model (M10) significantly further 
decreased the AIC value from 1220 to 1205 units, which left the 𝐹𝐹𝑀 model 
being preferred to all models based on 𝑊𝑇, but not to the allometrically scaled 
𝐵𝑆𝐴 model (M6). Both 𝑊𝑇 and the 𝐵𝑆𝐴 models were insensitive to sex (i.e. M4 
and M7). Therefore, the final model was selected from the two candidates 
allometrically scaled 𝐵𝑆𝐴 (M6) and 𝐹𝐹𝑀 + sex (M10).  We note that allometric 
scaling of 𝐹𝐹𝑀  + sex provided no benefit, since the estimated allometric 
exponent of the 𝐹𝐹𝑀 + sex model (M10) was 1.05 indicating essentially linear 
scaling and this was subsequently fixed to 1 (i.e. M11).  It is now seen that M11 
has a marginally lower AIC value than M6 (allometrically scaled BSA). Also 
when interpreting an exponent on 𝐵𝑆𝐴 we note that 𝐵𝑆𝐴 is proportional to 
𝑊𝑇
2
3  (i.e. 𝑊𝑇0.67 ), and thus scaling 𝐵𝑆𝐴  raised to a power of 1.58, i.e. 
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(𝑊𝑇0.67)1.58 would yield a model that is approximately a linear scaling on 𝑊𝑇 
( ≈ 𝑊𝑇1 ) and hence this scaling on 𝐵𝑆𝐴  appears to have no biological 
plausibility.  
Table 6.2 Summary of model selection from various size descriptors 
Model No. Covariate(s) Model Exponent (𝜽 𝒊𝒛 ) a AIC 
M1 NA Base NA 1275 
M2 𝑊𝑇 Linear 1 (fixed) 1211 
M3 𝑊𝑇 Allometric 0.79 1207 
M4 𝑊𝑇 +  𝑆𝑒𝑥 Allometric 0.79 1208 
M5 𝐵𝑆𝐴 Linear 1 (fixed) 1215 
M6 𝐵𝑆𝐴 Allometric 1.58 1204 
M7 𝐵𝑆𝐴 +  𝑆𝑒𝑥 Allometric 1.65 1204 
M8 𝐹𝐹𝑀 Linear 1 (fixed) 1222 
M9 𝐹𝐹𝑀 Allometric 0.82 1220 
M10 𝐹𝐹𝑀 +  𝑆𝑒𝑥 Allometric 1.05 1205 
M11 𝐹𝐹𝑀 +  𝑆𝑒𝑥 Linear 1 (fixed) 1203 
NA not applicable, 𝑊𝑇  total body weight, 𝐵𝑆𝐴  body surface area, 𝐹𝐹𝑀  fat-free mass, 
𝐴𝐼𝐶 Akaike Information Criteria, a Estimated unless mentioned as ‘fixed’ 
 
All of the tested clinical chemistry markers were found to be not 
significant during the successive modelling steps and thus were not included in 
the model. The structure of the final models for females and males are shown 
in the Eq 6.12 and Eq 6.13 respectively, along with their parameter estimates in 
Table 6.3. The plots of GoF and VPC are shown in Figure 6.1 and Figure 6.2 
respectively.  




Eq 6.12 Final model structure of lean liver volume for females.  
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Eq 6.13 Final model structure of lean liver volume for males. 
 





Mean (IQR) RSE (%) 
Female Male Female Male Female Male 
𝜽    (mL) 1250 1420 
1255 




𝝈 (mL) 241.5 
238 
(227 - 250) 
14 
𝜃𝐿𝐿𝑉 population standard lean liver volume, 𝜎 standard deviation of the residual error, IQR 




Figure 6.1 Goodness-of-fit plots of lean liver volume (   ) for females (a) 
and males (b) of the final model 



























Predicted   (mL)




Figure 6.2 Visual predictive check (VPC) plots of the final model. 
Fat-free mass (𝐹𝐹𝑀)  is calculated using Kulkarni’s model. The red and the black lines 
represent the percentiles of the observed and simulated data respectively. The solid lines 
represent the 50th percentile (median) while the dotted lines represent the 5th and 95th 
percentiles respectively. The shaded area represents the 95% confidence interval of the model 
predicted percentiles.  
 
6.4. Discussion 
In this work, we have investigated the most relevant size descriptor of 
lean liver volume (𝐿𝐿𝑉), which provides a measure of ‘functional’ 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒. 
This finding would provide the theoretical basis of the 𝐶𝐿 𝑣𝑠. 𝐹𝐹𝑀 relationship, 
and can help rationalise maintenance dose scaling in obese patients. 
Physiological properties such as liver size and function are known to vary 
with body size [220]. By convention, total liver volume (𝐿𝑉) has been used to 
describe the liver size, and the available predictive models of 𝐿𝑉  had 
considered 𝐵𝑆𝐴 as the body size descriptor [221]. There are currently no models 
to predict 𝐿𝐿𝑉 and its relation to body size which is a more relevant descriptor 
of ‘functional’ 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒, especially in the obese. In this work, we showed that 
𝐹𝐹𝑀, in conjunction with sex, described the size related variation in 𝐿𝐿𝑉 better 
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than the traditional descriptor 𝐵𝑆𝐴 (Table 6.2). This supports the observation 
that 𝐹𝐹𝑀 + 𝑠𝑒𝑥 is the best descriptor of basal metabolic rate (BMR) in human, 
which was reported to describe 63% of the inter-individual variability of BMR 
[222, 223]. It is also known that BMR of the whole body is majorly defined by the 
metabolic activities of the ‘functional’ cell mass of various organs, which 
depends on their size [224]. As discussed, for the liver, 𝐿𝐿𝑉 is a more accurate 
descriptor of the ‘organ size’ that is metabolically active, irrespective of body 
size and composition. Therefore in theory, 𝐹𝐹𝑀 + 𝑠𝑒𝑥 should be the descriptor 
of 𝐿𝐿𝑉. Hence, choice of 𝐹𝐹𝑀 was finally made based on biological plausibility, 
apart from the statistical preference over 𝐵𝑆𝐴 . Further stepwise covariate 
modelling with available clinical chemistry measures including liver function 
markers did not result in any additional covariates in the final model. Hence, 
the final model retained 𝐹𝐹𝑀 and sex as the covariates.  
Selection of the 𝐹𝐹𝑀  model was important because Janmahasatian’s 
model (𝐹𝐹𝑀𝐽𝑎𝑛)  largely deviated (i.e. over-predicted) from the Kulkarni’s 
model predictions (𝐹𝐹𝑀𝐾𝑢𝑙) (see Table 4.2 and Figure 4.2 of Chapter 4: ). In the 
absence of measured 𝐹𝐹𝑀 data, there was no direct evidence which supports 
the selection of one 𝐹𝐹𝑀  model over the other in this work. However, 
Srigiripura et al. [105] had reported that 𝐹𝐹𝑀𝐽𝑎𝑛 substantially over-predicted the 
observed 𝐹𝐹𝑀  data in Indian males, measured by bio-impedance analysis 
(BIA), whereas Kulkarni’s model best predicted the observed data among the 
four different 𝐹𝐹𝑀 models tested, including 𝐹𝐹𝑀𝐽𝑎𝑛 . They reported that the 
mean error [95%CI] of the prediction by the Janmahasatian’s model (𝐹𝐹𝑀𝐵𝐼𝐴 −
𝐹𝐹𝑀𝐽𝑎𝑛 ) and the Kulkarni’s model (𝐹𝐹𝑀𝐵𝐼𝐴 − 𝐹𝐹𝑀𝐾𝑢𝑙 ) were -3.76 [(-7.96) – 
(0.44)] kg and 0.33 [(-4.26) – (4.91)] kg respectively. This could be due to the fact 
that Kulkarni’s model was developed in a large cohort of Indian population, 
while the Janmahasatian’s model was developed in a population of mainly a 
European ancestry. Therefore, 𝐹𝐹𝑀𝐾𝑢𝑙 predictions were used during modelling 
throughout this work based on the assumption that 𝐹𝐹𝑀𝐾𝑢𝑙  reasonably 
approximates the true 𝐹𝐹𝑀 in Indian subjects. 
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The estimate (95% CI) of the exponent, i.e. 𝜃𝑠𝑖𝑧𝑒 in M10 was 1.05 (0.86 – 
1.24), which implies that 𝐿𝐿𝑉 scales linearly with 𝐹𝐹𝑀, and hence it was fixed 
to 1 in the final model (M11). This in turn, would support the linear scaling of 
𝐶𝐿 by 𝐹𝐹𝑀 as per Eq 6.1 to Eq 6.3. This might appear contradictory to the 
average relationship derived by McLeay et al. [60], i.e. 𝐶𝐿 ∝ 𝐹𝐹𝑀2/3, since the 
95% CI of the estimate did not include 2/3. However, their meta-analysis 
involved pooling drugs from a range of mechanisms (i.e. renal, hepatic, and 
mixed) and extents (i.e. low and high liver extraction ratios) of elimination. It is 
possible that elimination that is dependent on perfusion (as in high extraction 
ratio drugs) may have different limiting anatomical conditions than liver 
volume. 
 It is noted that liver intrinsic clearance (𝐶𝐿𝑖𝑛𝑡,𝑢𝐻 ) is believed to be 
proportional to 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 (i.e. Eq 6.1) on the assumption that in vitro intrinsic 
clearance (𝐶𝐿𝑖𝑛𝑡,𝑢) and other physiological scaling factors as shown in Eq 6.14 
are constant across the human 𝐹𝐹𝑀 range (i.e. not affected by obesity) [66]. 
These physiological scaling factors include CYP abundanc ([𝐶𝑌𝑃] , 
microsomal protein per gram of liver (𝑀𝑃𝑃𝐺𝐿), etc., however, wide variability 
across individuals has been reported and the cause is poorly understood [225-
227]. Particularly, the influence of obesity on expression and function of CYP 
enzymes (that might affect 𝐶𝐿𝑖𝑛𝑡,𝑢, [𝐶𝑌𝑃] and 𝑀𝑃𝑃𝐺𝐿) have remained mostly 
inconclusive [11]. In addition, the true 𝐶𝐿 (total) vs. 𝐹𝐹𝑀 relationship can be 
masked in reality, if protein binding variation is large across normal and 
obese individuals. Therefore, in the absence of the predictability of these 
additional variance components, it might be acceptable to assume that the 
linear relationship between 𝐿𝐿𝑉 and 𝐹𝐹𝑀 translates to 𝐶𝐿 (thus dose) vs. 𝐹𝐹𝑀 
relationship, particularly for low-clearance drugs. Notably, this would 
require sex to be also considered while scaling 𝐶𝐿 by 𝐹𝐹𝑀 as per the final 
model M11 in Table 6.2. On the contrary, allometric scaling by 𝑊𝑇 does not 
have the additional covariate sex, as inclusion of sex (M3 vs. M4 in Table 6.2) 
did not improve the model fit. Also, the estimated exponent for 𝑊𝑇 was close 
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to its theoretical value of 0.75 [94]. Therefore, the conventional allometric 
scaling of 𝐶𝐿 by 𝑊𝑇 may still appear a plausible scaling method based on the 
results. However, the objective of this work was not to recommend the right 
size scaler for 𝐶𝐿 (and dose), rather to investigate the theoretical relationship 
between 𝐶𝐿 and 𝐹𝐹𝑀, if exists. The choice of dose scaler should be guided by 
biological and clinical relevance. At least for 𝐹𝐹𝑀 (among others), a biological 
plausibility exists, as 𝐹𝐹𝑀 relates to BMR. 
 
𝐶𝐿𝑖𝑛𝑡,𝑢𝐻 = 𝐶𝐿𝑖𝑛𝑡,𝑢 × [𝐶𝑌𝑃] × 𝑀𝑃𝑃𝐺𝐿 ×  𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 
Eq 6.14 Equation for hepatic intrinsic clearance. 
 
The estimates (IQR) of population standard 𝐿𝐿𝑉 measure, i.e. 𝜃𝐿𝐿𝑉  were 
1250 mL (1226 – 1281) and 1420 mL (1402 – 1442) for females and males 
respectively (Table 6.3), which were similar to the median 𝐿𝑉  measures 
reported by Yu et al. [228] and Vauthey et al. [229] in Korean and Western 
populations respectively. Since, these median 𝐿𝑉 measures were reported for 
patients without liver abnormality (e.g. steatosis) they were expected to closely 
approximate the median 𝐿𝐿𝑉  in the respective populations and hence, 
indirectly support the 𝜃𝐿𝐿𝑉  estimates in this work. Considering separate 
exponents for males and females (i.e. sex as a covariate on the exponent) did 
not additionally improve the model fit over a fixed exponent of 1. Further, the 
standard 𝐹𝐹𝑀 values, i.e. 40 kg and 55 kg used in the model (corresponding to 
the median values in the data) well represented the population 𝐹𝐹𝑀 as evident 
from a large population survey conducted by NHANES [230]. This implies that 
the 𝜃𝐿𝐿𝑉  estimates in this study well represent a larger population, and not 
limited to Indians.  The final model is shown in here in Eq 6.15 and Eq 6.16. 




Eq 6.15 Final model of lean liver volume in females. 
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Eq 6.16 Final model of lean liver volume in males 
 
The final model performed well according to the bootstrap results (Table 
6.3) and VPC plots (Figure 6.2). According to the final model, population 𝐿𝐿𝑉 
estimate per kg of 𝐹𝐹𝑀 was higher in females (i.e. 31 mL) than in males (i.e. 26 
mL), which is also apparent in the data (Figure 6.3). This observation is partly 
supported by the findings of Kwo et al. [231] where a higher (~ 36%) 𝐿𝑉 per kg of 
𝐹𝐹𝑀 was reported in females than in males, both without any liver disease. A 
possible explanation of the higher ratio in females could be that 𝐿𝐿𝑉 per kg of 
𝑊𝑇 is similar between females and males while 𝐹𝐹𝑀 per kg of 𝑊𝑇 is lower in 
females than males. 
 
 
Figure 6.3 Plots of observed lean liver volume (   ) data against fat-free 
mass (𝑭𝑭𝑴), stratified by sex. 
The orange and the blue circles represent female and male respectively. The brown and dark 
blue lines represent the regression lines for females and males respectively. 
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In addition, a potential application of 𝐿𝐿𝑉 model could be in vitro-in vivo 
extrapolation of 𝐶𝐿 (IVIVE) in obese. Use of IVIVE, as a ‘bottom up’ approach 
has been recommended for predicting the initial dose in clinical pharmacology 
studies that include obese patients, in the absence of prior information of 𝐶𝐿 in 
this special population [112, 114, 232]. One motivating example is drug 
development in non-alcoholic fatty liver disease (NAFLD) that includes non-
alcoholic steatohepatitis (NASH), where nearly 20 investigational drugs are 
under clinical development pipeline [76, 233]. For non-flow dependent drugs (i.e. 
low-extraction), the key step in IVIVE is to scale the intrinsic clearance of the 
liver (𝐶𝐿𝑖𝑛𝑡,𝑢𝐻) from the in vitro intrinsic clearance data (𝐶𝐿𝑖𝑛𝑡,𝑢). This needs 
scaling for 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒  with respect to body size. By convention, total liver 
volume (𝐿𝑉)  is commonly considered for 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒  and scaled with a 𝐵𝑆𝐴 
based equation [221]. This might lead to substantial over-estimation of 𝐶𝐿 and 
dose in most (~90%) obese patients due to presence of steatosis and hence 𝐿𝐿𝑉 
would be a better descriptor of 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒  in IVIVE, at least for the low-
extracted compounds, in order to predict the right dose in obese. On the other 
hand, no conclusion can be drawn from this study whether 𝐿𝐿𝑉  can be 
considered as a potential dose scaler in standard ‘top down’ approach. In top-
down approach, it is common to test all available scalers like 𝑊𝑇 , 𝐵𝑆𝐴, 𝐹𝐹𝑀  etc. 
where 𝐿𝐿𝑉 can be additionally tested. Although measurement of 𝐿𝐿𝑉 needs CT scan it 
can be predicted by the model. This would need demonstration of improved 
scaling of 𝐶𝐿 by 𝐿𝐿𝑉 as compared to the standard size descriptor like 𝑊𝑇, 𝐹𝐹𝑀. 
At least, in the case of comparison with 𝐹𝐹𝑀, 𝐿𝐿𝑉 is least likely to perform 
better given its proportional relationship with 𝐹𝐹𝑀 . However, validation 
studies are required for a conclusive remark.    
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6.5. Conclusion  
A model to predict lean liver volume (𝐿𝐿𝑉) from readily available patient 
variables was developed and evaluated. Fat-free mass (𝐹𝐹𝑀) and sex were 
found to be the best body size descriptor to scale 𝐿𝐿𝑉  . 𝐿𝐿𝑉 is likely an 
appropriate representation of the functional size of the liver, particularly in the 
obese, and correlates with 𝐹𝐹𝑀. 𝐹𝐹𝑀 has recently emerged as an alternative 
body size scalar for drug clearance (𝐶𝐿) in obese patients. Whether 𝐹𝐹𝑀 and 
drug 𝐶𝐿 scale linearly is currently under debate. The utility of the 𝐿𝐿𝑉 model in 
scaling drug 𝐶𝐿  and dose requirements of hepatically cleared drugs, 
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Obesity is known to influence drug clearance (𝐶𝐿) due to changes in body 
size and composition, with obese patients often requiring a different dose than 
standard adults [183, 214, 215]. Prior information about body size and composition 
driven changes in 𝐶𝐿 can help identify an initial dose for designing clinical 
pharmacology studies involving obese patients. Such studies are typically not 
performed during drug development and hence are often limited to post-
marketing clinical studies [24]. In some exceptional situations, obese patients are 
studied during the drug development phases in order to meet the 
requirement(s) of the specific therapeutic areas, such as non-alcoholic 
steatohepatitis (NASH) [81, 234].  
Recently, an in vitro-in vivo extrapolation (IVIVE) based approach has 
been proposed for predicting 𝐶𝐿 change in the obese population [112, 114, 235]. 
IVIVE of 𝐶𝐿  refers to the scaling of in vitro (unbound) intrinsic clearance 
(𝐶𝐿𝑖𝑛𝑡,𝑢) data to hepatic intrinsic clearance (𝐶𝐿𝑖𝑛𝑡,𝑢𝐻) as shown in Eq 7.1 of this 
chapter and in Eq 6.14 of Chapter 6:  [66]. This involves scaling of the relevant 
physiological variables such as CYP abundance 
([𝐶𝑌𝑃], 𝑎𝑠 𝑝𝑚𝑜𝑙 𝑚𝑔⁄ 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛), microsomal protein per gram of 
liver (𝑀𝑃𝑃𝐺𝐿) , and 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒  by body size. Here, 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒  represents the 
functional size of the liver that describes the volume of liver where drug 
elimination occurs. While the influence of body size and composition on the 
variation of 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 has been well quantified [221], their influence on other 
variables i.e. [𝐶𝑌𝑃] and 𝑀𝑃𝑃𝐺𝐿 has not been determined [225, 226]. Therefore the 
accuracy of 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻scaling would largely depend on the accuracy in scaling of 
𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 at an individual level. Theoretically, scaling of intrinsic clearance is 
particularly important for low-extraction drugs (e.g. warfarin) since in vivo 𝐶𝐿 
is approximated by 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻 when corrected for relevant factors, e.g. free 
fraction in blood (𝑓𝑢,𝑏) as per the ‘well-stirred’ model (Eq 7.2, Eq 7.3). Thus, 𝐶𝐿 
prediction of low-extraction drugs in a differently sized population (i.e. obese) 
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would largely depend on accurate prediction of individual 
(functional) 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒.  
𝐶𝐿𝑖𝑛𝑡,𝑢𝐻 = 𝐶𝐿𝑖𝑛𝑡,𝑢 × [𝐶𝑌𝑃] × 𝑀𝑃𝑃𝐺𝐿 × 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 
Eq 7.1 Scaling of hepatic intrinsic clearance by liver size (same as Eq 6.14 
Chapter 6: ) 
 
𝐶𝐿𝐻 =
𝑄𝐻 × 𝑓𝑢,𝑏 × 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻
𝑄𝐻 + 𝑓𝑢,𝑏 × 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻
 
Eq 7.2 Well-Stirred Liver model for hepatic clearance 
 
If, [𝑓𝑢,𝑏 × 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻] ≪ 𝑄𝐻 then 𝐶𝐿 ≈ 𝑓𝑢,𝑏 × 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻 
Eq 7.3 Approximation of hepatic clearance for low-extraction drugs 
    
Antipyrine can be considered as a classic example for phase-1 
metabolism. It is completely metabolised by multiple CYP enzymes in the liver 
and freely distributes in total body water by passive diffusion [236]. Antipyrine 
has a systemic 𝐶𝐿 that approximately equals its 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻 satisfying Eq 7.3 
[237] 
because its unbound intrinsic clearance (𝐶𝐿𝑖𝑛𝑡,𝑢𝐻) is less than 5% of liver blood 
flow (𝑄𝐻) [238] and its free fraction in blood (𝑓𝑢,𝑏) is almost equal to 1 [6] due to 
negligible plasma protein binding and blood cell partitioning [239]. In addition, 
antipyrine is ~100% absorbed after oral administration without evidence of 
pre-systemic elimination [240]. Hence, variability in antipyrine 𝐶𝐿 is expected to 
be largely driven by the variation in 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 and enzymatic content and/or 
activity.  
Traditionally, total liver volume (𝐿𝑉) is used to describe functional 
𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 and is scaled to the individual using body surface area (𝐵𝑆𝐴) [221]. 
However, it is unclear if 𝐿𝑉  accurately describes functional 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 in the 
obese population. From a biological point of view, 𝐿𝑉  represents the 
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summation of the lean liver volume (𝐿𝐿𝑉) and liver fat (𝐿𝐹𝐴𝑇) as shown in Eq 
7.4 (also shown in Eq 6.4 of Chapter 6: ). The lean portion of the liver primarily 
consists of hepatocytes that contribute to drug elimination where as the 
metabolic activity of 𝐿𝐹𝐴𝑇  is considered minimal [60]. In healthy livers, the 
presence of 𝐿𝐹𝐴𝑇 is negligible (<2% of 𝐿𝑉) [216, 217] and thus 𝐿𝑉 is a sufficient 
approximation of the 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒. However, nearly 90% of obese patients have 
some degree of steatosis [110, 111] a condition where liver fat is > 5% of 𝐿𝑉 and 
reported to be as high as ~ 50% of 𝐿𝑉 [79, 115, 218]. In this group of patients, 𝐿𝑉 
would be an over-approximation of functional 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒, and hence scaling of 
𝐶𝐿𝑖𝑛𝑡,𝑢𝐻 by 𝐿𝑉 would potentially over-estimate 𝐶𝐿. Therefore, we hypothesise 
that 𝐿𝐿𝑉 is a closer approximation of the functional 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 universally that 
can be particularly useful in scaling 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻 in the obese.  
𝐿𝑉 = 𝐿𝐿𝑉 + 𝐿𝐹𝐴𝑇 
Eq 7.4 Components of total liver volume (same as Eq 6.4 of Chapter 6:  
 
The objective of this work is to assess the application of 𝐿𝐿𝑉  in 𝐶𝐿 
extrapolation in overweight and obese patients (BMI >25 kgm2). 
 
7.2. Materials and Methods 
Antipyrine was chosen as a model drug to test the 𝐿𝐿𝑉 hypothesis since 
𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 is expected to describe the inter-individual variation of antipyrine 𝐶𝐿 
to a reasonable extent. Published individual 𝐶𝐿 data of antipyrine along with 
measured 𝐿𝑉 and other patient characteristics were identified from a previous 
publication, extracted, and summarised in Table 7.1 [64]. Patients (N=21) had no 
evidence of liver, kidney, or heart disease and had not received any 
chemotherapy/radiation/medication for the previous six months. Each patient 
was administered a single oral dose of 1200 mg antipyrine and 𝐶𝐿  was 
determined from their salivary concentrations.   
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Patient characteristics including sex, total body weight (𝑊𝑇) , body 
surface area (𝐵𝑆𝐴) , and fat-free mass (𝐹𝐹𝑀) were available. 𝐹𝐹𝑀  was 
measured by using dual energy X-ray absorptiometry (DXA) and body fat 
(𝐵𝐹𝐴𝑇) percentage values were calculated from the corresponding 𝐹𝐹𝑀 and 
𝑊𝑇. In this analysis, participants were grouped into normal weight (𝐵𝑀𝐼 ≤ 25 
kg/m2) and overweight (𝐵𝑀𝐼 > 25 kg/m2) categories. The overweight group 
includes obese patients as per the classical definition of obesity, i.e. 𝐵𝑀𝐼  > 
30kg/m2. The reported Individual 𝐿𝑉 values were measured by CT scan. The 
𝐿𝐿𝑉 values were then predicted by the 𝐿𝐿𝑉 model (Eq 7.5, Eq 7.6) that was 
developed in the previous chapter (see Eq 6.15 and Eq 6.16 of Chapter 6: ) [241], 
which incorporates 𝐹𝐹𝑀  and sex. The individual 𝐿𝑉 values (observed) were 
plotted against the corresponding 𝐿𝐿𝑉  values (predicted) in Figure 7.1. The 
individual 𝐶𝐿 values were plotted against their 𝐿𝑉 and 𝐿𝐿𝑉 values in Figure 7.2 
and their coefficients of determinations (𝑅2) were compared. A higher 𝑅2 value 
would be indicative of a higher degree of correlation, and hence assumed to be 
a more appropriate scaler of 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒. 
 




Eq 7.5 Lean liver volume model for females (same as Eq 6.15 of Chapter 6:  
 




Eq 7.6 Lean liver volume model for males (same as Eq 6.16 of Chapter 6:  
  




The mean (range) of the calculated 𝐿𝐿𝑉  values were 1245.9 (1027.2 – 
1527.4) mL and 1226.6 (1024.0 – 1594.3) mL in normal and overweight groups 
respectively. The calculated mean 𝐿𝐹𝐴𝑇 (range) values were 8.2% (0 – 14.9%) 
and 29.3% (2 – 70.8%) in the normal and overweight groups (Table 7.1). 
 
Table 7.1 Summary of patient characteristics reported by Nawaratne et al. [64]. 
Characteristics Median (range) 
Sub-group Normal weight Overweight 
Sample Size (N) 8 (Male = 5, Female = 3) 13 (Male = 9, Female = 4) 
𝐵𝑀𝐼 (kg/m2) 23.6 (21.1–24.9) 28.7 (25.2 – 35.8) 
𝐵𝑆𝐴 (m2) 1.75 (1.51 – 1.95) 1.88 (1.65 – 2.15) 
𝐹𝐹𝑀 (kg) a 48.5 (32.1 – 59.4) 47.7 (32.0 – 62.0) 
𝐵𝐹𝐴𝑇 (%) 28.7 (19.7 – 41.6) 43.4 (24.4 – 55.9) 
𝐿𝑉 (mL) b 1316.0 (1090.0 – 1610.0) 1535.0 (1225.0 – 1989.0) 
𝐿𝐿𝑉 (mL) c 1245.9 (1027.2 – 1527.4) 1226.6 (1024.0 – 1594.3) 
𝐿𝐹𝐴𝑇 (%) 8.2 (0 – 14.9) 29.3 (2.0 – 70.8) 
𝐶𝐿 (L/h) 1.2 (0.7 – 3.3) d 1.5 (0.9 – 2.3) e 
𝐵𝑀𝐼 body mass index, 𝐵𝑆𝐴 body surface area, 𝐹𝐹𝑀 fat-free mass, 𝐿𝑉 total liver volume, 𝐿𝐿𝑉 
lean liver volume, 𝐵𝐹𝐴𝑇  body fat, 𝐿𝐹𝐴𝑇  liver fat (as percentage of 𝐿𝐿𝑉 ), 𝐶𝐿  clearance, a 
Measured by dual energy X-ray absorptiometry, b measured by computerised tomography, c 
predicted by Eq 7.5 and Eq 7.6, d, e clearance was reported for 6 and 11 patients respectively, 
The clearance (𝐶𝐿) was calculated after single oral dose of 1200 mg antipyrine. 
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In the normal weight groups, the values of 𝐿𝑉  and 𝐿𝐿𝑉  are scattered 
around the line of unity (Figure 7.1a) indicating that 𝐿𝑉  is a reasonable 
approximation of 𝐿𝐿𝑉. Where as in overweight groups, 𝐿𝑉 values are scattered 
above the line of unity (Figure 7.1b) indicating that 𝐿𝑉 overestimates 𝐿𝐿𝑉 which 
suggests that in these patients 𝐿𝑉 would overestimate functional capacity. In 
the scatter plots of antipyrine 𝐶𝐿 values of the normal weight group (Figure 
7.2a, Figure 7.2b), 𝑅2 values were 0.43 and 0.58 against 𝐿𝑉 and 𝐿𝐿𝑉 respectively. 
In the overweight group (Figure 7.2c, Figure 7.2d), the values of 𝑅2 are 0.17 and 
0.36 against 𝐿𝑉 and 𝐿𝐿𝑉 respectively.  
 
 
Figure 7.1 Individual measured total liver volume (  ) vs. predicted lean 
liver volume (   ) in (a) normal weight (𝑩𝑴  <25 kgm2, n=8) and (b) 
overweight (𝑩𝑴  >25 kgm2, n=13) patients as reported by Nawaratne et al. [64] 





























Figure 7.2 Antipyrine clearance (  ) vs. total liver volume (  ) and lean liver 
volume (   ) plots of the study population reported by Nawaratne et al. [64]. 
The upper row (a, b) and lower row (c, d) represent the normal weight (𝐵𝑀𝐼  25 kgm2, n=8) 
and overweight (𝐵𝑀𝐼 >25 kgm2, n=13) subgroups respectively. The broken line represents the 
regression line, and the R2 represents the coefficient of determination. 
 
7.4. Discussion 
In this work, 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒 is used to represent the ‘functional’ size of liver 
where drug elimination occurs. The results of this work suggest that total liver 
volume (𝐿𝑉) over-estimates the ‘functional’ 𝐿𝑖𝑣𝑒𝑟 𝑆𝑖𝑧𝑒  for overweight and 
obese individuals. 
The mean 𝐿𝑉 value was 1535.0 (1225.0 – 1989.0) in the overweight group 
which was higher than the mean 𝐿𝑉 value of 1316.0 (1090.0 – 1610.0) mL in the 
normal weight group (Table 7.1). However, the mean (range) 𝐿𝐿𝑉 values were 
not very different between these two groups, i.e. 1226.6 (1024.0 – 1594.3) mL 
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groups, respectively. This implies the presence of substantial amounts of liver 
fat (𝐿𝐹𝐴𝑇) in the over-weight group which adds extra volume to the liver while 
the functional liver volume is only minimally affected. The calculated mean 
(range) 𝐿𝐹𝐴𝑇 in the over-weight group was 29.3% (2.0 – 70.8) which was much 
higher than 8.2% (0 – 14.9%) 𝐿𝐹𝐴𝑇 in the normal weight group. This indicates 
that the difference between these two descriptors of liver size (i.e. 𝐿𝑉 and 𝐿𝐿𝑉) 
is expected to be significantly larger in the over-weight individuals than their 
normal weight counterparts (see Figure 7.1 and Table 7.1). In this dataset, the 
median difference (𝐿𝑉 − 𝐿𝐿𝑉) was 25% and 6% in the over-weight and the 
normal weight groups respectively.  
Overall, 𝐿𝐿𝑉  described about 36% of the variance of antipyrine 𝐶𝐿  in 
overweight patients which was about 2-fold higher than 17% variation that was 
described by 𝐿𝑉 (Figure 7.2c, Figure 7.2d) . In normal weight patients, both 𝐿𝑉 
and 𝐿𝐿𝑉 described the variance of 𝐶𝐿 to a similar extent as evidenced from 1.3 
fold improvement in the 𝑅2 value from 0.43 (against 𝐿𝑉) to 0.58 (against 𝐿𝐿𝑉) 
(Figure 7.2a, Figure 7.2b). This implies that 𝐿𝑉  is less likely to represent 
‘functional’ size of the liver particularly in overweight individuals (that 
includes obese) because of steatosis, and hence conventional approaches of 
scaling the hepatic intrinsic clearance by 𝐿𝑉  needs to be revisited with the 
proposed adoption of 𝐿𝐿𝑉 as the predictor. Interestingly, approximately half of 
the variability in antipyrine 𝐶𝐿 in the normal weight group was described by 
fat-free mass (as the covariate of 𝐿𝐿𝑉) which is similar to other influential 
covariates (e.g. creatinine clearance for renally cleared drugs [242]. Importantly 
we see that the predictive performance of 𝐿𝐿𝑉 as a covariate for 𝐶𝐿 was poorer 
in the overweight group than normal weight group which indicates that 
additional processes occur in the overweight group that are not described by 
𝑙𝑖𝑣𝑒𝑟 𝑠𝑖𝑧𝑒, which might potentially link back to changes in metabolic activity of 
oxidative enzymes.  
Future IVIVE studies which include a range of drugs and a variety of 
populations (e.g. different ethnicities) are needed to validate the wide use of 









DISCUSSION AND CONCLUSION 
 
 



























In this thesis, pharmacokinetic (PK) scaling methods using body size and 
composition were assessed. Total body weight (𝑊𝑇) is a widely-used measure of 
body size but fat-free mass (𝐹𝐹𝑀) is increasingly used for PK scaling as it describes 
both body size and composition. 
The traditional ‘one size fits all’ scheme of drug dosing has been consistently 
questioned in the literature [243-246] due to its implications on drug safety and 
effectiveness, and the scope of dose scaling has been well recognised in this regard 
[247, 248]. In this thesis, dose scaling refers to dose extrapolation from standard adults 
to differently sized groups of patients (i.e. children and the obese) based on 
differences in body size and/or composition. Dose scaling is most relevant for drugs 
that have a narrow therapeutic window, e.g. aminoglycosides [248, 249].  
Dose scaling is aimed to achieve a target PK exposure, e.g. average steady state 
concentration (𝐶𝑝,𝑠𝑠,𝑎𝑣𝑔 ) that has been proven to be efficacious in the standard 
population. The attainment of target PK exposure is a common strategy to scale the 
initial dose, which might be subjected to further adjustments based on other factors 
such as pharmacodynamics (PD) response(s) in the patient. Therefore, scaling of the 
initial dose is based on the underlying assumption that a similar exposure-effect 
relationship exists across the populations. Under this assumption, dose scaling (in 
this thesis) actually simplifies to scaling of pharmacokinetics (PK). This work has 
particularly focussed on maintenance dose scaling that is needed for chronic drug 
therapy. Hence, this work has particularly assessed the standard scaling methods of 
drug clearance (𝐶𝐿) using 𝑊𝑇 and 𝐹𝐹𝑀. 
 The first aim of the thesis was to assess the empirical ways of choosing the 
allometric exponent. Conventionally, allometric scaling refers to a less than 
proportional scaling of 𝐶𝐿 by 𝑊𝑇, where use of an exponent of 3/4 commonly used 
[61, 69]. On the other hand, the traditional ‘mg/kg’ dosing that is mostly practised in 
the clinic assumes a proportional scaling (i.e. exponent 1) of 𝐶𝐿. Due to lack of 
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consensus over the right value of the exponent, it is empirically determined with the 
data either by choosing from the set of a priori values mentioned above or by 
estimating it. In either way, the accuracy of the empirically determined value of the 
exponent is limited by the study design. Therefore, choice of the allometric exponent 
should be supported by appropriate study design which has been addressed in 
Chapter 2.  
Typical to the first approach, the exponent is chosen by comparing the model 
fits (e.g. AIC) of covariate models carrying possible a priori values (i.e. 0.67, 0.75, 1) 
and selecting the one that gives the lowest AIC value. However, this method risks 
choosing the wrong exponent. The fundamental flaw is that this method inherently 
assumes that the true exponent belongs to the tested set of a priori values, which may 
not be true as Calvier et al. [97] have indicated that the allometric exponent can range 
between 0.5 to 1.2. Even if such an assumption is made, it is still impossible to choose 
the true value in regular clinical pharmacology studies (less than 200 adults 
excluding children) that are often inadequately (<80%) powered. Under regular 
circumstances (with 40-60% BSV in 𝐶𝐿 ), more than 250 adult participants are 
required to choose the correct exponent given the options of theory-based allometric 
scaling (0.75) and linear scaling (1) exponents. Furthermore, identification of the 
correct exponent from choices of theory-based allometry (0.75) and body surface area 
(BSA)-based scaling (0.67) is practically impossible with any sort of regular study 
design as it requires >1000 adult participants.  
The second approach that empirically estimates the exponent has the 
advantage of not depending upon any a priori assumption. However, this method 
always carries the risk of over-estimating the exponent, particularly if the studies are 
under-powered. This is known as selection bias which was described for linear 
models by Ribbing et al. [56]. In this work, the bias in the estimated exponent is found 
to be directly (inversely) related to study power. The higher the study power the 
lower is the estimate bias, which means the higher is the chance of estimating the 
true exponent. Based on the simulation-estimation based analysis, a cut-off point of 
80% power has been identified beyond which the bias in the estimate of exponent 
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becomes minimal. In this work, it is also shown that study power is positively 
related with the study design variables sample size, study population (i.e. covariate 
range) and BSV of 𝐶𝐿. Therefore, further assessment was done to determine the 
minimal study design requirements that can ensure an optimal power of ≥80%. 
Under regular circumstances (with 40% BSV in 𝐶𝐿), it is possible to achieve the 
required power with about 100 adult participants without the need of including 
children in the study. The sample size requirement can be drastically cut down if 
children (>2 years of age) and adolescents are included in the study along with 
adults, and all age groups are stratified in equal proportions. As per the analysis, 10-
20 participants under stratified design can minimise the bias below 10%.  However, 
it has been also noted that such a low sample size may lead to imprecise estimate of 
the exponent. A sample size of about 50 participants including children and 
adolescents (stratified) appeared optimal for estimating the allometric exponent 
accurately and precisely. Notably, such a study design resemble regular clinical 
studies that include minors. Hence estimation of the allometric exponent appeared to 
be a reasonable approach to determine the scaling relationship between 𝐶𝐿 and 𝑊𝑇. 
Similar power requirement needs to be considered in case of empirical 
allometric scaling of 𝐶𝐿 by 𝐹𝐹𝑀. This is important since there is no consensus on the 
𝐹𝐹𝑀 exponent as well and it is often estimated empirically [250]. However, the exact 
study design requirement may be slightly different than 𝑊𝑇 based scaling to achieve 
the optimal power. While extrapolating the findings, the range of covariate needs to 
be considered in this case. In the 𝑊𝑇 based analysis it has been shown that the range 
of covariate values (i.e. 𝑊𝑇) has a positive influence on the power. This explains the 
benefit of including children in the study cohort and a size of 50 participants were 
adequate to estimate the exponent. Since the range of 𝐹𝐹𝑀 values would always be 
narrower than 𝑊𝑇 in the population the sample size requirement would be higher. 
This needs to be assessed in a separate analysis in the future.  
Overall, the findings of Chapter 2 indicates that empirical estimation can be a 
good choice to determine the allometric exponent for body size and composition 
given the study design is optimal to achieve at least 80% power. In drug 
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development, the early phase (first in human to proof of concept) clinical trials 
typically recruit standard adult population (excluding children) and may not reach 
the required sample size of 100. Such studies are likely to be under-powered to 
estimate the exponent of body size and hence to estimate clearance. A biased 
estimate of the exponent can lead to biased prediction of 𝐶𝐿 if extrapolated to other 
sub-groups of population such as children and the obese that are studied at the post-
approval stage. Therefore, estimation of the allometric exponent is not recommended 
in under-powered studies. For under-powered studies, it would be wise to use 
mechanistic approaches like IVIVE (as shown in Chapter 7) if data are available.  
Although a theoretical value has been proposed for 𝑊𝑇 it is currently lacking 
for scaling by 𝐹𝐹𝑀. There is an expectation that 𝐶𝐿 scales with 𝐹𝐹𝑀 linearly (i.e. 
exponent 1) since drug elimination almost exclusively occurs in the fat-free portion 
of body [25]. Some researchers believe that 𝐶𝐿  should be scaled in the obese by 
𝐹𝐹𝑀3/4 since it is equivalent to the theoretical allometric scaling with an additional 
correction for body composition [126, 199]. This is perhaps because allometric scaling 
conclusions were made on normal physiological considerations which does not 
include obesity. For example, the observed inter-species scaling of BMR was based 
on animals having normal body composition, since obese animals are outliers in 
nature. Noteworthy to mention that use of the 3/4 exponent in pharmacology was 
built on two phenomena: (1) inter-species scaling of basal metabolic rate (BMR) and 
(2) the theory of “quarter power law” proposed by West et al. [94]. However, there is 
limited evidence or support that can validate the universality of these phenomena 
(discussed below).  
 First, the exponent 3/4 was originally adopted from the observed inter-species 
scaling of BMR by using a 3/4 power to body weight [251], with the underlying 
assumption that drug clearance (𝐶𝐿) is proportional to BMR. However, there is no 
empirical evidence to support this assumption. BMR is a measure of the overall rate 
of endogenous metabolic processes (measured as oxygen consumption from samples 
of expired air [252]) that are active within the entire cellular mass of a human body at 
basal condition [253, 254]. On the other hand, 𝐶𝐿 is indicative of body’s capacity of 
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eliminating xenobiotics by metabolism and/or excretion that are limited to the 
clearing organ(s) and further to a specific set of hepatocellular enzymes. Unlike 
BMR, 𝐶𝐿 does not merely represent the metabolic rate, and can be rate limited by a 
range of physiological variables such as liver blood flow (e.g. propanolol, lidocaine 
[62]), plasma protein binding (e.g. warfarin [255]), and active hepatocellular transport 
(e.g. atorvastatin [256, 257]). Therefore, proportionality between BMR and 𝐶𝐿 may not 
exist universally.  
 Secondly, the “quarter power” law was derived on an excellent theoretical 
framework that describes the rate of mass transfer across the branching vasculature 
(from aorta to capillary level) of mammalian cardio-vascular system. Notably, the 
key assumption of West’s model was that the metabolic rate (“𝐵”) is proportional to 
volumetric flow rate (“𝑄”). Therefore, they actually determined the relationship 
between “𝑄” and body size (“𝑀”) to be scaled by 3/4 power (i.e. 𝑄 =  𝑀3/4), and 
thus claimed that metabolic rate (“𝐵”) scales with 𝑀3/4. The key assumption of 𝐵 ∝
𝑄 perhaps is suitable for describing the metabolism of endogenous substrates where 
the metabolic processes might be rate limited by the supply of fresh oxygenated 
blood. However, clearance of xenobiotics need not to be necessarily rate limited by 
their supply to the metabolically active cells of the clearing organ (e.g. liver), but can 
also be rate limited by clearing organ’s intrinsic capacity (known as intrinsic 
clearance). In the case of xenobiotic metabolism, mid to high extraction drugs are 
likely to follow the former assumption, where as the low-extraction drugs are most 
likely to follow the latter assumption. Hence, whether the quarter power theory by 
West et al. is a universal approximation for drug 𝐶𝐿  is unclear. Even for high 
extraction drugs, the validity of theory based allometry in the obese is debatable. 
This is because the fractal analysis (by West et al.) for mammalian cardio-vascular 
system did not consider obese physiology, where pathological alterations in cardiac 
output [258] and peripheral blood flow (especially to the clearing organs [62, 259]) has 
been well documented.   
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Overall, there is a paucity in the knowledge of correct value of the exponent for 
scaling 𝐶𝐿. In this context, the second aim was to find out a theoretical value of the 
allometric exponent for scaling 𝐶𝐿 by 𝐹𝐹𝑀. The findings of Chapter 6 suggests that 
the theoretical value should be 1 which indicates proportional scaling of 𝐶𝐿 by 𝐹𝐹𝑀. 
This relationship is particularly applicable for low-clearance drugs (hepatically 
cleared) where systemic 𝐶𝐿 approximates to hepatic intrinsic clearance (𝐶𝐿𝑖𝑛𝑡,𝑢𝐻). 
This is of great importance because achieving low-extraction is one of the primary 
goals of drug discovery projects, in order to ensure less dose and dosing frequency 
in the clinic [108, 109]. Since functional liver size is a key determinant of the predictable 
part of the variation in 𝐶𝐿𝑖𝑛𝑡,𝑢𝐻, its relationship with 𝐹𝐹𝑀 is expected to translate to 
𝐶𝐿 vs. 𝐹𝐹𝑀 relationship. Functional liver size should be best described by lean liver 
volume (𝐿𝐿𝑉) as it excludes all liver fat that is present in substantial amount in most 
obese patients [79, 110, 111, 115]. The results suggest that 𝐿𝐿𝑉 scales linearly with 𝐹𝐹𝑀.  
Whether such linear scaling of 𝐶𝐿 by 𝐹𝐹𝑀 would be applicable to moderate to 
high clearance drugs was not assessed in this thesis. Theoretically, 𝐶𝐿  of high 
clearance drugs approximates to hepatic blood flow which is assumed to be certain 
percentage (~25%) of cardiac output under regular circumstances [66]. Cardiac output 
is believed to scale with 𝐵𝑆𝐴, and thus 𝐵𝑆𝐴 is conventionally used to scale liver 
blood flow [66]. Whether liver blood flow scales with 𝐹𝐹𝑀  better than 𝐵𝑆𝐴  is 
unknown. Likewise, how liver blood flow scales to 𝐹𝐹𝑀 (i.e. the exponent) is also 
not known. Such mechanistic understanding might help better describe the scaling 
exponent of high clearance drugs by 𝐹𝐹𝑀. 
However, scaling of 𝐶𝐿 of high clearance drugs may not be needed for the 
obese as has been shown in the literature. Studies of various high extraction drugs 
such as propanolol, verapamil, lidocaine, sufentanil, and paclitaxel did not show any 
statistical differences in 𝐶𝐿 between obese and non-obese individuals [62]. Since 𝐶𝐿 of 
these drugs approximates to liver blood flow, results of these studies indicate that 
hepatic blood flow remains unaltered in obesity. Obesity, with an otherwise normal 
heart function,  increases cardiac output due to increased stroke volume and heart 
rate that causes increased perfusion to the tissues [112]. Obesity driven fatty 
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infiltration (steatosis) in the liver, at the same time, causes sinusoidal narrowing and 
decrease liver perfusion thereby. It has been postulated that as a results of these two 
opposing influences of obesity on liver, the hepatic blood flow remains unaltered [62] 
in obese. 
The third aim of this thesis was to explore whether the expected proportional 
relationship between 𝐶𝐿  and 𝐹𝐹𝑀  appears is evident empirically. This has been 
assessed by a model-based meta-analysis (MBMA) and described in Chapter 5. The 
MBMA only considered drugs that are preferentially cleared by liver and fall into 
the low-clearance category (<30 L/hr). The result suggests an estimated average 
exponent of 0.68 which is near to the 𝐵𝑆𝐴 based scaling exponent 2/3. However, 
there was 45% variation in the exponent between drugs. This may be due to the 
variation in other factors (mostly unpredictable) such as protein binding and enzyme 
abundance which are poorly understood. Although the estimated value of 0.68 well 
aligns with the estimated average value of 𝐹𝐹𝑀 exponent by McLeay et al. [60] there 
is limited evidence to support the similarity from theoretical perspective. This is 
because their analysis was based on a pooled dataset including different categories 
of drugs, e.g. low- and high clearance and hepatic and renal clearance, whereas we 
only considered low-clearance hepatically-cleared drugs.   
In the classic ‘top-down’ approach, the accuracy of scaling 𝐶𝐿 by body size is 
very much dependent on the accuracy of choosing the allometric exponent.  This 
thesis assessed how this traditional approach is limited by study design. An 
alternative approach that has been recently recommended involves the scaling of 𝐶𝐿 
of the target population by in vitro-in vivo extrapolation (IVIVE) [112, 114, 232]. The utility 
of this approach has been particularly shown for selecting the initial dose for obese 
patients in clinical studies that are typically done at the post-approval stage. This 
involves the use of total liver volume (𝐿𝑉) as a scaler. However, this approach may 
result in the over-estimation of drug 𝐶𝐿 in obese individuals as LV may potentially 
over-represent functional liver size.  
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In this context, the fourth aim of this thesis was to assess the current standard 
of IVIVE for predicting 𝐶𝐿 in obese individuals. In particular, the potential of 𝐿𝐿𝑉 
was assessed in Chapter 7 in comparison to 𝐿𝑉 which is the current scaler for liver 
size. In IVIVE, accuracy of 𝐶𝐿  prediction largely depends on the accuracy of 
functional liver size prediction. Functional liver size represents the size of the liver 
that actively contributes to drug elimination, which excludes liver fat. More than 
90% of obese patients have non-alcoholic fatty liver disease (NAFLD) [110, 111], where 
𝐿𝑉 over-estimates the functional size due to the presence of substantial liver fat 
(steatosis). The analysis of the antipyrine dataset in Chapter 7 suggests that 𝐿𝐿𝑉 is a 
better descriptor of functional liver size in the obese. This implies that 𝐿𝑉  over-
estimated the functional liver size (i.e. 𝐿𝐿𝑉 ) by as much as 70% in the dataset 
(corresponding to the maximum %liver fat in Table 7.1 of Chapter 7: ). The finding of 
high liver fat content is well aligned with several literature reports [79, 115, 218], where 
liver fat was measured in obese population by magnetic resonance imaging (MRI). 
Because of the better description of the functional liver size, 𝐿𝐿𝑉  improved the 
correlation with antipyrine 𝐶𝐿 in the obese as compared to 𝐿𝑉. However, further 
validation studies with larger datasets are required to adopt 𝐿𝐿𝑉 in IVIVE based 
dose prediction in obese patients.  
In practice, predictive models are preferred to avoid experimental methods of 
𝐹𝐹𝑀 measurement which are too resource intensive for regular use. These methods 
were described in Chapter 3: . The model developed by Janmahasatian et al. [102] is 
used extensively in clinical pharmacology because of its semi-mechanistic nature. 
However, a recent validation study reported by Srigiripura et al. [105] has shown that 
Janmahasatian’s model over-predicts 𝐹𝐹𝑀  in Indian population. This is expected 
since Jamahasatian’s model was largely based on data that arose from individuals of 
European descent who potentially have different body composition from other 
populations, e.g. Indians [196]. In this context, the fifth aim of the thesis was to 
develop an extension of Janmahasatian’s 𝐹𝐹𝑀  model that accounts for the inter-
ethnic difference in body composition wherever applicable. Another objective was to 
utilise the general extended model structure to develop an extended 𝐹𝐹𝑀 model in 
individuals of Indian descent.   
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The structure of the extended 𝐹𝐹𝑀 model was developed by incorporating a set 
of ethnicity specific parameters (Ψ ) into the existing Janmahasatian model by 
relaxing the key assumption of the original model. The assumptions and model 
development have been described in detail in Chapter 4. The extended model was 
further used to estimate the Ψ parameters for Indians using a dataset of 100 adult 
Indian patients. The extended model needs further validation in Indian population, 
preferably covering a wide range of 𝐵𝑀𝐼 . Since 𝐹𝐹𝑀  is measure of body 
composition, mechanistic models are expected to account for all possible causal 
factors that are known to influence body composition. The extended 𝐹𝐹𝑀 model, in 
this regard, gives the flexibility to account for the causal factors between relevant 
ethnicities, in terms of incorporating estimable correction parameters (Ψ) into the 
existing Janmahasatian’s model. By this way, the extension of Janmahasatian’s 
model potentially extends its applicability to other patient populations.   
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8.2. Limitations and future implications 
 
The results of the simulation-estimation based work in Chapter 2 was based on 
a ‘true’ exponent 0.75. There was no intension to support or oppose the use of the 
theory based exponent (i.e. 0.75) in this work; the value was used just for the sake of 
simulation where any value could have been used. 
In reality, however, the true exponent might vary, as pointed out by Calvier et 
al.[260]. A smaller value than 0.75 would indicate a smaller effect size than the current 
simulation scenarios. The smaller the effect size the larger would be the required 
sample size to achieve the required power (80%) of identifying 𝑊𝑇 as a statistically 
significant covariate. This is because the magnitude of the difference between the 
null (i.e. base model) and the alternative hypothesis (i.e. true exponent) would be 
smaller (than the current analysis) for a true value less than 0.75. On the other hand, 
a larger true value of the exponent would require a smaller sample size (than100 
adults) to accurately estimate the exponent in regular clinical pharmacology studies. 
Therefore, additional analysis needs to be done using at least the minimum and the 
maximum possible values of allometric exponent (i.e. 0.5 and 1.20, as hypothesised 
by Calvier et al) as the ‘true’ values for simulation.    
A simple one compartment unit model with IV bolus input was considered in 
the simulation-estimation analysis where only one parameter (i.e. 𝐶𝐿) has a single 
covariate (i.e. 𝑊𝑇 ). More complex situations might be expected in reality. For 
example, 𝑊𝑇 is often found as a covariate of volume of distribution (𝑉) as well and 
𝐶𝐿 can have multiple covariates in addition to 𝑊𝑇 (e.g. age). Moreover, in practice, 
multiple body size descriptors (e.g. 𝑊𝑇 , 𝐹𝐹𝑀 , 𝐵𝑆𝐴 ) are tested during covariate 
model building and often provide reasonable model fit and this can potentially 
impact the power to select the best covariate and accurately estimate the exponent. 
Such considerations can further have influence on the minimum sample size 
requirements which are currently unknown based on this analysis. Therefore, such 
additional scenarios need to be tested in the future to more closely mimic clinical 
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studies. Further considerations such as oral dosing and correlation between 
parameters should also be incorporated.  
The meta-analysis in Chapter 5 revealed disconnect between the theoretical (i.e. 
1) and empirical (i.e. ~0.67) values of the exponent for scaling 𝐶𝐿 by 𝐹𝐹𝑀. However, 
the current meta-analysis may not be fully conclusive due to the lack of adequate 
power to estimate the exponent. This happened because a few studies in the 
literature have reported individual data of 𝐶𝐿 and 𝐹𝐹𝑀 for low-clearance drugs. A 
more comprehensive analysis including more low-clearance drugs with a range of 
hepatic elimination mechanisms is needed to confirm the true exponent. Additional 
pooling of high-clearance drugs might be performed as well to check for its potential 
confounding effect on the empirical value of the exponent; this would also improve 
the study power to estimate the exponent.  
The extended Janmahasatian model developed in Chapter 4 needs to be 
validated with an external 𝐹𝐹𝑀 dataset in Indian population, preferably with a wide 
range of 𝐵𝑀𝐼. This should also be accompanied with a comparison of the predictions 
from the original Janmahasatian’s model and the Kulkarni’s model which was 
developed in Indians. Such comparative validation would help confirm the 
applicability of the extended 𝐹𝐹𝑀 model. Model extension can also be considered for 
other ethnicities as well (e.g. pacific islanders), where significant alteration in body 
composition has been documented [104, 196].   
The potential application of 𝐿𝐿𝑉 model in IVIVE of 𝐶𝐿 in the obese has been 
briefly examined in Chapter 7. This work is limited by the small dataset which 
includes one model drug, antipyrine. Future efforts should be made in validating the 
𝐿𝐿𝑉’s application by using in vitro and in vivo data of drugs that cover a range of 
mechanisms of hepatic elimination, e.g. different CYP isoforms.  
Further to it, applicability of 𝐿𝐿𝑉 may be restricted to obese patients who are at 
the early stages of fatty liver disease (NAFLD). The current study population (in 
Chapter 6) most likely represent the early stage NAFLD patients, since there was no 
evidence of structural and functional abnormality in their livers as demonstrated by 
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their normal ultra-sonography scan and normal liver function test results. In 
advanced fibro-inflammatory stages of NAFLD (i.e. Non-alcoholic steatohepatitis to 
cirrhosis), substantial hepatocellular loss occurs due to tissue necrosis which is 
replaced by scar tissue (i.e. collagen). These scar tissues are not metabolically active. 
Therefore, in advanced NAFLD patients, 𝐿𝐿𝑉 may not represent the true functional 
liver size and may potentially over-estimate hepatic 𝐶𝐿 if used for IVIVE. 
Overall, the choice of exponent of body size should be made based on the 
targeted population (Figure 8.1). If dose scaling is meant for patients within standard 
body size range, the traditional ‘mg/kg’ dosing that underpins linear scaling of 𝐶𝐿 
by 𝑊𝑇 appears to be no different than allometric scaling that assumes a non-linear 
scaling of 𝐶𝐿 (see Figure 2.6 and Figure 2.7). Apart from the exponent, the choice of 
scaler itself (i.e. 𝑊𝑇  vs. 𝐹𝐹𝑀 ) would hardly influence the predictions in this 
population, since scaling by 𝐹𝐹𝑀 would be equivalent to a less than proportional 
scaling (i.e. non-linear) by 𝑊𝑇. Hence, considering the complexity of mathematical 
calculations associated with allometric scaling and/or 𝐹𝐹𝑀  prediction, the 
traditional ‘mg/kg’ dosing appears an acceptable method of dose scaling in the 
standard population. 
On the other hand, choice of scaling method becomes critical when dose scaling 
is intended for a differently sized population such as obese or children. When 𝐶𝐿 is 
extrapolated outside the standard body size range, a wrong choice of exponent of 
𝑊𝑇 can cause deviation in 𝐶𝐿 (from true value) as high as 2-fold and 4-fold in obese 
and children (≥3 years of age) respectively (see Figure 1.6). Since there is no 
consensus on the true value of the exponent, a reasonable approach would be to 
estimate the value from an adequately powered (at least 80%) study. Studies with a 
minimum of 100-200 adult participants within standard body size range appears to 
be sufficiently powered to accurately estimate the exponent. Such design typically 
resembles phase 2b to phase 3 studies under standard drug development regime. 
However, most of the post-approval clinical pharmacology studies might be limited 
by sample size (hence power). For those studies, inclusion of children and 
adolescents can help achieve the required power with sample size as low as 10-50; 
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otherwise, pooling of studies might be another alternative. The empirical approach 
should also be considered when 𝐹𝐹𝑀 is used as the scaler in order to account for 
body composition. This is because a linear scaling by 𝐹𝐹𝑀 (as per the expectation) 
has been confounded by the empirical values of the exponent that suggest a less than 
proportional scaling. Since, within the standard population, 𝐹𝐹𝑀 varies similar fold 
to that of 𝑊𝑇, a similar sample size requirement of 100-200 would also be required to 
estimate the exponent of 𝐹𝐹𝑀. Hence, this general study design requirement (to 
achieve power) applies to both the chosen size scalers and needs to be considered 
irrespective of the mechanism of elimination of the drug.   
For under-powered studies (that do not meet the above design criteria), an 
alternative ‘bottom-up’ approach can be considered at least for hepatically 
eliminated drugs, where 𝐶𝐿 is scaled by IVIVE. Particularly, for non-flow dependent 
drugs, the accuracy of IVIVE scaled 𝐶𝐿 in differently sized population would largely 
depend on the accuracy of scaling the ‘functional’ liver size in the target population. 
At least for obese, it has been shown that 𝐿𝐿𝑉 is potentially a better descriptor of the 
‘functional’ liver size than 𝐿𝑉, which needs further evaluation. However, scaling of 
‘functional’ liver size in children was not subject to assessment in this thesis. For 
flow dependent drugs, the key would be to understand the scaling of liver blood 
flow with body size, which was not assessed in this work. At least for obese, a 
general hypothesis is that liver blood flow remains unaltered (in spite of increased 
cardiac output) due to sinusoidal narrowing and/or increased peripheral resistance, 
which renders 𝐶𝐿 of flow-dependent drugs unaffected [62]. If IVIVE cannot be readily 
applied (e.g. renally cleared drugs, lack of data), an alternative approach could be to 
scale 𝐶𝐿  using a fixed exponent that appropriately supports the biology. For 
example, if there is evidence that GFR is proportional to renal blood flow, and blood 
flow scales to 𝑊𝑇3/4  (as shown for cardiac output by West et al. [94]), then an 
exponent of 0.75 can be a possible choice. Alternatively, if there is evidence that GFR 
scales to 𝐹𝐹𝑀 linearly [65], then linear scaling of 𝐶𝐿 by 𝐹𝐹𝑀 can be a choice. Similar 
scaling relationship of (hepatic) blood flow and WT can also be considered for 
choosing the fixed exponent for high extraction drugs, if presence of any 
confounding physiological effects (e.g. sinusoidal narrowing) are least expected in 
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the target population. Therefore, if a fixed exponent needs to be used, the choice of 
its value should be justified by a priori knowledge of the biology, which was not 
subject to assessment in this thesis.   
 
Figure 8.1 Flow chart for guiding the selection of dose scaling method in clinical practice 





In this thesis, methods of scaling drug clearance (𝐶𝐿) using body size (i.e. 𝑊𝑇) 
and composition (i.e. 𝐹𝐹𝑀) were assessed. When scaling 𝐶𝐿 by 𝑊𝑇 in typical clinical 
pharmacology studies, the selection of the allometric exponent from a set of 
plausible a priori values (e.g. 2/3, 3/4) can potentially lead to biased prediction of 𝐶𝐿. 
Alternatively, accurate estimation of the exponent is possible provided that the 
study is adequately (>80%) powered. Studies consisting of only adults or studies 
that additionally include children and adolescents can accurately estimate the 
allometric exponent with a minimum of 100 or 10 participants respectively. 
For studies that do not meet the required design (i.e. inadequately powered), 
fixing the exponent to a biologically plausible value would be appropriate. This also 
applies to the use of 𝐹𝐹𝑀. For scaling 𝐶𝐿 by 𝐹𝐹𝑀, the theoretical value is found to be 
1 in this thesis, which has been determined via modelling the relationship between 
lean liver volume (𝐿𝐿𝑉) and 𝐹𝐹𝑀. However, a meta-analysis of published individual 
data has estimated this exponent to be 2/3, which is equivalent to body surface area 
(𝐵𝑆𝐴) based scaling.  
The theoretical value of the allometric exponent for 𝐹𝐹𝑀 based scaling remains 
inconclusive. Therefore, a ‘bottom-up’ approach using in vitro-in vivo extrapolation 
(IVIVE) of 𝐶𝐿 might be a reasonable alternative for initial dose scaling. For dose 
scaling particularly in obese patients, the accuracy of IVIVE scaled 𝐶𝐿 would depend 
on the accuracy of the descriptor of ‘functional’ liver size. This work has shown that 
𝐿𝐿𝑉 is a more accurate descriptor of ‘functional’ liver size than total liver volume 
(𝐿𝑉) particularly in the obese. Therefore, 𝐿𝐿𝑉 has a potential use in IVIVE based 
scaling of 𝐶𝐿 and can help the selection of the initial dose for studies that include 
obese patients. 
Finally, an extended 𝐹𝐹𝑀 model based on the commonly used Janmahasatian’s 
model was developed and shown to predict 𝐹𝐹𝑀 in patients of Indian descent. The 
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general structure of the extended 𝐹𝐹𝑀  model can be used to develop ethnicity-
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A1.1. Results of Objective 1 and Objective 2 with additional populations 
The results under objective 1 and 2 including two additional populations i.e. 
Aall and Ball along with the population A and B of the main text have been shown in 
Table A1.1 and Table A1.2 (i.e. extension to the Table 2.5 and Table 2.6 respectively 
of the main text). Population Aall and Ball represent adults including obese (i.e. all-
comer adults) and unstratified cohorts of population B. Looking at tables, it is 
evident that stratification of study cohort based on age groups of the population B 
did not improve the power as compared to its all-comer counterpart (Ball). Although 
inclusion of obese patients in the study (Aall) theoretically improves the power 
compared to the population A (excluding obese) the results of the obese population 
may not be valid in reality. The use of 0.75 and 0.67 in scaling of clearance (CL) 
originated on the grounds that basal metabolic rates across normal-weighted species 
can be scaled by (𝑊𝑇)
3
4  [93, 94, 116-118] or by (𝑊𝑇)
2
3  [92, 123, 124]. Notably, the concept of 
allometry was developed to scale for physiologically mature normal body size (on 
the basis that obese animals in nature are uncommon) and not for body composition. 
Hence, the use of allometric scaling in obese is not fundamentally supported [126]. 
The use of linear scaling in obese is also not supported biologically since 𝐶𝐿 is not 
anticipated to correlate linearly with the additional 𝑊𝑇  gained due to excess 
adiposity which contributes little to the 𝐶𝐿. Hence, there is no evidence for the 
existence of a general scaling factor in obesity based on 𝑊𝑇  that is biologically 
plausible. The results of this work are not anticipated to be applicable if obese 
participants are included in the study and a different size metric (e.g. fat-free mass 
[25, 60, 91, 103, 106, 107, 137]) that appears biologically more plausible should be considered. 
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Aall 470 30 >1000 100 >1000 220 
B 70 10 200 20 500 40 









Aall 390 50 990 170 >1000 400 
B 90 10 370 30 830 60 
Ball 90 10 360 30 820 60 
1 






Aall 30 50 90 160 200 360 
B 10 10 20 40 50 80 
Ball <10 10 20 40 50 70 
𝑁80 values were rounded off to nearest 10’s multiple, NA not applicable 
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Table A1.2 Summary of power (%) and estimate bias (%) in all scenarios  
Population N 














10 46 39 21 115 15 193 
20 73 14 31 75 18 145 
50 98 2 63 26 35 65 
100 100 0 87 5 55 27 
200 100 1 99 1 85 7 
500 100 0 100 0 100 0 
1000 100 0 100 0 100 0 
 
Aall 
10 62 22 27 91 18 165 
20 87 5 44 43 25 92 
50 100 -1 78 8 46 37 
100 100 1 98 2 78 11 
200 100 0 100 0 97 1 
500 100 1 100 1 100 1 
1000 100 1 100 1 100 1 
 
B 
10 100 0 81 8 53 27 
20 100 0 97 0 79 9 
50 100 -1 100 -1 99 -2 
100 100 -1 100 -1 100 -2 
200 100 0 100 -1 100 -1 
500 100 0 100 0 100 0 
1000 100 0 100 -1 100 -1 
 
       
Ball 
10 96 0 76 10 51 29 
20 100 -1 96 -1 77 8 
50 100 0 100 0 99 0 
100 100 -1 100 -1 100 -1 
200 100 0 100 -1 100 -1 
500 100 0 100 0 100 0 
1000 100 0 100 -1 100 -1 
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Figure A1.1 Distributions of the covariates in the populations used in the 
simulation 
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A1.2. MATLAB simulation-estimation code for Objective 1: 
 
Sim-Est code 1: 
Consider changing the details of following BLOCKS as required before run ...................................... 1 
Set up environment ............................................................................................................................ 1 
BLOCK-1: Simulation setting ............................................................................................................... 1 
BLOCK-2:Default setting ..................................................................................................................... 1 
BLOCK-3:Reads covariate database (e.g. population A or B).............................................................. 2 
BLOCK-4: Defines vectors ................................................................................................................... 2 
BLOCK-5: Loop for sim-est of NREP=1000 replicates.......................................................................... 2 
BLOCK-6: Below loop repeats the sim-est steps if any NONMEM estimation is ................................ 2 
BLOCK-7:Generates NONMEM input file (.csv) .................................................................................. 2 
BLOCK-8: Estimation ........................................................................................................................... 3 
BLOCK-9: Picks up Objective function values ..................................................................................... 3 
BLOCK-10: Ensures avoiding aborted NONMEM runs ........................................................................ 4 
BLOCK-11: Post-estimation analysis ................................................................................................... 4 
BLOCK-12: Calculates power out of 1000 replicates .......................................................................... 4 
Consider changing the details of following BLOCKS as required before run 
BLCOK-1: Change the simulation setting as per the specific scenario 
BLCOK-3: Change the database name and column# 
BLOCK-8: Change the path of NONMEM .bat file and .ctl file name. 
Importantly, change the exponent values within the .ctl files 
according 
to the simulation scenarios below: 
if EXP = 0.67, then false1 = 0.75 and false2 = 1 
if EXP = 0.75, then false1 = 0.0.67 and false2 = 1 
if EXP = 1, then false1 = 0.75 and false2 = 0.67 
BLOCK-9 & 11: Change the path of .smy files 




BLOCK-1: Simulation setting 
NSUB = 100;        % sample size 
EXP = 0.75;        % true exponent 
SD_ETA = 0.4;      % SD of ETA (log-normal) 






BLOCK-2: Default setting 
NREP = 1000;                            % number of replicates 
V  = 1;                                 % standard volume 
CL = 0.693;                             % standard clearance 
dose = 1 ;                              % unit dose 
trange = [0; 0.25; 0.5; 1; 3; 5];       % sampling schedule 
AUC= dose/CL;                           % standard AUC 
C_ave = AUC/max(trange);                % average concentration 
SD_EPS1 = 0.1;                          % SD of EPS1 (exponential 
error) 
SD_EPS2 = 0.1*C_ave;                    % SD of EPS2 (additive 
error),i.e. 10% of average concentration 
BLOCK-3: Reads covariate database (e.g. population A or B) 
[NUM,TXT,RAW] = xlsread('population-A.xls');  % reads NHANES data 
weight = NUM(:,4);                            % define the column# 
of WT (here 4th column) 
BLOCK-4: Defines vectors 
count_all1 = [];                        % data vector-1 for all 
success records 
count_all2 = [];                        % data vector-2 for all 
success records 
BLOCK-5: Loop for sim-est of NREP=1000 replicates 
for j=1:NREP 
    rng(j);                             % sets the seed 
BLOCK-6: Below loop repeats the sim-est steps if any NONMEM estimation is 
aborted (i.e. no objective function value is obtained) 
    for m = 1:1000 
BLOCK-7: Generates NONMEM input file (.csv) 
   %Below loop generates dataset for NONMEM input and stores in "data_rep" 
 
    WT = datasample(weight,NSUB);                 % random covariate  







    ETA = 0+ SD_ETA.*randn(NSUB,2);               % ETA vectors for CL and V 
    data_rep = [];                                % vector for NONMEM input 
 
for i = 1:NSUB 
    CLi = CL *(WT(i,1)/70)^EXP * exp(ETA(i,1));   % ith subject's CL 
    Vi = V * exp(ETA(i,2));                       % ith subject's V 
    Ci = [];                                      % vector for ith subject's conc. 
 
  for t = 1:length(trange)                        % loop for every time point 
    Ct = (dose/Vi)*exp((-CLi/Vi)*trange(t,1));    % conc. at each time point 
    Ci = [Ci; Ct]; 
  end 
 
    DV =[];                                       % DV vector for ith subject 
 
    % Below loop adds residual error to ith subject's conc. and stores in DV 
 
  for t = 1:length(trange)                        % loop for every time point 
    EPS1 = 0+ SD_EPS1.*randn(1,1);                % generate EPS1 
    EPS2 = 0+ SD_EPS2.*randn(1,1);                % generate EPS2 
 
    if t==1 
         C_obs= 0;                                % observed conc. 
    else C_obs = Ci(t,1)*exp(EPS1)+ EPS2; 
    end 
 
    DV =[DV;C_obs]; 
 
  end 
 
   AMT = [dose; zeros(length(trange)-1,1)];       % generate dose column 
   MDV = [1;zeros(length(trange)-1,1)];           % generate MVD  








   % Below functions creates ith individual's dataset and adds into 
"data_rep" 
 
   data_ind = 
[repmat(i,length(trange),1),trange,DV,AMT,MDV,repmat(WT(i,1),length(
trange),1)]; 
   data_rep =[data_rep; data_ind]; 
 
end 
    csvwrite('input.csv',data_rep);     % creates NONMEM input file 
in .csv format 
BLOCK-8: Estimation 
    %Below functions call NONMEM .ctl files sequentially saved in 
the same folder to estimate using 'input.csv' 
    %For example, .ctl files for true, false1 and false2 models are 
saved as 
    %"est_true.ctl", "est_false1.ctl" and "est_false2.ctl" 
 
    !C:\NONMEM_7.2.0_For_Desktop\nm720\nm7\bin\wfn.bat gf reg & nmgo 
est_true.ctl; 
    !C:\NONMEM_7.2.0_For_Desktop\nm720\nm7\bin\wfn.bat gf reg & nmgo 
est_false1.ctl; 
    !C:\NONMEM_7.2.0_For_Desktop\nm720\nm7\bin\wfn.bat gf reg & nmgo 
est_false2.ctl; 
BLOCK-9: Picks up Objective function values 
    % Below functions pick up the respective OFVs from .smy files of NONMEM outputs 
 
    NM_output = fopen('D:\Projects\AllomScaling\est_true.reg\est_true.smy'); 
    A = textscan(NM_output,'%s','delimiter',''); 
    B = str2mat(A{1,1}(2,1)); 
    C = sscanf(B,'%f'); 
    if prod(size(C))== 1 
    OFV_true = 'NaN'; 
    else OFV_true =C(2,1); 
 







    fclose(NM_output); 
 
    NM_output = 
fopen('D:\Projects\AllomScaling\est_false1.reg\est_false1.smy'); 
    A = textscan(NM_output,'%s','delimiter',''); 
    B = str2mat(A{1,1}(2,1)); 
    C = sscanf(B,'%f'); 
    if prod(size(C))== 1 
    OFV_false1 = 'NaN'; 
    else OFV_false1 =C(2,1); 
    end 
    fclose(NM_output); 
 
    NM_output = 
fopen('D:\Projects\AllomScaling\est_false2.reg\est_false2.smy'); 
    A = textscan(NM_output,'%s','delimiter',''); 
    B = str2mat(A{1,1}(2,1)); 
    C = sscanf(B,'%f'); 
    if prod(size(C))== 1 
    OFV_false2 = 'NaN'; 
    else OFV_false2 =C(2,1); 
    end 
    fclose(NM_output); 
BLOCK-10: Ensures avoiding aborted NONMEM runs 
    % Below 'if-else' statements ensure to repeat the simulaion-
estimation 
    % steps if any NONMEM run is aborted 
 
 if OFV_true== 'NaN'; 
    continue 
elseif OFV_false1== 'NaN'; 
    continue 
elseif OFV_false2== 'NaN'; 
    continue 
else 
    break 
 end 
    end 





BLOCK-11: Post-estimation analysis 
    count1 = OFV_true<OFV_false1; 
    count2 = OFV_true<OFV_false2; 
    count_all1 = [count_all1;count1]; 
    count_all2 = [count_all2;count2]; 
end 
BLOCK-12: Calculates power out of 1000 replicates 
    power1 = sum(count_all1)*100/NREP; 
    power2 = sum(count_all2)*100/NREP; 
    result = [power1,power2]; 
    csvwrite('result.csv',result);        % result is generated in 
.csv file 
 
    toc 
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Sim-Est code 2: 
Consider changing the details of following BLOCKS as required before run ...................................... 1 
Set up environment ............................................................................................................................ 1 
BLOCK-1: Simulation setting ............................................................................................................... 1 
BLOCK-2:Default setting ..................................................................................................................... 1 
BLOCK-3:Reads covariate database (e.g. population A or B).............................................................. 2 
BLOCK-4: Defines vectors ................................................................................................................... 2 
BLOCK-5: Loop for sim-est of NREP=1000 replicates.......................................................................... 2 
BLOCK-6: Below loop repeats the sim-est steps if any NONMEM estimation is ................................ 2 
BLOCK-7:Generates NONMEM input file (.csv) .................................................................................. 2 
BLOCK-8: Estimation ........................................................................................................................... 3 
BLOCK-9: Picks up Objective function values ..................................................................................... 3 
BLOCK-10: Ensures avoiding aborted NONMEM runs ........................................................................ 4 
BLOCK-11: Post-estimation analysis ................................................................................................... 4 
BLOCK-12: Calculates power & bias and percentiles of exponent estimates out of 1000 replicates 4 
Consider changing the details of following BLOCKS as required before run 
BLCOK-1: Change the simulation setting as per the specific scenario 
BLCOK-3: Change the database name and column # 
BLOCK-8: Change the path of NONMEM .bat file and .ctl file name 
BLOCK-9 & 11: Change the path of .smy and .smr files 




BLOCK-1: Simulation setting 
NSUB = 100;        % sample size 
EXP = 0.75;        % true exponent 
SD_ETA = 0.4;      % SD of ETA (log-normal) 
BLOCK-2: Default setting 
NREP = 1000;                            % number of replicates 
V  = 1;                                 % standard volume 
CL = 0.693;                             % standard clearance 
 






dose = 1 ;                              % unit dose 
trange = [0; 0.25; 0.5; 1; 3; 5];       % sampling schedule 
AUC= dose/CL;                           % standard AUC 
C_ave = AUC/max(trange);                % average concentration 
SD_EPS1 = 0.1;                          % SD of EPS1 (exponential 
error) 
SD_EPS2 = 0.1*C_ave;                    % SD of EPS2 (additive 
error),i.e. 10% of average concentration 
BLOCK-3: Reads covariate database (e.g. population A or B) 
[NUM,TXT,RAW] = xlsread('population-A.xls');  % reads NHANES data 
weight = NUM(:,4);                            % define the column# 
of WT (here 4th column) 
BLOCK-4: Defines vectors 
count_all = [];                         % data vector 
EXP_est_all = [];                       % data vector 
EXP_est_all_discard = [];               % data vector 




    rng(j);                             % sets the seed 
BLOCK-6: Below loop repeats the sim-est steps if any NONMEM estimation is 
aborted (i.e. no objective function value is obtained) 
    for m = 1:1000 
BLOCK-7: Generates NONMEM input file (.csv) 
   %Below loop generates dataset for NONMEM input and stores in "data_rep" 
 
    WT = datasample(weight,NSUB);       % random covariate sampling 
    ETA = 0+ SD_ETA.*randn(NSUB,2);     % ETA vectors for CL and V 
    data_rep = [];                      % vector for NONMEM input 
 
 






for i = 1:NSUB 
    CLi = CL *(WT(i,1)/70)^EXP * exp(ETA(i,1));   % ith subject's CL 
    Vi = V * exp(ETA(i,2));                       % ith subject's V 
    Ci = [];                                      % vector for ith subject's conc. 
 
  for t = 1:length(trange)                        % loop for every time point 
    Ct = (dose/Vi)*exp((-CLi/Vi)*trange(t,1));    % conc. at each time point 
    Ci = [Ci; Ct]; 
  end 
 
    DV =[];                                       % DV vector for ith subject 
 
    % Below loop adds residual error to ith subject's conc. and stores in DV 
 
  for t = 1:length(trange)                        % loop for every time point 
    EPS1 = 0+ SD_EPS1.*randn(1,1);                % generate EPS1 
    EPS2 = 0+ SD_EPS2.*randn(1,1);                % generate EPS2 
 
    if t==1 
         C_obs= 0;                                % observed conc. 
    else C_obs = Ci(t,1)*exp(EPS1)+ EPS2; 
    end 
 
    DV =[DV;C_obs]; 
 
  end 
 
   AMT = [dose; zeros(length(trange)-1,1)];       % generate dose column 
   MDV = [1;zeros(length(trange)-1,1)];           % generate MVD column 
 
   % Below functions creates ith individual's dataset and adds into "data_rep" 
 
   data_ind =  








   data_rep =[data_rep; data_ind]; 
 
end 
    csvwrite('input.csv',data_rep);     % creates NONMEM input file 
in .csv format 
BLOCK-8: Estimation 
    %Below functions call NONMEM .ctl files sequentially saved in 
the same folder to estimate using 'input.csv' 
    %For example, .ctl files for base and covariate models are saved 
as 
    %"est_base.ctl" and "est_cov.ctl" 
 
    !C:\NONMEM_7.2.0_For_Desktop\nm720\nm7\bin\wfn.bat gf reg & nmgo 
est_base.ctl; 
    !C:\NONMEM_7.2.0_For_Desktop\nm720\nm7\bin\wfn.bat gf reg & nmgo 
est_cov.ctl; 
BLOCK-9: Picks up Objective function values 
    % Below functions pick up the respective OFVs from .smy files of NONMEM outputs 
 
    NM_output = fopen('D:\Projects\AllomScaling\est_base.reg\est_base.smy'); 
    A = textscan(NM_output,'%s','delimiter',''); 
    B = str2mat(A{1,1}(2,1)); 
    C = sscanf(B,'%f'); 
    if prod(size(C))== 1 
    OFV_base = 'NaN'; 
    else OFV_base =C(2,1); 
    end 
    fclose(NM_output); 
 
    NM_output = fopen('D:\Projects\AllomScaling\est_cov.reg\est_cov.smy'); 
    A = textscan(NM_output,'%s','delimiter',''); 
    B = str2mat(A{1,1}(2,1)); 
    C = sscanf(B,'%f'); 
 






if prod(size(C))== 1 
    OFV_base = 'NaN'; 
    else OFV_cov =C(2,1); 
    end 
    fclose(NM_output); 
BLOCK-10: Ensures avoiding aborted NONMEM runs 
    % Below if else statements ensure to repeat the simulaion-
estimation 
    % steps if any NONMEM run is aborted 
 
 if OFV_base== 'NaN'; 
    continue 
elseif OFV_cov== 'NaN'; 
    continue 
else 
    break 
 end 
    end 
BLOCK-11: Post-estimation analysis 
Below function picks up the estimate of EXP from .smr file 
    NM_output = fopen('D:\Projects\AllomScaling\est_cov.reg\est_cov.smr'); 
    A = textscan(NM_output,'%s','delimiter',''); 
    B = str2mat(A{1,1}(5,1)); 
    D = B(1,12:35); 
    E = sscanf(D,'%f'); 
    EXP_est = E(2,1); 
    fclose(NM_output); 
 
  % Below function does log-likelyhood ratio test 
 
    LLR = OFV_base - OFV_cov; 
    count = LLR > 3.84; 
    count_all = [count_all;count]; 
 
   % Below functions ensure that only the significantly different exponent estimates(LLR > 3.84)are 
considered for bias calculation 
 





if count == 1 
        EXP_est_all = [EXP_est_all; EXP_est]; 
    else 
        EXP_est_all_discard = [EXP_est_all_discard; EXP_est]; 
    end 
end 
BLOCK-12: Calculates power & bias and percentiles of exponent estimates out of 1000 replicates 
    power = sum(count_all)*100/NREP; 
    bias = (median(EXP_est_all)- EXP)*100/EXP; 
    result = [power,bias, quantile(EXP_est_all,[0.025 .50 0.975])]; 
    csvwrite('result.csv',result);           % result is generated 
in .csv file 
 
    toc 
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A1.4. NONMEM codes for Objective 1: 
A1.4.1. Code for ‘est_true.ctl’ file (called from Sim-Est code-1 of MATLAB) 
 
; To fit the Matlab simulated data (input.csv) using true covariate model 
  
$PROB Allom Scaling-Objective 1 
$INPUT ID TIME DV AMT MDV WT    
$DATA ..\input.csv IGNORE=# 
$SUBR ADVAN1 TRANS2 
 
$PK 
   TVCL=THETA(1)*(WT/70)**0.75      ;covariate model 
   TVV=THETA(2) 
   CL=TVCL*EXP(ETA(1))                       ;BSV model 
   V=TVV*EXP(ETA(2))                           ;BSV model 
   S1=V                                                    ;scale conc. 
 
$ERROR 
   Y=F*EXP(EPS(1))+EPS(2)         ; combined error 
  
$THETA 
   (0.1,0.693)     ; CL 
   (0.01,1)        ; V 
 
$OMEGA 
   0.1             ; PPVCL 
   0.1             ; PPVV 
 
$SIGMA  
   0.01            ; RUVPROP 
   0.01             ; RUVADD 
 
$EST MAX=9990 SIG=5 PRINT=1 METHOD=1 INTERACTION NOABORT 
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A1.4.2. Code for ‘est_false1.ctl’ file (called from Sim-Est code-1 of MATLAB) 
 
; To fit the Matlab simulated data (input.csv) using false1 covariate model  
 
$PROB Allom Scaling-Objective 1 
$INPUT ID TIME DV AMT MDV WT    
$DATA ..\input.csv IGNORE=# 
$SUBR ADVAN1 TRANS2 
 
$PK 
   TVCL=THETA(1)*(WT/70)**0.67    ;covariate model 
   TVV=THETA(2) 
   CL=TVCL*EXP(ETA(1))                     ;BSV model 
   V=TVV*EXP(ETA(2))                         ;BSV model 
   S1=V                                                  ;scale conc. 
 
$ERROR 
   Y=F*EXP(EPS(1))+EPS(2)          ;combined error 
 
$THETA 
   (0.1,0.693)       ; CL 
   (0.01,1)          ; V 
 
$OMEGA 
   0.1          ; PPVCL 
   0.1          ; PPVV 
 
$SIGMA  
   0.01          ; RUVPROP 
   0.01          ; RUVADD 
 
$EST MAX=9990 SIG=5 PRINT=1 METHOD=1 INTERACTION NOABORT 
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A1.4.3. Code for ‘est_false2.ctl’ file (called from Sim-Est code-1 of MATLAB) 
;To fit the Matlab simulated data (input.csv) using false2 covariate model  
$PROB Allom Scaling-Objective 1 
$INPUT ID TIME DV AMT MDV WT    
$DATA ..\input.csv IGNORE=# 
$SUBR ADVAN1 TRANS2 
 
$PK 
   TVCL=THETA(1)*(WT/70)      ;covariate model 
   TVV=THETA(2) 
   CL=TVCL*EXP(ETA(1))           ;BSV model 
   V=TVV*EXP(ETA(2))               ;BSV model 
   S1=V                                         ;scale conc. 
 
$ERROR 
   Y=F*EXP(EPS(1))+EPS(2)      ;combined error 
 
$THETA 
   (0.1,0.693)       ; CL 
   (0.01,1)          ; V 
 
$OMEGA 
   0.1          ; PPVCL 
   0.1          ; PPVV 
 
$SIGMA  
   0.01          ; RUVPROP 
   0.01          ; RUVADD 
 
$EST MAX=9990 SIG=5 PRINT=1 METHOD=1 INTERACTION NOABORT 
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A1.5. NONMEM codes for Objective 2:  
A1.5.1. Code for ‘est_base.ctl’ file (called from Sim-Est code-2 of MATLAB) 
;To fit the Matlab simulated data (input.csv) using base model  
$PROB Allom Scaling-Objective 2 
$INPUT ID TIME DV AMT MDV WT    
$DATA ..\input.csv IGNORE=# 
$SUBR ADVAN1 TRANS2 
 
$PK 
   TVCL=THETA(1)     
   TVV=THETA(2) 
   CL=TVCL*EXP(ETA(1))         ;BSV model 
   V=TVV*EXP(ETA(2))            ;BSV model 
   S1=V                                      ;scale conc. 
 
$ERROR 
   Y=F*EXP(EPS(1))+EPS(2)     ;combined error 
    
$THETA 
   (0.1,0.693)     ; CL 
   (0.01,1)        ; V 
 
$OMEGA 
   0.1          ; PPVCL 
   0.1          ; PPVV 
 
$SIGMA  
   0.01          ; RUVPROP 
   0.01          ; RUVADD 
 
$EST MAX=9990 SIG=5 PRINT=1 METHOD=1 INTERACTION NOABORT 
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A1.5.2. Code for ‘est_cov.ctl’ file (Sim-Est code-2 of MATLAB) 
;To fit the Matlab simulated data (input.csv) using covariate model to estimate 
exponent  
$PROB Allom Scaling-Objective 2 
$INPUT ID TIME DV AMT MDV WT    
$DATA ..\input.csv IGNORE=# 
$SUBR ADVAN1 TRANS2 
 
$PK 
   TVCL=THETA(1)*(WT/70)**THETA(2)             ;covariate model 
   TVV=THETA(3) 
   CL=TVCL*EXP(ETA(1))                                         ;BSV model 
   V=TVV*EXP(ETA(2))                                          ;BSV model 
   S1=V                                                                     ;scale conc. 
 
$ERROR 
   Y=F*EXP(EPS(1))+EPS(2)        ;combined error 
 
$THETA 
   (0.1,0.693)       ; CL 
   (0.01,1)       ; EXP 
   (0.01,1)       ; V 
 
$OMEGA 
   0.1            ; PPVCL 
   0.1            ; PPVV 
 
$SIGMA  
   0.01            ; RUVPROP 
   0.01            ; RUVADD 
 
$EST MAX=9990 SIG=5 PRINT=1 METHOD=1 INTERACTION NOABORT 
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 =  
𝐵𝑀 × 𝑓𝐹𝑀
𝜌𝐹𝑀







 =  
𝑓FM
𝜌FM







 =  
𝑓FM
𝜌FM
 +  






 =  







 =  







 =  







 =  𝑓FM × (𝜌FFM − 𝜌FM) + 𝜌FM 
 
 
𝑓FM × (𝜌FFM − 𝜌FM) =
𝜌FM × 𝜌FFM
𝜌BM









− 𝜌FM)  
 
Putting the values of    𝜌FM = 0.90 and    𝜌FFM = 1.10 in Eq 3.6 of main text (as 
per human cadaver analysis in the following section), it becomes the popularly 
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A2.2.  Derivation of body composition constants from human cadaver analysis 
Various methods of determining body composition in human largely depends 
on a universal value of some constants e.g. 𝜌FM, 𝜌FFM, 𝑅water/FFM  which is a key 
assumption of these methods. Therefore, it is very essential to understand how these 
body composition constants were derived. A thorough literature survey was carried 
out for this purpose and described here. 
A2.2.1.      (0.90 g/mL):  
Fidanza et al. (1953) collected samples of subcutaneous and internal fat during 
surgery from human subjects. Upon ether extraction of the fat samples, they 
measured the densities at 37°C and reported. As evident from the results, the inter-
individual variability of body fat density is quite negligible across the sexes and 
various physical status. It is also noted that the difference in fat densities from 
different parts of the body is trivial.  




Physical State Ds (g/mL) Di (g/mL) 
1 F 76 Moderate thin 0.8998 0.8998 
2 F 56 Well nourished 0.8992 0.9002 
3 M 38 Well nourished - 0.8998 
4 M 54 Well nourished 0.9009 0.9004 
5 M 53 Obese 0.9006 0.8999 
   Mean 0.9001 ± 0.0004 0.9000 ± 0.0001 
Ds and Di are the densities of subcutaneous and internal fat respectively, refer to Fidanza et al. 
[144] for detail calculations  
A2.2.2. 𝐰    /    (0.73):  
Schoeller compiled all the 𝐹𝐹𝑀 water content data published in the literature 
till date which were determined by complete analysis of water, protein, fat and 
mineral of human cadavers. Water content was calculated as the percentage of 𝐹𝐹𝑀 
from the chemical analysis results.  
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𝑊𝑎𝑡𝑒𝑟 ( 𝐹𝐹𝑀) =
 𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑊𝑎𝑡𝑒𝑟 (𝑘𝑔)
𝑇𝐵𝑊(𝑘𝑔) − 𝐹𝑎𝑡 𝑊𝑒𝑖𝑔ℎ𝑡(𝑘𝑔)
    
 















Forbes et al. 
(1953) 




2 M 25 71.8 Uraemia 72.62 
3 M 46 53.8 Cerebral injury 68.36 








Knight et al., 
1986 
6 F  59 25.9 Cervical cancer 73.00 




Moore et al., 
1968 





In addition, water/𝐹𝐹𝑀 ratio has been widely studied in many mammalian 
species (mouse, rat, rabbit, dog, seal, monkey) and found to be consistent with 
human (73%). 
A2.2.3.     (1.10 g/mL): 
The density of 𝐹𝐹𝑀 was calculated from the chemical analysis data of three 
male cadavers mentioned above in the Table A2.2 (cadaver # 2, 3, 4) by Brozek et al. 
(1963) and the calculation is shown in Table A2.3 below. The 𝐹𝐹𝑀 weight (𝑊𝑇𝐹𝐹𝑀) of 
the individual cadavers were calculated by adding the weights of the water 
(𝑊𝑇𝑤𝑎𝑡𝑒𝑟 ), protein (𝑊𝑇𝑝𝑟𝑜𝑡𝑒𝑖𝑛 ) and body mineral (𝑊𝑇𝑚𝑖𝑛𝑒𝑟𝑎𝑙 ). Protein weight was 
determined by multiplying the nitrogen content with 6.25 and body mineral weight 
was determined by multiplying the ash value with 1.0354. These scaling factors 
represent the 16% average nitrogen content in protein and 96.58% the ash content in 
the whole body [145].  Volume of water, protein and mineral components were 
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calculated by dividing their weights by their corresponding reported densities at 






𝑉𝑤𝑎𝑡𝑒𝑟 + 𝑉𝑝𝑟𝑜𝑡𝑒𝑖𝑛 + 𝑉𝑚𝑖𝑛𝑒𝑟𝑎𝑙
    
 

















2 618.0 166.0 77.7 621.9 123.9 25.6 1.12 
3 551.0 186.0 55.9 554.5 138.8 18.4 1.11 
4 679.0 144.0 49.7 683.3 107.5 16.4 1.08 
      Mean 
1.10 ± 
0.01 
Refer to Brozek et al. [145] 
 
A2.2.4.  RTBK/FFM (68.1 mmol/kg 𝑭𝑭𝑴): 
Summary of the calculations is presented in Table A2.4. Forbes et al. (1956), did 
chemical analysis of two human cadavers (# 9,10 in Table A2.4) and collected data 
from two preveously reported cadaver analysis data (#1, 8 in Table A2.4), where 
cadavers were appearantly free from any serious disease. 
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NR b 70.0 NRb 66.8 
9c M 46 53.8 Fractured skull 66.5 
10d M 60  
Found dead in hotel 
room 
66.6 
    Mean 68.1 ± 2.99 
a From Table A2.2, not reported whether incident happened in fresh or salt water; b not 
reported; c Post-mortem findings: Tissues appeared in a normal state of hydration with no 
abnormality; d Post-mortem findings: Tissues appeared in a normal state of hydration but 
severe abnormalities were observed: arteriosclerosis of abdominal aorta and coronary 
arteries, hemorrhages in edges of mitral and tricuspid valves but no definite endocarditis, 
moderate cardiac enlargement moderate fatty degeneration of myocardium and liver and 
marked passive congestion of both lungs. 
A2.3. Derivation of DXA equations (Eq 3.30, Eq 3.31 and Eq 3.32 of main text) 
Figure 3.2 in the main text represents a schematic of a pixel which corresponds 
to an infinite depth of tissue with infinite set of composition (of lean, fat and bone 
mineral) through which X-ray beams travel and the cross sectional area represents 
the pixel area. As the X-ray beams traverse through a pixel area, physical 
interactions take place with the tissue components that reduce beam intensity, 
referred to as attenuation and is recorded by the DXA scanner. The attenuation holds 
an inverse relationship with the incident beam energy, therefore attenuation of 
higher energy (𝐴𝐻) is lower than that of lower energy (𝐴𝐿) beam.  
          𝐴𝐿 = 𝑙𝑛
(𝐼)𝐿
(𝐼0)𝐿






For a particular energy, attenuation also depends on the fractional composition 
and density (mass/unit volume of pixel) of each component (lean, fat and bone 
mineral) of that particular pixel. For example, a soft tissue pixel ([fat] or [lean] or [fat 
+ lean]) attenuates less than a bone mineral containing pixel (it could be either [bone 
+ lean] or [bone + lean + fat], since bone is directly attached to skeletal muscle) 
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because of difference in individual fractional masses of each component. Also, a 
bone mineral containing pixel of an osteoporosis patient will attenuate less than that 
of a healthy subject because of less bone mineral mass/unit volume of pixel. 













Therefore, the ‘r’ value of 𝑖th pixel containing all the three components can be 
expressed as below. 
𝑟𝑖 = 𝑓𝑓𝑎𝑡𝑖
× 𝑟𝑓𝑎𝑡 + 𝑓𝑙𝑒𝑎𝑛𝑖 × 𝑟𝑙𝑒𝑎𝑛 + 𝑓𝑏𝑜𝑛𝑒𝑖 × 𝑟𝑏𝑜𝑛𝑒  
 
where, 𝑓𝑓𝑎𝑡𝑖
, 𝑓𝑙𝑒𝑎𝑛𝑖  and  𝑓𝑏𝑜𝑛𝑒𝑖are the fractional masses of fat, lean and bone 
mineral in 𝑖th  pixel and 𝑟𝑓𝑎𝑡, 𝑟𝑙𝑒𝑎𝑛 and 𝑟𝑏𝑜𝑛𝑒 values are known from previous work by 
Pietrobelli et al. [172] or can be determined experimentally with animal tissues. 
Therefore, whole body DXA records the ‘𝑟𝑖’ values of all pixels generated, and then 
solves the fractional masses.  
Derivation of lean fraction of soft tissue: Since more than two unknown fractions in 
the previous equation cannot be solved, it is therefore necessary to conduct this in a 
two stage process.  In the first stage, pixels related to bone mass are separated from 
the non-bone pixels of a whole body scan.  This is performed based on a threshold 
value of ‘r’, below which non-bone (soft) tissue pixels appear and the bone 
containing pixels appear above it. This then simplifies the system and the non-bone 
(soft) pixels are now considered to be a standard two component system of lean and 
fat tissue and thus ‘r’ of 𝑖 th soft tissue pixels (𝑟ST𝑖) can be defined the following 
equation. 
𝑟ST𝑖 = 𝑓𝑓𝑎𝑡𝑖
× 𝑟𝑓𝑎𝑡 + 𝑓𝑙𝑒𝑎𝑛𝑖 × 𝑟𝑙𝑒𝑎𝑛  
 
Pietrobelli et al. [172] calculated the theoretical values of 𝑟𝑓𝑎𝑡 =1.21 based on 
elemental composition of human triglycerides, 𝑟𝑙𝑒𝑎𝑛 =1.36 based on elemental 
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composition of lean tissue obtained from a reference man (theoretical elemental 
composition of a man having standard body composition) and from eleven healthy 
volunteer men studied using neutron activation analysis-whole body counting. They 
further, validated these values to be 𝑟𝑓𝑎𝑡 = 1.20 and 𝑟𝑙𝑒𝑎𝑛 = 1.40 experimentally by 
using animal fat and lean tissues. Therefore, 𝑟𝑓𝑎𝑡  and 𝑟𝑙𝑒𝑎𝑛  values can be 
experimentally determined prior to the whole body DXA scan. Given, 𝑟𝑓𝑎𝑡 and 𝑟𝑙𝑒𝑎𝑛 
are known a priori, solution for 𝑓𝑙𝑒𝑎𝑛𝑖  in the previous equation can be obtained by 
rearranging as below, since (𝑓𝑓𝑎𝑡𝑖
+ 𝑓𝑙𝑒𝑎𝑛𝑖) = 1.  
 
𝑟ST𝑖 = (1 − 𝑓𝑙𝑒𝑎𝑛𝑖) × 𝑟𝑓𝑎𝑡 + 𝑓𝑙𝑒𝑎𝑛𝑖 × 𝑟𝑙𝑒𝑎𝑛 
𝑟ST𝑖 = 𝑟𝑓𝑎𝑡 − 𝑓𝑙𝑒𝑎𝑛𝑖
× 𝑟𝑓𝑎𝑡 + 𝑓𝑙𝑒𝑎𝑛𝑖 × 𝑟𝑙𝑒𝑎𝑛 




          (Eq 3.30 in the main text) 
 
Further, the average fraction of lean tissue in the whole body’s soft tissue mass, 
i.e. 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇) can be determined by dividing the summation of all 𝑓𝑙𝑒𝑎𝑛𝑖 values by total 







   (Eq 3.31 in the main text) 
 
Derivation of bone mineral content (𝐵𝑀𝐶): In the next step, the bone mineral areal 
densities (g/cm2), i.e. 𝑀BM𝑖  are computed from all the bone pixels using the 
following equation [266, 267], where [µmBM]L or H
 are respective mass attenuation 
coefficients of bone mineral at both energy levels. 
𝑀BM𝑖(g/cm
2)  =
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Attenuations (AL,  AH)  are directly measured by the DXA instrument, the 
attenuation coefficients ([µmBM]L
, [µmBM]H
) can be fixed to their theoretical values 
0.9039 and 0.3159 (from standard elemental composition of bone mineral), 
respectively as derived by Pietrobelli et al. [172] or can be experimentally determined. 
In this case, 𝑟ST is representative of all non-bone (i.e. soft) tissues which can vary 
widely depending upon the composition in the particular pixel. Several 
approximations have been used to impute the value of 𝑟ST including the average 
over all soft tissues and a uniform soft tissue composition surrounding the bones 
across the whole body. This approximation is known as the uniform distribution 
model [268], and is restricted to the spinal bones only, as most of the bones deviate 
from this assumption. Other, and more recent, approximations are being used which 
account for a weighted average of 𝑟ST in the bone containing pixels and calculates the 
𝑀BM𝑖. This approach is known as weighted linear distribution model 
[268]. Total BMC 
thus, can be estimated by multiplying each 𝑀BM𝑖 with their pixel area and summing 
them up, where 𝑁BM represents total number of bone mineral pixels. 
𝐵𝑀𝐶 (𝑔)  = ∑ 𝑀𝐵𝑀𝑖(𝑔/𝑐𝑚




 (Eq 3.32 in the main text) 
 
A2.4. Limitation of Assumptions  
The typical values used for these parameters are 𝜌FM = 0.90 g/mL, 𝜌FFM = 1.10 
g/mL, 𝑅water/FFM = 0.73 , 𝑅TBK/FFM = 68.1  mmol/kg 𝐹𝐹𝑀 , [K
+]𝑖 = 150  mmol/L, 
𝑓AT = 0.8, 𝜌AT = 0.95 g/mL. These deviations are largely due to biological variation 
caused by various factors such as age, disease, pregnancy etc, apart from natural 
inter-individual variation in healthy adult population. 𝜌FM remains fairly constant 
because of negligible variation occurs in animal fat composition. On the other hand, 
𝜌FFM is expected to vary widely because of the biological variation in its composition 
i.e. water, protein, carbohydrate, minerals. Disease states [188] can alter 𝜌FFM and also, 
it is known that children (1.068 to 1.096 g/mL) [186] and body builders (1.091 ± 0.012 
g/mL) have lower values [269] of 𝜌FFM . However, the universality of 𝜌FFM  was 
reported across sex, race and range of adiposity [270]. Similarly, 𝐹𝐹𝑀 calculation from 
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𝑇𝐵𝑊 entirely depends on the assumed constant 𝑅water/FFM which is very susceptible 
to (patho)physiological changes caused by disease, age etc. For example, higher 
𝑅water/FFM (~0.80) ratio was reported in children at one month 
[187]) of age, which 
gradually normalises to adult value. Similar to 𝑇𝐵𝑊 , 𝑇𝐵𝐾  measurement entirely 
depends on the assumed constant 𝑅TBK/FFM  which is very susceptible to 
(patho)physiological changes caused by disease, age etc. For example, lower 
𝑅TBK/FFM (54-62 mmol/kg 𝐹𝐹𝑀 [154]) ratio was reported in children. Moreover, deficit 
in 𝑇𝐵𝐾  does not necessarily decrease the 𝐹𝐹𝑀  proportionately in certain 
pathological conditions such as in solid tumours [189]. This is primarily because K+ is 
restricted to the intracellular space or the body cell mass which constitutes only 50-
60% of 𝐹𝐹𝑀 . Further to this, water migration from intracellular to extracellular 
compartment during 𝑇𝐵𝐾 deficit can lower the 𝑅TBK/FFM ratio. Also, the assumed 
value of [K+]𝑖 = 150 mmol/L is not constant and is reported to vary during diseases 
causing acid-base imbalance [159] or due to therapeutic intervention (e.g. β-blockers) 
[190, 191]. For CT/MRI, measurements are dependent on assumed values of 𝑓AT and 
𝜌AT. Although 80% fat content (𝑓AT = 0.8) is commonly used in literature [99, 176, 177] it 
should be noted that it is not universal. A range of 54% – 85% fat content [271] and an 
even a higher range of 62% – 91% [177] have been reported by other researchers based 
on human cadaver analysis. Moreover, 𝑓AT is positively correlated with adiposity 
(  fat = 0.327 + 0.0124 ×  adiposity) [271]. But, the influence of gender, ethnicity, 
pathological status on this parameter is not well understood. In addition, 𝜌AT also 
varied between 0.925 – 0.970 gm/mL among the cadavers studied. However, 
variation in 𝑓AT and 𝜌AT is not important to consider for densitometry based methods 
that also derive 𝐹𝑀 as the first step to drive 𝐹𝐹𝑀. Therefore, universal use of these 
constants can lead to erroneous result in 𝐹𝐹𝑀  determination and thus, is not 
advisable under such circumstances 
A2.5. Operational limitations 
First of all, the total number of whole body counters installed across the world 
is very few and those are mostly attached to nuclear plants for routine safety 
evaluation of the workers. Therefore, the use of whole body counting in regular 
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body composition studies can be ruled out. Also, hydrometry based on 𝐵𝑟− or 𝐶𝑙− 
dilution space is not a feasible option to determine 𝐹𝐹𝑀 since it requires 𝐼𝐶𝑊 to be 
measured in parallel by whole body counting. Most of the remaining methods 
require access to an in house set up and thus are not suitable for field studies. 
Hydrostatic weighing requires access to in house pool, hydrometry requires access 
to LC-MS or scintillation counters installed in a laboratory, BOD POD, DXA, CT and 
MRI instruments are also not portable. Therefore, bioimpedance analysis and 
anthropometry are the only options available for field studies. For in house studies, 
hydrostatic weighing is not a preferred method of choice since it requires the subject 
to submerge under the water with maximal exhalation. On the other hand, CT is not 
recommended for the purpose of body composition analysis due to its high radiation 
exposure and MRI, in spite of being free from ionising radiation is very costly and 
has limited access. Among the remaining methods, isotope dilution is practically 
limited by its long waiting time for equilibration, limited access to analytical 
instruments, i.e. LC-MS (2H2O, H218O), scintillation detector (3H2O) and particularly, 
the tritium dilution (3H2O) is not advisable for use in children and child bearing 
women due to radiation exposure. Therefore, BOD POD, anthropometry, 
bioimpedance analysis and DXA appear to be reasonably feasible options for 𝐹𝐹𝑀 
measurement from operational point of view. Due to less practical constraints, these 
four methods are mostly fit for clinical use. A detailed list of advantages and 
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Table A2.5 Examples of 𝑭𝑭𝑴 calculation for a standard 70 kg man using standard values of parameters 
Method based on Measurement 
Primary 
Outcome 








































𝐹𝐹𝑀 = 𝑊𝑇 × (1 − 𝑓𝐹𝑀) 
𝜌FM = 0.90 
g/mL 
 





𝑊𝑇, 𝑉𝐵, 𝑉𝐿, 𝐵𝑆𝐴 𝜌𝐵𝑀 =
𝑊𝑇




(𝑋1), (𝑋2),  
(𝑋3), (𝑋4)  
𝜌𝐵𝑀 = 𝐶1 −𝑚1 × 𝑋1 +𝑚2 × (𝑋1)
2
−𝑚3 × 𝑋2 −𝑚4



















𝑇𝐵𝑊 = 40 
kga 

















𝑍 or 𝑅, 𝐻𝑡, 𝑊𝑇, 
Age, Sex (M=1, 
F=0) 




× [𝑆𝑒𝑥] + 𝜃3
× [𝑊𝑇] + 𝜃4






 𝑊𝐵𝐶 40K content 𝑇𝐵𝐾 𝑇𝐵𝐾 =
 𝑅𝑎𝑑𝑖𝑜𝑎𝑐𝑡𝑖𝑣𝑒 𝐾 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 
0.000118 × 39.102
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Method based on Measurement 
Primary 
Outcome 

















































= 0.8375 c 
 
 
𝐵𝑀𝐶  = 3 kg 
d 
𝐹𝐹𝑀
= 𝑊𝑇𝑆𝑇 × 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇)
+ 𝐵𝑀𝐶 
𝑟𝑓𝑎𝑡  = 1.21 
 

























𝑉𝐴𝑇 = 14.74 
kg e 
 
𝐹𝐹𝑀 = 𝑊𝑇 − 𝑉𝐴𝑇 × 𝜌𝐴𝑇
× 𝑓𝐴𝑇 
ρAT = 0.95 
gm/mL 
 
𝑓AT = 0.80 
58.8 
a for a standard 70 kg man [147]; b dose corrected with urine, c calculated from total soft tissue rST  value of 1.334 of a reference man [172]; d average value of several male subjects 
(unpublished  data from Taylor et al. [272]), e mean adipose tissue volume of six cadavers studied [271] 
𝑊𝑇 total body weight, ∆WT difference between 𝑊𝑇 in air (𝑊𝑇𝑎𝑖𝑟) and 𝑊𝑇 in water (𝑊𝑇𝑤𝑎𝑡𝑒𝑟), 𝜌BM total body density, 𝐹𝑀 fat mass, 𝐹𝐹𝑀 fat-free mass,  𝜌FM density of 𝐹𝑀, 
𝜌FFM density of 𝐹𝐹𝑀, 𝑓FM fraction of 𝐹𝑀 in 𝑊𝑇, 𝑉𝐵 total body volume, 𝑉𝐿 lung volume, 𝐵𝑆𝐴 body surface area, δ instrument specific constant, X1sum of seven skin folds, 
X2 age, X1  waist circumference, X4  fore arm circumference, 𝑚1 = 4.115 × 10
−4 , 𝑚2 = 0.0069 × 10
−4 , 𝑚3 = 2.2631 × 10
−4 , 𝑚4 = 59.239 × 10
−4 , 𝑚5 = 190.632 × 10
−4 , 𝐶1 =
11010 × 10−4, 𝐶2 = 11470 × 10
−4, 𝑇𝐵𝑊 total body water, 𝑍 impedance, 𝑅 resistance, 𝐻𝑡 height, Rwater/FFM ratio of 𝑇𝐵𝑊 to 𝐹𝐹𝑀, 𝑊𝐵𝐶 whole body counting, 𝑇𝐵𝐾 total body 
potassium, RTBK / FFM  ratio of 𝑇𝐵𝐾  to 𝐹𝐹𝑀 , 𝐴𝐿 , 𝐴𝐻  attenuation of low and high energy beams respectively, 𝐵𝑀𝐶  bone mineral content,  
𝑟ST𝑖 attenuation ratio of 𝑖
th soft tissue pixel, 𝑓𝑙𝑒𝑎𝑛 (𝑆𝑇) average fraction of lean in soft tissue, 𝑓𝑙𝑒𝑎𝑛𝑖 fraction of lean in 𝑖
 th pixel, 𝑟𝑓𝑎𝑡 attenuation ratio of fat, 𝑟𝑙𝑒𝑎𝑛 attenuation ratio 
of lean, 𝑁𝑆𝑇 total number of soft tissue pixels, CT computerised tomography, MRI magnetic resonance imaging, 𝑉𝐴𝑇 volume of adipose tissue, 𝑙 inter-slice distance, 𝑁𝑠 number 
of slices, ρAT density of adipose tissue, 𝑓AT fractional fat content in adipose 
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Table A2.6 Various models published in literature for predicting body composition 
SL 
# 
Model Author Description 
Population used for model 
development 
1 𝐹𝐹𝑀 = 𝑃1 ×𝑊𝑇 + 𝑃2 × 𝐻𝑡 − 𝑃3 Hume [178] 
𝑃1= 0.32810 (male), 0.29569 (female), 
𝑃2= 0.33929 (male), 0.41813 (female), 
𝑃3= 29.5336 (male), 43.2933 (female). 
𝐻𝑡 in cm;  
N = 29 (male) + 27 (female); 
Weight range: 42.9-132.8 kg 
(male) and 44.7-115.5 kg 
(female); Age range: 40-77 years 
(male) and 37-80 years (female) 





 James [101, 183] 
𝑃4 = 1.1 (men), 1.07 (women),  
𝑃5 = 128 (men), 148 (women).  
𝐻𝑡 in cm. 
N = 89 (male) + 94 (female); 
weight range: 32.3-121.8 kg; age 
range: 16-84 years 
3 𝐹𝐹𝑀 = 𝑃6 ×𝑊𝑇 + 𝑃7 × 𝐻𝑡2  
Garrow and 
Webster [180] 
𝑃6= 0.285 (male), 0.287 (female),  
𝑃7= 12.1 (male), 9.74 (female), 
𝐻𝑡 in metre   
N = 24 (male) + 105 (female);  
weight range: 43.5-126 kg;  range 
of BMI: 16.7 - 50.1 kg/m2;  range 
of height: 1.57-1.86 m 
4 
𝐹𝑀 = 𝑃8 × 𝐵𝑀𝐼 + 𝑃9 ×𝑊𝑇 + 𝑃10 × 𝐴𝑔𝑒
− 𝑃11 Heitmann [181] 
𝑃8= 0.988 (male), 0.988 (female), 
𝑃9= 0.242 (male), 0.344 (female), 
𝑃10= 0.094 (male), 0.094 (female),  
𝑃11= 30.180 (male), 30.180 (female) 
N = 72 (male) + 67 (female); 
Range of body fat: 7.2 - 42.3 kg; 
Age range: 35-65 years 
5 
 𝐹𝑀 = 𝑃12 × 𝐵𝑀𝐼 + 𝑃13 × 𝐴𝑔𝑒 − 𝑃14
× 𝑆𝑒𝑥 − 𝑃15 
Deurenberg 
[182] 
𝑃12= 1.2 (adult), 1.51 (children), 
𝑃13= 0.23 (adult), 0.70 (children),  
𝑃14= 10.8 (adult), 3.6 (children),  
𝑃15= 5.4 (adult), 1.4 (children);  
sex =1 (male) or 0 (female) 
N = 521 (males) + 728 (females) 
including older men and 
children ; Age range: 7 - 83 years; 
𝐵𝑀𝐼 range: 13.9 - 40.9 kg/m2 




9.27 × 103 ×𝑊𝑇




𝑃16 = 6.68 × 103 (male), 8.78 × 103 
(female);  
𝑃17= 216 (male), 244 (female) 
N= 168 (male) + 205 (female);   
weight range: 40.7-216.5 kg;  𝐵𝑀𝐼 
range: 17.1-69.9 kg/m2; age 
range: 18-82 years 
7 
𝐹𝐹𝑀obesefemale = −11.41 + 0.354 ×𝑊𝑇
+ 11.06 × 𝐻𝑡  Bucaloiu [184]  𝐻𝑡 in metre 
N= 70 (Morbidly obese females);  
𝐵𝑀𝐼: 48.3 ± 4.8 kg/m2;  weight: 



















9.27 × 103 ×𝑊𝑇




𝑃18= 0.88 (male), 1.11 (female);  
𝑃19= 0.12 (male), 0.11 (female);  
𝑃20=  13.4 (male), 7.1 (female),  
𝑃21= −12.7 (male), −1.1 (female) 
N= 515 (male) + 496 (female);   
𝐵𝑀𝐼 range: 12 - 44.9 kg/m2; age 
range: 3 - 29 years 
𝐹𝐹𝑀 fat-free mass in kg, 𝐹𝑀  fat mass in kg, 𝑊𝑇 total body weight in kg, 𝐵𝑀𝐼 body mass index in kg/m2 𝐻𝑡 height,  Age in year 
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Table A2.7 Operational advantages, disadvantages and reliability of 





















- No body size 
limitation 
- Experimentally     
challenging: not 
suitable for unfit 
subjects, e.g. 
children, frails 
- Subjects needs 
to be trained 
well 
- Not suitable 
for field studies 
Precision/Variability of 𝜌BM:  
- Reported SD of 𝜌BM measured 
in multiple subjects at multiple 
occasions was 0.008 g/mL, 
given both the subject and 





- Suitable for all 
including 
children  
- No body size 
limitation 
- Not suitable 
for field studies 
Precision of 𝑉𝐵:  
- Reported CV value was < 0.1% 
for an inanimate object having 
comparable volume to an adult 
human and measured in 
multiple occasions  
Anthropometry 
- High patient 





- Suitable for all 
including 
children 
- Suitable for 
field studies 
- Identifying the 
waistline in 
severely obese 
subjects is often 
difficult 
Precision of skinfold thickness 
(𝑋1): variable 
- subject to anthropometrist’s 
skill 
- variability can be limited 
within 5% if properly trained 






















- No age 
limitation  
- No body size 
limitation 

















MS) needed for 
2H2O, H218O  
- 𝐼𝐶𝑊 by 𝑇𝐵𝐾 is 
not 
recommended if 
altered [K+]𝑖 is 
suspected 







Precision of 𝑇𝐵𝑊:  
- Depends on the analytical 
technique used  
- CV of 1-2% noted with LC-MS 
- But 2-4% for other analytical 
methods 
 
Precision of 𝐸𝐶𝑊, 𝐼𝐶𝑊:  
- Not well characterised as with 
isotope dilution 
- 𝑇𝐵𝑊 measurement by adding 
𝐸𝐶𝑊  and 𝐼𝐶𝑊  is likely to lack 
precision, as errors with both 
variable will be added up 
 
Accuracy of 𝑇𝐵𝑊:  
- Isotope dilution slightly 
overestimates 𝑇𝐵𝑊  by about 
1% due to non-aqueous 
exchange 
 
Accuracy of 𝐸𝐶𝑊, 𝐼𝐶𝑊:  
- Unknown due to lack of direct 
chemical analysis method 















- Fast and non-
invasive 
procedure 
- No age 
limitation 
- No body size 
limitation 
- Suitable for 
field studies   







Precision/Variability of 𝑍:  
- CV of within day and between 
day measurements was shown 
to be   0.3-0.8% and 0.9-1.7% 
respectively 
Accuracy of 𝐹𝐹𝑀:  






















- Non-invasive  
- Suitable for all 
including 
children 
- Limited access: 
very few 
laboratory 
across the world 
have whole 
body counters  
 
Precision/Variability of 𝑇𝐵𝐾:  
- 2-5% precision in adults for a 
typical whole body counting 
- Worse in infants, about 8-12%  
Accuracy of 𝑇𝐵𝐾: unknown 
- Unknown due to the lack of 




















that of natural 
background 
radiation/day 
received by us 
- Non-invasive  










Precision/Variability of %𝐹𝑀:  
- CV of 1.89% was reported for 
20 subjects over four 
consecutive days 
 
Accuracy of %𝐹𝑀:  
- DXA can have 1-3% error in 
%𝐹𝑀 if  compared with results 
of multi-compartmental 
analysis of body composition  














- MRI is safe (no 
ionising 
radiation) 
- Both are non-
invasive 
- MRI is suitable 
for all including 
children 
- Newer MRI 
scanners have 
larger gantry 
size: fit severely 
obese subjects 









- Old scanners 




- Both are not 
cost effective 
Precision of VAT:  
- An average CV  of 0.6% and 
0.7% were reported for intra 
and inter-observer error in VAT 
measurement from the same 
scan 
Accuracy of VAT:  
-Unknown, because comparison 
between imaging derived VAT 
and direct chemical analysis 
data of cadaver has not been 
reported  
- Only the quality of tissue has 
been compared between 
imaging and biopsy results in 
human. For example, liver fat 
index determined by MRI 
strongly correlates with biopsy 
data from the same subjects 
a for all the three densitometry based methods, accuracy is measured in terms of error in %𝐹𝑀, which is 
highly variable and can be attributed primarily to the biological variation in 𝜌FFM ; 𝜌BM  total body 
density, 𝑉𝐵 total body volume, 𝑇𝐵𝑊 total body water, 𝐸𝐶𝑊 extracellular water, 𝐼𝐶𝑊 intracellular water, 
𝑍 impedance, 𝐹𝐹𝑀 fat-free mass, 𝐹𝑀 fat mass, 𝑇𝐵𝐾 total body potassium, 𝑉𝐴𝑇  volume of adipose;  
 
  









Figure A2.2 Schematic representation of AC current flow through body water 
  
(a) Low frequency (b) High frequency
Cell
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Figure A3.1 Observed individual    vs. 𝑭𝑭𝑴 plots 
Plots are for acetaminophen glucuronidation (a), acetaminophen sulfation (b), acetaminophen 
oxidation (c), antipyrine (d), efavirenz (e), moxifloxacin (f), ribavirin (g) and theophylline (h). 
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